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The FATZ/calsarcin/myozenin family of proteins has three members FATZ-1 
(calsarcin-2/myozenin-1), FATZ-2 (calsarcin-1/myozenin-2) and FATZ-3 (calsarcin-
3/myozenin-3) all localized in the Z-disk and with have high homology to each other at 
their N- and C-terminals. The FATZ family has been shown to interact with γ-filamin, 
α-actinin, telethonin, ZASP (Cypher/Oracle) and calcineurin. Together with Prof. O. 
Carpen we noted that all three members of the FATZ family share high homology with 
myotilin, palladin and myopalladin at their extreme C-terminal. In fact the final 5 amino 
acids of FATZ-3 and myotilin are identical (ESEEL), as are those of FATZ-2 and 
palladin (ESEDL). Computer analysis of the sequences of these proteins indicated that 
the last four amino acids were considered a probable class III PDZ binding motif 
(X[DE]X[IVL]). Searches of protein sequence databases revealed that the C-terminal 
E[ST][DE][DE]L motif is present almost exclusively in the FATZ family of proteins, 
myotilin, palladin and myopalladin and is evolutionary conserved in these proteins from 
zebrafish to humans indicating its importance for their biological function. 
A main object of this study was to determine if the proteins with this new type of Class 
III PDZ binding motif at their C-terminal could indeed bind PDZ domains. Since both 
the FATZ family and myotilin bind ZASP-1 which is a PDZ domain protein we wanted 
to discover if these interactions occurred via the PDZ domain of ZASP. To do this we 
collaborated with Prof. G Valle whose group use the AlphaScreen technique to study 
protein-protein interactions. Biotinylated phosphorylated and non-phosphorylated 
peptides were designed based on the final C-terminal 5 amino acids of the FATZ 
family, myotilin, palladin and myopalladin as well as a control peptide ESEEE having E 
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instead of L as its last amino acid. Native protein was also produced for use in 
AlphaScreen experiments, both to full length proteins and proteins lacking the terminal 
5 amino acids. Since ZASP belongs to the Enigma family of proteins the PDZ domains 
of other members such as ALP and CLP-36 were also checked for their interactions. 
The results presented here show that the terminal amino acids were responsible and 
crucial for the interaction with the PDZ domain and that phosphorylation modulated this 
interaction. These results were further confirmed by in vitro binding experiments such 
as GST pull-down and PDZ Array. Another Enigma family member RIL was found to 
bind to this new motif based on PDZ array experiments. The results presented in this 
thesis demonstrate that proteins of the FATZ family, myotilin, palladin and myopalladin 
interact with the PDZ domains of Enigma family members via their final C-terminal 
amino acids. Therefore these final 5 amino acids may represent a new type of class III 
PDZ binding motif specific for the PDZ domain of Enigma proteins. 
I found another binding partner for FATZ-3, namely the I-band protein Ankrd2 whose 
binding I mapped to the N-terminal of FATZ-3. 
The second object of this thesis was to study the tertiary structure FATZ-3 by using 
protein crystallography. I faced a lot of difficulties expressing and producing native full-
length FATZ-3 protein first in bacteria and then using the Baculovirus expression 
system. It was challenging to obtain enough native purified protein for crystallization 
studies. I was able to do so using the C-terminal region of FATZ-3 protein (171 amino 
acids) and undertook crystallization studies at the laboratory of Prof. Kristina Carugo. I 
tried about 300 crystallization conditions and started to obtain crystals after 1 month. 







A-band  Anisotropic in polarised light 
ABD   Actin-binding domain 
ADP   Adenine di-phosphate   
ALP   Actinin-associated LIM protein 
AlphaScreen Amplified Luminescent Proximity Homogeneous Assay 
Ankrd2  Ankyrin repeat domain 2 protein 
AP   Alkaline phosphatase 
AR LGMD  Autosomal recessive Limb-Girdle Muscular Dystrophy 
ATP   Adenine tri-phosphate 
BCIP   5-bromo-4-chloro-3-indolyl phosphate 
BSA   Bovine serum albumin 
Calsarcin  denotes calcineurin associated sarcomeric protein  
CD   Circular dichroism 
CH   calponin homology 
CHO Chinese hamster overy  
CnA  Calcineurin subunit A 
CLP C-terminal LIM domain protein 
COS-7 monkey, African green, kidney 
Co-IP  Co-immunoprecipitation 
DARP  Diabetes-related Ankyrin Repeat Protein 
DCM   Dilated cardiomyopathy 
DHPLC Performance liquid chromatography 
Dlg Discs large protein 




DMD   Duchenne Muscular Dystrophy 
EBP50 Ezrin-radixin-moesin binding phosphoprotein-50 
ECL   Enhanced chemiluminescence 
ENH   Enigma homologue protein 
FATZ  γ-filamin, Alpha-actinin and Telethonin binding protein 
FL   Full lenght 
GFP   Green fluorescent protein 
GST   Glutathione S-transferase 
HA   Hemagglutinin 
HCM   Hypertrophic cardiomyopathy 
hCLIM1 carboxyl terminal LIM domain protein 
HMERF  Hereditary myopathy with early respiration failure 
HRP   Horseradish peroxidise 
Ig   Immunoglobulin 
IKEPP  Intestinal and kidney enriched PDZ protein 
IPTG   Isopropyl-β-D-thiogalactoside 
IVTT   In vitro transcribed and translated 
kDa   Kilo Dalton     
LB   Luria Broth 
LGMD  Limb girdle muscular dystrophy 
LIMK LIM domain kinase  
LIM domains Designated LIM for the first three proteins in which it was 
discovered in, Lin11, Isl-1 & Mec-3 
MARP  Muscle ankyrin repeat protein 
M-band   Mittel, meaning middle in German  
MDM2  Mouse double minute 2 
MHC   Myosin heavy chain 
MFM  myofibrillar myopathy 
Abbreviations 
6 
MLP   Muscle LIM protein 
MRF   Myogenic regulatory factor 
MURFs  Muscle Specific RING-finger proteins 
NBT   Nitro blue tetrazolium 
NFAT Nuclear factor of activated T-cells 
Ni-NTA  Nitrilo-tri-acetic acid 
OD600  Optical density at 600 nm 
ORF   Open reading frame 
PAGE  PolyAcrylamide gel electrophoresis 
PBS   Phosphate buffered saline 
PDVF  Polyvinyldifluoride 
PDZ domains The name comes from the first three proteins that has been 
discovered in, PSD-95 , Dlg and ZO-1  
PEG   Poly ethylene glycol 
PKC   Protein kinase C 
PML   Promyelocytic leukemia protein 
PSD-95 Post-synaptic density 95 kDa 
RIL Reversion induced protein 
SDS   Sodium dodecyl-sulphate 
Sf9 Spodoptera frugiperda 
SLRs   spectrin-like repeats 
TB   Terrific broth 
TEV Tobacco Etch Virus  
TID   Telethonin interacting domain 
UV Ultraviolat light  
ZASP  Z-band alternatively spliced PDZ domain protein  
Z-disk   Zwischen, meaning between in German 
ZO-1 Zonula occludens 1 protein 
 
7 




The function of muscle in the body is to produce force and cause motion, either 
locomotion or movement within internal organs. Most muscle contraction occurs 
without conscious thought and is necessary for survival. Our hearts contract without us 
thinking about it, our intestines contract while digesting food and we breathe all without 
conscious thought. Although movements such as walking, running, writing or even 
turning our head require conscious thought they are so automatic that usually we are 
unaware that they result from signals sent to the brain to tell our body parts to move. 
Muscle is the contractile tissue of the body and is derived from the mesodermal layer of 
embryonic germ cells. Muscle fibres are bound together by perimysium into bundles 
which group together to form a muscle which is enclosed in a sheath of epimysium (Fig 
1). Muscle spindles are distributed throughout the muscles and provide sensory 
feedback information to the central nervous system. Individual muscle fibres are 
surrounded by endomysium. The muscle myofibre is composed of several nuclei and 
myofibrils. Myobrils are made up of sarcomeres, the basic contractile unit of muscle 
that are composed of fibres of actin and myosin. 
Muscle can be classified into three types: 1) Skeletal muscle (striated, voluntary muscle) 
is anchored by tendons to bone and enables movement of the skeleton. These muscles 
are highly specialised for rapid force production. An average adult male has 40-50% of 
skeletal muscle whereas an average adult female has 30-40%. 2) Cardiac muscle 
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(striated, involuntary muscle) is an intermittently contracting muscle that maintains the 
blood supply to the organs of the body. 3) Smooth muscle (non-striated, involuntary 
muscle) is found within the walls of organs and structures such as the oesophagus, 
stomach, intestines, bronchi, uterus, urethra, bladder, and blood vessels, and unlike 
skeletal muscle, smooth muscle is not under conscious control. Smooth muscles are 
involuntary muscles. Skeletal muscles can be divided into two main types; Type I, slow 
oxidative, slow twitch, or "red" muscle is dense with capillaries and is rich in 
mitochondria and myoglobin, giving the muscle tissue its characteristic red colyes our. 
It can carry oxygen and sustain aerobic activity. Type II which is less dense in 
mitochondria and myoglobin it is the fastest muscle type in humans. It can contract 
more quickly and with a greater amount of force than oxidative muscle, but can sustain 
only short, anaerobic bursts of activity before muscle contraction becomes painful. 
Cardiac and skeletal muscles are "striated" in that they contain sarcomeres and are 
packed into highly-regular arrangements of bundles; smooth muscle has neither. While 
skeletal muscles are arranged in regular, parallel bundles, cardiac muscle connects at 
branching, irregular angles. Striated muscle contracts and relaxes in short, intense 
bursts, whereas smooth muscle sustains longer or even near-permanent contractions. 
Although the three (skeletal, cardiac and smooth) types of muscle have significant 
differences all three use the movement of actin against myosin to create contraction. In 
skeletal muscle, contraction is stimulated by electrical impulses transmitted by nerves, 
the motor nerves and motoneurons in particular. Cardiac and smooth muscle 
contractions are stimulated by internal pacemaker cells which regularly contract, and 
propagate contractions to other muscle cells with which they are in contact. All skeletal 
Introduction 
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muscle and many smooth muscle contractions are facilitated by the neurotransmitter 
acetylcholine. 
Muscular activity accounts for much of the body's energy consumption. All muscle cells 
produce adenosine triphosphate (ATP) molecules which are used to power the 
movement of the myosin heads. Muscles contain ATP in the form of creatine phosphate 
which is generated from ATP and can regenerate ATP when needed by the action of 
creatine kinase. Muscles also store glucose in the form of glycogen. Glycogen can be 
rapidly converted to glucose when energy is required for sustained, powerful 
contractions. Within the voluntary skeletal muscles, the glucose molecule is 
metabolized in a process called glycolysis, the oxidation of glucose. Glucose is oxidized 
to either lactate or pyruvate. Under aerobic conditions, the dominant product in most 
tissues is pyruvate and the pathway is known as aerobic glycolysis. Aerobic glycolysis 
of glucose to pyruvate, requires two equivalents of ATP to activate the process, with the 
subsequent production of four equivalents of ATP and two equivalents of NADH. One 
mole of glucose is oxidised to two moles of pyruvate accompanied by the net 
production of two moles each of ATP and NADH. Muscle cells also contain globules of 
fat, which are used for energy during aerobic exercise. The aerobic energy systems take 
longer to produce the ATP and reach peak efficiency, and require many more 
biochemical steps, but produce significantly more ATP than anaerobic glycolysis 
When oxygen is depleted, as for instance during prolonged vigorous exercise, the 
dominant glycolytic product in many tissues is lactate and the process is known as 
anaerobic glycolysis. Under anaerobic conditions and in erythrocytes under aerobic 
conditions, pyruvate is converted to lactate by the enzyme lactate dehydrogenase 
(LDH), and the lactate is transported out of the cell into the circulation. The conversion 
Introduction 
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of pyruvate to lactate, under anaerobic conditions, provides the cell with a mechanism 
for the oxidation of NADH (produced during the G3PDH reaction) to NAD+; which 
occurs during the LDH catalyzed reaction. This reduction is required since NAD+ is a 
necessary substrate for G3PDH, without which glycolysis will cease. Normally, during 
aerobic glycolysis the electrons of cytoplasmic NADH are transferred to mitochondrial 
carriers of the oxidative phosphorylation pathway generating a continuous pool of 
cytoplasmic NAD+. Aerobic glycolysis generates substantially more ATP per mole of 
glucose oxidized than does anaerobic glycolysis. The utility of anaerobic glycolysis, to a 
muscle cell when it needs large amounts of energy, stems from the fact that the rate of 
ATP production from glycolysis is approximately 100X faster than from oxidative 
phosphorylation. During exertion muscle cells do not need to energize anabolic reaction 
pathways. The requirement is to generate the maximum amount of ATP, for muscle 
contraction, in the shortest time frame. This is why muscle cells derive almost all of the 
ATP consumed during exertion from anaerobic glycolysis. 
Cardiac muscle can readily consume any of the three macronutrients (protein, glucose 
and fat) without a 'warm up' period and always extracts the maximum ATP yield from 
any molecule involved. The heart and liver will also consume the lactic acid produced 











Figure 1. The relationship between muscle fibres and the connective tissues of the 
tendon, epimysium, perimysium and endomysium. Enlargement shows an expanded 
view of a single muscle fibre containing several nuclei, myofibrils and filaments. (the 
Figure is taken from Fox, S.I. Human Physiology, 4th Ed.) 
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2 The sarcomere 
2.1 The structure of the sarcomere 
All striated muscles are built of subunits known as sarcomeres. These sarcomeres are 
approximately 2-3 µm long and 1-2 µm in diameter and link end to end to form thin 
strands known as myofibrils (Craig and Padron, 2004). The striation pattern in muscle 
results from alternating ordered arrays of myofilaments, i.e. myosin and actin filaments 
(Cooke, 1995). Figure 2 is a schematic diagram of the sarcomere depicting the 
following features; thick and thin filaments, A band, M-band, I –band and Z-disk. Thick 
filaments are composed of mainly of myosin whereas thin filaments are composed of 
actin filaments associated with tropomyosin and troponin. The bands in the sarcomere 
were originally named according to their features under a polarized light microscope. 
The central A-band (Anisotropic in polarised light) is the region where thick and thin 
filaments interdigitate and is composed of a hexagonal array of aligned, bipolar myosin 
filaments and adjacent filaments that are cross-linked at their centres by proteins of the 
M-band (Mittel, meaning middle in German). Electron microscopy images of the A-
band showed that there are six thin filaments surrounding one thick filament in a 
hexagonally arrangement and myosin heads extend to interact with actin forming 
crossbridges. The region of the A-band without any actinomyosin overlap is called the 
H-zone (Heller, meaning bright in German). The regions containing only actin 
filaments are termed I-bands (Isotropic in polarised light) and this surrounds the Z-disk. 
Actin overlaps partly with myosin and extends to the Z-disk (Zwischen, meaning 
between in German) at both ends of the sarcomere therefore the Z-disk is the border 
between each sarcomere. The actin filaments are polar structures, and Z-disc proteins 
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serve to provide a mechanical link between actin arrays of opposite polarity from 
adjacent sarcomeres (Huxley and Niedergerke, 1954; Huxley and Hanson, 1954). 
The thick and thin filaments represent the main contractile units of the sarcomere. The 
myosin heads slides along the actin (thin filaments) through a binding interaction which 
is stimulated by ATP, ADP and inorganic phosphate (Pi). The contraction starts with 
myosin binding to actin, and the binding of ATP to myosin reduces the affinity of this 
interaction resulting in the separation of the myosin head from the actin protein, then the 
myosin head hydrolyses ATP and producing ADP; this reaction generates the power 
needed to move the myosin head along the actin filament. The replacement of ADP with 
ATP increases the affinity of binding of the myosin head towards actin. This cycle of 
ATP hydrolyses and addition of ADP represents the main force generation that is 
required for filament movement which results in the contraction of the sarcomere which 


































































































































































































Thin filaments are mainly composed of Actin. This protein is responsible for diverse 
cellular functions such as motility, cytokinesis and contraction. Actin filaments form 
two twisted α-helices that associate with the regulatory proteins tropomyosin and 
troponin. CapZ stabilizes and prevents depolymerization of actin filaments by binding 
their plus (+) ends. Moreover it attaches actin filaments to the Z-disk and also binds α-
actinin-2 (Casella et al., 1987; Papa et al., 1999). Early in myofibril assembly, thin  
filament components associate with nascent Z-lines to form the first identifiable 
structures called I-Z-I complexes (Holtzer et al., 1997). Several Actin isoforms exist, 
each encoded by separate genes whose expression patterns are regulated 
developmentally and in a tissue specific manner. Their sequences and molecular 
structures are very similar. Two muscle-specific isoforms, cardiac and skeletal actins, 
are co-expressed at varying levels depending on the species, muscle fibre and 
developmental stage. Vascular and visceral actins are expressed in smooth muscle and 
also in striated muscle fibres transiently during development. Two non-muscle actins, 
the cytoplasmic isoforms, are co-expressed with other actin isoforms in many tissues. 
Mutations in actin can lead to different diseases such as actin myopathy and nemaline 
myopathy characterized by myofibrillar structural abnormalities and muscle weakness 
(Ilkovski et al., 2001; Nowak et al., 1999) and also familial dilated cardiomyopathy 
(DCM) and heart failure, characterized by impaired force transmission and hypertrophic 
cardiomyopathy (HCM) (Olson et al., 2000; Olson et al., 1998). Thus single amino acid 
substitutions in actin can result in distinct clinical manifestations, depending on the 





1.3 The Z-disk 
1.3.1 The structure of the Z-disk 
At the beginning of myofibrillogenesis α-actinin rich Z bodies are formed that are the 
precursors of the Z-disk (Rhee et al., 1994; Sanger et al., 2000). These Z-bodies are just 
below the plasma membrane and are connected with stress fibre-like structure made up 
of actin and non-muscle myosin resembling adhesion junctions found in non-muscle 
cells. The Z-body matures to a striated structure of three filament components; thin 
filament made up of actin and actin-binding proteins and thick filament consisting of 
oligomerized myosin (muscle) and titin (Clark et al., 2002; Granzier and Labeit, 2004) 
as well as intermediate filaments mainly composed of desmin that surround the 
myofilaments at the Z disk in cardiomyocytes (Clark et al., 2002) and link it to 
desmosomes, focal adhesion junctions, and the nucleus. 
Sarcomeres are separated from one another by the Z-disk, the borderline between 
sarcomeres. The Z-disk keeps the structure of the sarcomere in register by tethering 
actin and transmits tension during muscle contraction. Filaments from neighbouring 
sarcomeres overlap at the Z-disk and are cross-linked by tight interaction with α-actinin-
2 which is a major component of the Z-disk (Hoshijima, 2006). Alpha-actinin-2 is 
assembled in the Z-disk as homodimers and aligned in an antiparallel fashion, cross-
linking actin and organizing its polarized orientation (Frank et al., 2006) (fig 3). The 
width of the Z-disk varies depending on the type of muscle. The Z-disc in skeletal 
muscle fast-twitch fibres has a width of about 30-50 nm (Luther, 1991; Luther, 2000), 
while in cardiac muscle and skeletal slow-twitch fibres its width is about 100-140 nm 










































































































































































































































































































































































































































































































1.3.2 Z-disk proteins 
It is now clear that the Z disk is not just a simple mechanical structure but a centre for 
interactions and signalling in the sarcomere. In recent years the number of proteins 
localised in the Z-disk has increased dramatically but not as much as their interactions 
among themselves as well as other proteins not normally localised in the Z-disc such as 
cytoskeletal proteins, nuclear proteins and kinases to mention just a few. 
MLP (CSPR3) is a LIM protein downregulated in the adult skeletal muscle up regulated 
(Arber et al., 1994). MLP is highly expressed in developing and adult heart. Its 
importance is demonstrated by the fact that the MLP-null mouse develops severe 
cardiac dysfunction which resembles human dilated cardiomyopathy (Arber et al., 
1997). Muscle PDZ-LIM proteins are thought to act as adapters in transmitting 
mechanical stress signals from the Z-disk to the nucleus will be dealt with in more detail 
later in the Introduction. Some PDZ-LIM proteins are also present in heart for example 
ZASP, ALP, enigma and CLP-36. The Z-disk contains many other proteins such as the 
FATZ (Calsarcin/Myozenin) family, ZASP (Cypher/Oracle), myotilin, myopalladin, 
myopodin, enigma homology protein, filamin-C, telethonin, desmin, obscurin and titin 
to mention just a few. As mentioned before most of these proteins interact with each 
other as well as signalling proteins; for example the FATZ family interacts with and 
negatively controls calcineurin which it localises to the Z-disk (Frey and Olson, 2002; 
Frey et al., 2000). Mutations in several Z-disk proteins has been shown to cause 
cardiomyopathies and or muscular dystrophies, for instance mutations in ZASP (Vatta 
et al., 2003), FATZ-2 (Osio et al., 2007) and myotilin (Hauser et al., 2002) have been 
found in patients suffering from cardiomyopathy. The network of interactions of the Z-
disk proteins strengthens the Z-disk and allows it to withstand the force caused by the 
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contraction of the sarcomere. As noted before this places the Z-disk at the centre of the 
sarcomeric structure (Hoshijima, 2006). Some Z-disk proteins are discussed below and 
in other sections however I am aware that this is by no means a fully detailed or 
comprehensive review of all Z-disk proteins. 
 
1.3.2.1 Titin  
Titin spans the entire sarcomere and can be divided in three principal regions: Z-disk 
Titin, I-line Titin and M-line Titin. The Z-disk Titin represents the N-terminal part of 
the molecule and contains several Ig-like repeats that bind α-actinin (Ohtsuka et al., 
1997) and telethonin (Gregorio et al., 1998). Titin, together with telethonin and MLP 
constitutes a stretch sensor complex in cardiomyocytes (Knoll et al., 2002). The 
difference in number of alternatively spliced Ig-like repeats in titin isoforms varies 
between different muscle types and has been suggested to affect the number of cross-
links between α-actinin-2 and actin and hence to cause variations in Z-disk thickness 
(Gautel and Goulding, 1996). Moreover Z-disk titin interacts with Obscurin and small 
ankyrin 1 (sAnk1) (Kontrogianni-Konstantopoulos and Bloch, 2003), suggesting the 
existence of a complex implicated in the organization of the sarcoplasmic reticulum 
around the myofibril (Bang et al., 2001a). In addition to the structural and elastic 
properties of titin there is evidence that it is involved in signalling pathways. In fact I-
line Titin interacts and forms a complex with Calpain protease 94 (Sorimachi et al., 
1995) and all the members of the MARP family (CARP, Ankrd2 and DARP) (Miller et 
al., 2003). Remarkably, all I-band ligands of Titin are also found in the nucleus where 
they can participate in transcriptional and cell cycle regulation. It seems likely that this 
dual localization (I-band and nucleus) is not just a coincidence but reflects a dual 
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function for these proteins: being part of a Titin-based stretch sensing complex in the I-
band and regulating transcription in the nucleus. Furthermore, such dual localization 
may also provide a communication pathway between the I-band and nucleus that links 
stretch sensing to gene expression (Granzier and Labeit, 2004). 
The C-terminal region of titin is located in the M-line. This region contains a 
Serine/Threonine kinase activity that phosphorylates telethonin in developing muscle 
(Mayans et al., 1998). However, the upstream elements controlling the Titin kinase 
activation, its range of cellular substrates and its role in mature muscle are largely 
unknown. The elastic properties of the Titin molecule and the mechanical deformation 
of the M-band during stretch and contraction suggest that the signalling properties of the 
Titin kinase might be modulated by mechanically induced conformational changes 
(Lange et al., 2005). Also M-line Titin binds to the RING finger protein MURF-1 
(Centner et al., 2001) and nbr-1, which interacts with the MURF-2 binding protein p62 
(Lange et al., 2005). Nbr-1 acts as a cytoskeleton-associated kinase scaffolding protein 
that assembles large sarcomeric “signalosomes” through interactions with multiple 
elements, linking the Titin kinase to p62 and MURF-1 (Lange et al., 2005). 
Titin is involved in muscle disease; in fact mutations in the Titin gene, that affect the 
binding sites for Telethonin and α-actinin, have been found in patients with dilated 
cardiomyopathy and are thought to be correlated with the disease (Itoh-Satoh et al., 
2002). Mutations in the Titin gene that lead to autosomal dominant tibial muscular 
dystrophy were found to cause LGMD type 2J (Vainzof and Zatz, 2003) and a point 
mutation in the kinase domain that disrupts the binding with nbr-1 resulted in hereditary 





The Muscle Lim Protein is localized at the periphery of the Z-disk (Arber et al., 1997) 
and at the intercalated disc (Ehler et al., 2001). The ultrastructural analysis of MLP -/- 
murine cardiomyocytes revealed a misalignment of the Z-disk (Arber et al., 1997) and 
morphological defects at costameres and intercalated discs (Ehler et al., 2001) 
suggesting that MLP plays a primary role in maintaining the stability of these structures. 
The genetic ablation of MLP in the mouse results in DCM (Arber et al., 1997) and a 
point mutation in the human MLP gene has also been associated with this pathological 
condition. This single nucleotide mutation resulted in a severe charge change at position 
4 in the MLP protein (W4R) that lies within the N-terminal telethonin interacting 
domain (TID) of MLP, thus disrupting the binding between the two proteins and 
causing telethonin miss-localization and Z-line disruption. Since MLP binds telethonin, 
it was suggested that, together with titin, they could constitute a stretch sensor (Knoll et 
al., 2002). MLP is known to interact with MyoD (Kong et al., 1997) and has also been 
implicated in the communication with the nucleus especially in response to hypertrophic 
signals (Ecarnot-Laubriet et al., 2000). 
 
1.3.2.3 MURFs 
The MURFs (Muscle Specific RING-finger proteins) are a family of RING/B-box 
proteins expressed in striated muscle. Three MURF genes encode three highly similar 
proteins that can form homo- and heterodimers: MURF-1, MURF-2 and MURF-3 
(Centner et al., 2001). MURF-1 acts as a ubiquitin ligase, thereby controlling 
proteasome-dependent degradation of muscle proteins. Among its targets there are M-
line Titin, Nebulin, Myotilin and Telethonin. MURF-1 is part of the structural scaffold 
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of the M-line lattice but has also been implicated in the regulation of gene expression 
and myocardiocytic contractility (Witt et al., 2005). MURF-2 co-localizes both with 
MURF-1 in the M-line and with MURF-3 in microtubules (McElhinny et al., 2004). 
MURF-3 is a microtubule associated protein differentially expressed during myogenesis 
and up-regulated during differentiation, probably to stabilize microtubules (Spencer et 
al., 2000). This is the isoform of MURF located in the Z-line of skeletal muscle where it 
is though to act as a link between the sarcomeric and the microtubules compartments 
since it can bind MURF-1, MURF-2 and Z-disk and M-line proteins such as Titin 
(Spencer et al., 2000). 
 
1.3.2.4 Calpain 3  
Muscle-specific Calpain3/p94 is a Ca2+ dependent cysteine protease present both in the 
M-line and the I-line, where it binds to Titin (Sorimachi et al., 1995). Calpain3/94 is 
thought to have a regulatory function in the modulation of transcription factors and to be 
involved in the disassembly of sarcomeric proteins (Vainzof and Zatz, 2003). The 
importance of its function is suggested by the observation that mutations in the 
Calpain3/94 gene, with consequent loss of function, lead to LGMD type 2A (Richard et 
al., 1995). 
 
1.3.2.5 Nebulin and Nebulette 
Nebulin is an actin-binding protein which is localized in the I-band of skeletal muscle. It 
is a large protein (600-900 kDa) that together with Titin forms the third filament system 
of the myofibril. The C-terminal of the protein is located in the Z-disc, while the rest 
extends until the end of the thin filaments and its length is proportional to that of the 
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thin filament. Its binding with actin monomers is sensitive to both calcium and 
calmodulin (Wright et al., 1993). Nebulin also binds α-actinin (Nave et al., 1990). 
Mutations in nebulin can cause nemaline myopathy, an autosomal recessive disease. It 
has been suggested that nebulin acts as a template for the formation of actin filaments 
(Kruger et al., 1991). Nebulin is found only in skeletal muscle not in heart where a 
smaller protein called nebulette (109 kDa) that is highly homologous to the C-terminal 
of nebulin (Millevoi et al., 1998) is found. The C-terminal homology between nebulin 
and nebulette is thought to be necessary to conserve their binding to the Z-disk 




Alpha-Actinin was first discovered in 1964 (Ebashi and Ebashi, 1964). The α-actinin 
family of proteins plays a very important role in muscle contraction and in the 
organization of the cytoskeleton. It is a highly conserved family of actin binding 
proteins, which belong to the spectrin superfamily which includes spectrins, dystrophin 
and utrophin. Alpha-actinin is an antiparallel homodimer whose structure consists of 
three major domains; an N-terminal actin-binding domain (ABD) which is a highly 
conserved region with two calponin homology (CH1 and CH2) domains. The CH1 is 
responsible for binding actin, while the CH2 increases the binding affinity (Gimona et 
al., 2002). The central rod domain of α-actinin has tandem spectrin-like repeats (SLRs) 
which are less conserved than the ABD domain. The number of SLRs in α-actinin has 
changed during evolution, in vertebrates there are 4 SLRs. Some members of the 
spectrin super family can contain up to 30 SLRs. In α-actinin the SLRs are involved in 
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the formation of anti-parallel homodimers and they also bind other interacting proteins 
(Djinovic-Carugo et al., 2002; MacArthur and North, 2004; Thomas et al., 1997). The 
C-terminal region which consists of two EF hand (EFh) domains is important for the 
functional diversities of the α-actinin isoforms. 
In humans there are four isoforms of α-actinin, 1, 2, 3, and 4: which are encoded by 
ACTN1, ACTN2, ACTN3, and ACTN4, respectively. These isoforms share an 80% 
identity (Beggs et al., 1992; Honda et al., 1998; Millake et al., 1989) and can be 
characterized according to their biochemical properties, expression patterns and 
subcellular localisation into two groups; the non-muscle cytoskeletal (calcium sensitive) 
isoforms alpha-actinin-1 and 4 (Tang et al., 2001) and the muscle sarcomeric (calcium 
insensitive) isoforms α-actinin-2 and -3 (Blanchard et al., 1989; MacArthur and North, 
2004). Alpha-actinin-1 is concentrated at the ends of stress fibres in focal contacts and 
alpha-actinin-4 is localized in stress fibres and can also be translocated to the nucleus 
(Honda et al., 1998). The muscle isoforms lack five amino acids at the EFh domain 
which eliminates their ability to bind calcium. The EFh domain is also responsible for 
the interaction with titin (Ohtsuka et al., 1997) and ZASP (Faulkner et al., 1999). Alpha-
actinin-2 and -3 can be found mainly in the Z-disc, and to a lesser extent in sarcolemma. 
However α-actinin-3 is absent in cardiac muscles (Beggs et al., 1992; Hance et al., 
1999; Lazarides and Granger, 1978) and is not found in 16% of the world population, 
suggesting that other isoforms can compensate for its absence from the Z-disc of 
skeletal muscles, especially since there is no phenotypic changes seen when α-actinin-3 
is absent (North and Beggs, 1996). 
Several studies have shown the importance of α-actinin in muscle function since mice 
lacking α-actinin die due to degeneration of myofibrils and disruption of the Z-disc 
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(Fyrberg et al., 1998; Fyrberg et al., 1990; Roulier et al., 1992). It has also been found 
that over expression of a C-terminal deletion of α-actinin causes Z-disc hypertrophy 
(Lin et al., 1998; Schultheiss et al., 1992) and a mutation in α-actinin-2 (Q9P) has been 
found to be associated with dilated cardiomyopathy, this mutation disrupts the binding 




NF-AT3 is a transcription factor localized both in the Z-disk and in the nucleus. In 
normal conditions NF-AT3 is tethered to the Z-disk by calcineurin. NF-AT3 resides in 
the Z-disk because of its interaction with calcineurin. When a signal activates 
calcineurin, it de-phosphorylates NF-AT3 provoking its translocation into the nucleus. 




The Filamins are a family of cytoskeletal proteins which organize filamentous actin in 
networks and stress fibres. Filamins were first discovered as a family of non-muscle 
actin-binding proteins (Popowicz et al., 2006; Stossel et al., 2001; van der Flier and 
Sonnenberg, 2001). The name filamin refers to is filamentous colocalization with actin 
stress fibres (Wang et al., 1975). There are three main human isoforms of filamin A, B 
and C encoded respectively by the genes FLNA , FLNB and FLNC (Gorlin et al., 1990). 
The three isoforms share from 70-80% identity with each other and the exon-intron 
structure of all the isoforms is highly conserved (Chakarova et al., 2000; Xie et al., 
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1998). These isoforms are expressed in most human tissues with some difference in the 
expression pattern: filamin A is expressed in heart, lung, blood vessels and 
haematopoietic cells; filamin B is expressed in kidney and pancreas; filamin C is 
restricted to striated muscle and found predominantly in the Z-disc and in the 
intercalated disks (Maestrini et al., 1993; Takafuta et al., 1998). 
The structure of filamin consists of 24 Ig-like domains (or repeats), each domain is 
composed of 96 amino acids (Davies et al., 1978). The N-terminal of filamin contains 
two calponin homology (CH) domains containing 274 amino acids that form the ABD 
domain (Banuelos et al., 1998). The filamin protein forms a homodimer and electron 
micrographs showed this homodimer as an extended Y-shaped. The filamin dimer has a 
molecular weight of 280 kD (Hartwig and Stossel, 1981; Tyler et al., 1980). Himmel 
and colleagues have shown that the filamin Ig-like domain is sufficient for its 
dimerisation (Himmel et al., 2003) and serves as a platform for other molecules that 
participate in the regulation of filamin (Stossel et al., 2001). 
Apart from actin cross-linking in cytoskeleton (Hartwig and Stossel, 1981), filamin has 
many other functions such as linking extra-cellular proteins and the actin cytoskeleton 
with transmembrane receptors (Meyer et al., 1997). It also plays an important role in 
signal transduction by serving as a platform for a variety of signalling molecules. A 
mutation in the filamin C gene (FLNC) can cause myofibrillar myopathy (MFM), this 








Telethonin (Valle et al., 1997), also known as T-cap (Gregorio et al., 1998) is a small 
sarcomeric protein with a molecular weight of 19kD. The human telethonin shares 
around 90% homology with the mouse telethonin (Mason et al., 1999). The N-terminal 
of telethonin binds to the N-terminal of titin at the Z1 and Z2 Ig-like domains and both 
these domains and telethonin are localized in the Z-disk (Gregorio et al., 1998; Mues et 
al., 1998). The binding of telethonin to the N-terminal of titin is very important for Z-
disk stability since it has been shown in primary cultures of cardiomyocytes that 
overexpression of the titin N-terminal resulted in severe myofibril disruption. This 
observation as well as others suggests that telethonin plays a key role in positioning and 
anchoring the N-terminal of titin to the Z-disk (Gregorio et al., 1998; Zou et al., 2003). 
Telethonin is phosphorylated by titin kinase, located in the C-terminal of titin and 
activated by calcium/calmodulin binding during myocyte differentiation. Since the titin 
kinase domain is situated in the M-line, whereas telethonin is in the Z-disk, it has been 
proposed that during myofibrillogenesis the cytoskeleton undergoes reorganization and 
the titin C-terminal becomes transiently located in close proximity to telethonin, thus 
allowing its phosphorylation (Mayans et al., 1998). 
Crystal structure studies have shown that telethonin and titin form a sandwich complex 
through the interaction of both N-terminals, forming a dimeric assembly between titin 
and telethonin however the C-terminus of telethonin would also appear to be involved 
in the assembly of the titin/telethonin complexes (Pinotsis et al., 2006). Studies on the 
mechanical strength of the titin Z1Z2-telethonin complex have shown that it is able to 
withstand the force generated passive muscle stretch due to beta strand crosslinking as 
titin Z1Z2 in the absence of telethonin had reduced resistance to mechanical stress (Lee 
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et al., 2006). This data strengthens the hypothesis that telethonin is a key component of 
the N-terminal titin anchor. 
Telethonin was the first sarcomeric protein found to cause an autosomal recessive 
Limb-Girdle Muscular Dystrophy (AR LGMD). Two different mutations in the 
telethonin gene were identified in patients with LGMD 2G, both mutations giving rise 
to premature stop codons; the first mutation was a C157T transition in exon 2 and the 
second mutation was a deletion of two guanine nucleotides within four guanines at the 
junction of exon 1 and intron 1 (Moreira et al., 2000). The resulting truncated telethonin 
protein was not detected suggesting that it was rapidly degraded which may cause 
instability in the sarcomere structure (Moreira et al., 2000). Interestingly, the C-terminal 
truncation eliminates the domain of telethonin that is phosphorylated by titin kinase. 
Mutations in telethonin have been found in other muscle disorders for instance in 
patients suffering from hypertrophic cardiomyopathy (HCM) (two mutations T137I and 
R153H) and in a patient suffering from dilated cardiomyopathy (E132Q) (Hayashi et al., 
2004). In one case, an individual suffering from severe HCM with a heart septal wall 
thickness of 46mm had a mutation in telethonin (R70W). This individual had no other 
known mutations in genes associated with HCM, this mutation was in the binding site 
of telethonin with MLP (Bos et al., 2006). It has been suggested that the 
titin/MLP/telethonin complex together with α-actinin may play an important role as a 
stretch sensors controlling cardiac hypertrophy (Hayashi et al., 2004). It is worth noting 
that telethonin also binds to Ankrd2 (Kojic et al., 2004) that has been suggested as a 
stretch sensor in skeletal muscle and that the MARP family, of which Ankrd2 is a 
member, binds to the N2A region of titin and may form a complex with titin, calpain3 
and myopalladin (Miller et al., 2003). In cardiomyocytes telethonin binds the potassium 
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channel (IKS) β-subunit minK suggesting that a T-tubule-myofibril linking system may 
contribute to a stretch-dependent regulation of K+ flux (Furukawa et al., 2001). 
Telethonin can also bind protein kinase D (Haworth et al., 2004), MURF-1, a RING 
finger protein found in striated muscle (Witt et al., 2005) and the growth factor 
myostatin. It has been reported that over expression of telethonin inhibits the secretion 
of myostatin which would indirectly lead to an increase in the number of myoblasts 
since myostatin is a negative regulator of myoblast proliferation (Nicholas et al., 2002). 
Recently it was reported that MDM2 binds telethonin and that high levels of MDM2 can 
change the sub-cellular localization of telethonin, both proteins co-localised in the 
nucleus. It would appear that MDM2 can down regulate the protein level of telethonin 
through a ubiquitin-independent proteasomal pathway (Tian et al., 2006). Pertinent to 
this thesis telethonin is also able to bind members of the FATZ family of proteins 
(Faulkner et al., 2000; Kojic et al., 2004). 
 
 
1.8 The MARP family 
Since Ankrd1 (C-193/CARP/MARP) and Ankrd2 are similar both in sequence and in 
behaviour, it is possible that they play similar roles in heart and in skeletal muscle, 
respectively. Ankrd1 (CARP), Ankrd2 (ARPP) and DARP (Diabetes-related Ankyrin 
Repeat Protein, have been grouped together into the MARP family of Muscle Ankyrin 
Repeat Proteins (Miller et al., 2003). The up-regulation in expression of each MARP is 
induced by different stress stimuli: injury and hypertrophy in heart for Ankrd1 (Kuo et 
al., 1999); stretch and denervation in skeletal muscle for Ankrd2 (Kemp et al., 2000) 
and recovery following starvation for DARP (REF) indicating that these proteins could 
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be involved in muscle stress response pathways. The MARPs bind to the N2A region of 
titin and they are part of a Titin-N2A based complex together with Calpain3 and 
Myopalladin. This complex could be a stress sensor sending signals to the nucleus 
thereby regulating gene expression (Miller et al., 2003).  
 
1.8.1 Ankrd1 (also known as CARP) 
The Ankrd1 protein can shuttle between the sarcomere (I-band) and the nucleus. It is a 
nuclear co-factor downstream of the homeobox gene Nkx2.5 pathway and forms a 
physical complex with the ubiquitous transcription factor YB-1, thus acting as a 
negative regulator of HF-1 dependent pathways for ventricular muscle gene expression 
(Jeyaseelan et al., 1997; Zou et al., 1997) Ankrd1 expression is predominantly in 
cardiac muscle, with low levels in skeletal muscle. Its expression can be strongly 
induced in the regenerating myofibres of Congenital and Duchenne Muscular Dystrophy 
patients (Nakada et al., 2003). It can also be detected in the sarcomeric I-Z-I areas of 
regenerating skeletal muscle (Nakada et al., 2003) where it interacts with the I-band 
protein Myopalladin suggesting it may have a role in the maintenance of sarcomeric 
integrity (Bang et al., 2001b). 
 
1.8.2 Ankrd2 (ANKyrin Repeat Domain 2, also known as ARPP) 
Ankrd2 was first discovered as a protein that was up regulated during muscle stretch 
(Kemp et al., 2000). It is localized in the I-band and near the Z-line (Tsukamoto et al., 
2002). The Ankrd2 gene is located in the same region of human chromosome 10 as that 
of Ankrd1 (position 10q23.1) and its 9 exons encode a protein with a predicted 
molecular weight of 37 kD; exons 5, 6, 7, and 8 encoding the ankyrin repeats 
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(Moriyama et al., 2001; Pallavicini et al., 2001). There is a 43 % homology between 
Ankrd1 and Ankrd2 (Pallavicini et al., 2001). The human Ankrd2 protein shares a 89% 
similarity at the amino acid level with the mouse Ankrd2 and it is expressed in skeletal 
muscle and at a lower level in heart, kidney and prostate (Moriyama et al., 2001; 
Pallavicini et al., 2001). Ankrd2 expression in foetal heart is lower than that in adult 
heart and it has been suggested by Moriyama and colleagues (Moriyama et al., 2001) 
that Ankrd2 could be involved regulation of development in heart. In addition to 
ankyrin repeats domains, Ankrd2 has a nuclear localization signal (KKKRK) and a 
PEST-like sequence (Kemp et al., 2000; Moriyama et al., 2001; Pallavicini et al., 2001). 
It also contains several predicted phosphorylation sites for the following kinases: casein 
kinase I (CKI), casein kinase II (CKII), protein kinase C (PKC), extra-cellular signal 
regulated kinase (ERK), cAMP-dependent protein kinase, calmodulin-dependent protein 
kinase II and cGMP-dependent protein kinase (Moriyama et al., 2001; Pallavicini et al., 
2001). In myotubes Ankrd2 is localized both in the nuclei in PML nuclear bodies and 
diffusely in the cytoplasm (Pallavicini et al., 2001). Ankrd2 has been shown to interact 
with other Z-disk proteins such as telethonin and non-muscle proteins such as p53 and 
transcription factors such as PML, and YB-1 (Kojic et al., 2004). These interactions 
support the idea that Ankrd2 could act a transcription co-factor and it has also been 
hypothesized that Ankrd2 could be a stretch sensor in skeletal muscle shuttling between 







1.9 Myotilin, Palladin and myopalladin family  
1.9.1 Myotilin 
The myotilin gene maps at the chromosome locus 5q31 and mutations in this gene are 
responsible for a dominantly inherited limb-girdle muscular dystrophy (LGMD1A). 
Myotilin is a 57kD myofibrillar protein that is highly expressed in skeletal muscle and 
only weakly in heart. It has a unique N-terminal rich in serine residues, a 23 amino acid 
hydrophobic region (57-79 aa), two Ig-like domains (252-341 aa ; 351-441 aa) that 
share a high sequence homology with the Ig domains 7 and 8 of human titin and a short 
C-terminal tail (Salmikangas et al., 1999). Myotilin binds F-actin and efficiently cross-
links actin filaments into bundles as well as being able to decrease the rate of F-actin 
depolymerization which suggests that it could be involved in thin filament stabilization. 
It is able to crosslink actin since it can dimerize via Ig-like domains. Myotilin is 
localized in the Z-disk where it binds directly to α-actinin-2 and filamin C, the first 214 
residues of myotilin bind to the spectrin-like repeats 3 and 4 of α-actinin-2 and the 
myotilin C-terminal region containing the Ig-like domains binds to the Ig-like domains 
19-21 of filamin C. (van der Ven et al., 2000). Over expression of the C-terminal 
myotilin had an effect on the assembly of myofibrils in differentiating C2C12 myotubes 
whereas over expression of full-length myotilin induced formation of thick actin cables 
in non-muscle cells devoid of endogenous myotilin suggesting that myotilin may have a 
role in stabilizing the assembled actin bundles (Salmikangas et al., 2003). Not only 
filamin C but also filamin-A, filamin-B and filamin-Bvar-1 variant bind to myotilin 
(Gontier et al., 2005). Myotilin has also been shown to bind to FATZ-2 (calsarcin-1 
/myozenin-2) and to the C-terminal region of FATZ-1 (calsarcin-2/myozenin-1) 
(Gontier et al., 2005). 
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Patients suffering from Limb girdle muscular dystrophy type 1 A (LGMD1A) have 
mutations in myotilin. These mutations were a C450T missense mutation which 
converted residue 57 from threonine to isoleucine but did not disrupt the binding with α-
actinin (Hauser et al., 2000). The other two mutations were S55F and T57I, both located 
in the N-terminal of myotilin but outside the filamin C binding site (Hauser et al., 2002). 
Mutations in myotilin as well as ZASP, filamin C, desmin and αβ-crystallin can cause 
myofibrillar myopathy (Griggs et al., 2007; Selcen and Engel, 2004). 
 
1.9.2 Palladin 
Palladin was simultaneously discovered by two different laboratories, the mouse 
palladin was discovered by (Parast and Otey, 2000), while the human palladin was 
discovered by (Mykkanen et al., 2001). The human palladin shares a 91% homology 
with the mouse palladin. Palladin is expressed in muscle and non-muscle fibres. In 
muscles palladin is highly expressed in smooth and poorly expressed in skeletal, while 
in non-muscle fibres it is highly expressed in prostate, testis, ovary, small intestine, and 
colon (Mykkanen et al., 2001). There are three isoforms of palladin and their expression 
depends on cell type; the first isoform is a 90-92 kD protein which is the most abundant 
isoform of palladin and widely expressed in many cells and tissues, another isoform is 
around 140 kD which is less abundant than the previous isoform and is mostly 
expressed in embryonic mice while in adult mice it is mostly detected in smooth 
muscles (Mykkanen et al., 2001; Parast and Otey, 2000), the third isoform is a 200 kD 
isoform first found in developing heart and then in embryonic and neonatal bone (Otey 
et al., 2005). Palladin contains three IgC2 domains, the first IgC2 domain towards the 
N-terminal shares high homology with the first IgC2 domain, Z-disk-associated IgC2 
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domains of titin, and with the C-terminal IgC2 domains of myosin light chain kinase, 
while the middle and the C-terminal IgC2 domains of palladin share high homology 
with the myotilin N-terminal IgC2 domain; palladin and myotilin share a high 
homology at their N-terminal and C-terminal. Alpha-actinin colocalizes with palladin in 
stress fibres, focal adhesions, cell-cell junctions and the embryonic Z-disk. Palladin 
plays an important role in the organization of actin cytoskeleton and focal adhesions in 
cultured trophoblasts and fibroblast cells (Parast and Otey, 2000). The expression level 
of palladin is highly reduced in a number of tissues including heart, skeletal muscle, 
liver, and kidney, which indicates that palladin could be involved in establishing the 
cytoskeletal organization of cells during differentiation being replaced by other proteins 
when the cells are fully differentiated (Parast and Otey, 2000). Recently palladin has 
been found mutated members of a family suffering from pancreatic cancer, the mutation 
caused a change of an amino acid proline (hydrophobic) to serine (hydrophilic) (P239S) 
in a highly conserved region of palladin, the mutation was not found in healthy 
members of the family. It has been suggested that this mutated palladin in pancreatic 
cancer may cause cytoskeletal changes in the pancreatic cancer cells and may be 
responsible for strong invasive and migratory abilities of these tumours (Ronty et al., 
2007).  
 
1.9.3 Myopalladin  
Myopalladin is a 145 kD protein that interacts with nebulin, nebulette and α-actinin in 
the Z-disk and with CARP in the I-band. These interactions are important for the 
integrity of the sarcomere since over expression of myopalladin leads to the disruption 
of the sarcomeric structure suggesting that it could link the regulatory mechanisms of 
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the Z-disk to muscle gene expression through its interaction with Ankrd1 (Bang et al., 
2001b). Myopalladin is expressed in skeletal and cardiac muscle and it is localized 
predominantly in the Z-disk and to narrow segments of the I-band on either side of the 
Z-disk. Myopalladin contains five Ig domains, the last three Ig domains towards the C-
terminal are most related to the Ig domains of palladin, whereas the last two Ig domains 
towards the C-terminal of myopalladin shares high homology with the Ig domains of 
myotilin. Apart from the homology at the Ig domain level that myopalladin shares with 
palladin and myotilin, myopalladin shares 63% homology through its C-terminal with 
the C-terminal of palladin which includes the last three Ig domains (Bang et al., 2001b).  
Myotilin, myopalladin and palladin form a family which shares high amino acid 
homology and also high homology at the level of the Ig domains. All three proteins 
function as scaffolds that regulate actin organization (Otey et al., 2005).  
 
 
1.10 The FATZ family 
The FATZ (also known as calsarcin and myozenin) family was independently 
discovered by three different groups (Faulkner et al., 2000; Frey et al., 2000; Takada et 
al., 2001). The family consists of three proteins FATZ-1 (myozenin-1 or calsarcin-2), 
FATZ-2 (myozenin-2 or calsarcin-1) and FATZ-3 (myozenin-3 or calsarcin-3) (Frey 
and Olson, 2002) that are localised in the Z-disk (Faulkner et al., 2000; Takada et al., 
2001). Then name FATZ denotes filamin C, alpha-actinin and telethonin binding 
protein of the Z-disk (Faulkner et al., 2000), while the name calsarcin denotes 
calcineurin associated sarcomeric protein (Frey et al., 2000). The FATZ family are 
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sarcomeric proteins localized in the Z-disk of striated muscle (Faulkner et al., 2000; 
Frey et al., 2000).  
FATZ-1 (myozenin-1 or calsarcin-2) and FATZ-3 (myozenin-3 or calsarcin-3) are 
highly expressed in differentiated skeletal muscle in fast-twitch fibres, whereas FATZ-2 
(myozenin-2 or calsarcin-1) is expressed in adult cardiac muscle in slow-twitch fibres 
(Frey and Olson, 2002; Frey et al., 2000). The three proteins share a high homology at 
the N- and C-termini and less homology in the intervening region, which may indicate 
that these conserved regions have functional properties and could be protein binding 
domains (Frey and Olson, 2002; Frey et al., 2000). The family members tend to interact 
with the same proteins, for example filamin A, B and C, α-actinin-2 and -3, telethonin 
(Faulkner et al., 2000; Takada et al., 2001) as well as calcineurin (Frey et al., 2000), 
myotilin (Gontier et al., 2005) and ZASP. FATZ-1, FATZ-2 and FATZ-3 bind strongly 
to nine different splice variants of ZASP, some of these splice variants had only the N-
terminal PDZ domain and lacked the three C-terminal LIM domains, suggesting that the 
LIM domains were not involved in the interaction between ZASP and FATZ (Frey and 
Olson, 2002; Zhou et al., 2001). 
The FATZ family members also interact with calcineurin (calcium/ calmodulin-
dependent serine, threonine phosphatase). The catalytic activity of calcineurin is not 
crucial for the interaction with all three FATZ proteins, since it has been shown that 
these proteins bind to a mutated subunit of CnA lacking enzymatic activity (Frey and 
Olson, 2002; Frey et al., 2000). Immunostaining experiments showed that the 
interaction between calcineurin and FATZ occurs in the Z-disk (Frey et al., 2000). 
Calcineurin can be detected in the nucleus as well as the cytoplasm suggesting that 
FATZ may have a role in interacting with and localizing calcineurin to the Z-disk (Frey 
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et al., 2000). There are other examples of intracellular proteins that bind and localize 
signalling proteins to specific sites, for example; a family of anchoring proteins called 
AKAPs (A-kinase anchoring proteins) has been shown to tether protein kinase A (PKA) 
to centrosomes (Edwards and Scott, 2000). There is evidence that over expression of the 
FATZ proteins can inhibit calcineurin in vitro, which allows speculation that the FATZ 
family can serve as inhibitors or activators of calcineurin (Frey et al., 2000). 
 
1.10.1 FATZ-1 (calsarcin-2, myozenin-1) 
Human FATZ-1 was mapped to chromosome 10q22.1 (Faulkner et al., 2000). The 
FATZ-1 gene has six exons that encode for a 32 kD sarcomeric protein that is localized 
in the Z-disk. (Faulkner et al., 2000; Takada et al., 2001). This protein is expressed in 
skeletal muscle and to a lesser extent in heart; its expression is upregulated during 
differentiation (Frey et al., 2000). The human and mouse FATZ-1 proteins share a 90% 
identity (Faulkner et al., 2000). 
Secondary structure predictions show that FATZ-1 has two alpha helical domains at the 
N-terminal (A1; 1-72 aa ) and at the C-terminal (A2; 87-244 aa) regions, with a glycine 
rich region (in the middle between residues 95-175) and a short C-terminal tail of 
approximately 55 amino acids (Takada et al., 2001). These three regions, the two alpha 
helical and the glycine-rich, have also been named as CD1 (1-71 aa), CD2 (171-299 aa) 
and GRD (75-171 aa) respectively (Faulkner et al., 2000). As mentioned previously, 
FATZ-1 binds to several muscle proteins and some of these binding sites have been 
mapped; both α-actinin and filamin C bind to the full length FATZ-1 protein more 
particularly its to its C-terminal region (Faulkner et al., 2000). The FATZ-1 binding site 
on α-actinin-2 was mapped to the region that spans the SR3 and SR4 spectrin-like 
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repeats (431–719 aa) whereas FATZ-1 binds to filamin C at repeat 23.close to the C-
terminal. (Faulkner et al., 2000; Takada et al., 2001). FATZ-1 also binds to telethonin 
(Faulkner et al., 2000), calcineurin and ZASP (Frey and Olson, 2002; Frey et al., 2000). 
Recently it was found that the C-terminal of FATZ-1 binds to myotilin. It was also 
shown that FATZ-1 was able to bind not only the C-terminal of filamin-C, but also to 
filamin-A, filamin-B and the newly discovered filamin-Bvar-1 (van der Flier et al., 2002). 
From immunofluorescence experiments in CHO cells transfected with both FATZ-1 and 
myotilin it was noted that the punctuated distribution pattern of FATZ-1 was lost and 
that the double transfection pattern resembled that of myotilin. This indicates that 
myotilin might have a direct or an indirect effect in reorganizing the subcellular 
distribution of FATZ-1, it has also been shown that FATZ-1 and myotilin are localized 
in the Z-disk (Gontier et al., 2005). 
Very recently two synonymous single nucleotide substitutions in FATZ-1 (Ser 50 and 
Leu 255) were found in the DNA of DCM patients. The DNA of these 185 unrelated 
DCM patients was amplified by PCR, analyzed by high performance liquid 
chromatography (DHPLC) and then the abnormal peaks were sequenced to detect any 
mutations. In the same study in one patient a 2-bp insertion (178insCA) in exon 2 of 
PDLIM3 was found that resulted in a stop codon (M60Tfs1X). The potential role of 
these mutations in the pathogenesis of DCM is still unknown however it was concluded  
that they do not play a significant role in the genetic etiology of the idiopathic DCM 
(Arola et al., 2007). However considering to the recent report of cardiac hypertrophy in 
patients as a result of mutations FATZ-2 (Osio et al., 2007) and given that the FATZ 
family members are part of an intricate network of interactions of Z-disk proteins 
mutations in FATZ-1 could play a secondary role in DCM. 
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1.10.2 FATZ-2 (calsarcin-1, myozenin-2) 
FATZ-2 (calsarcin-1/myozenin-2) has been mapped on chromosome 4q26-q27. The 
FATZ-2 gene encodes a 264 amino acid protein, with a predicted molecular weight of 
30 kDa (Frey et al., 2000). Human and mouse FATZ-2 have an 88% identity at the 
amino acid level. FATZ-2 is localised at the Z-disk and was shown to be expressed in 
skeletal and cardiac muscles during embryogenesis and development, and then 
expressed exclusively in adult cardiac muscles (Frey et al., 2000) . In situ hybridizations 
using FATZ-2 as a probe showed that it is predominantly expressed in heart muscles 
(Frey et al., 2000) however FATZ-2 is also expressed in skeletal muscle in slow-twitch 
fibres whereas FATZ-1 is present in fast-twitch muscle fibres (Frey et al., 2000). FATZ-
2 is abundantly expressed in porcine heart with a pattern similar to that of the human 
FATZ-2, which suggests that pigs could be suitable models for studying the function of 
FATZ-2 in heart disease (Wang et al., 2006).  
FATZ-2 binds to α-actinin-2, α-actinin-3, filamin C and the catalytic subunit of 
calcineurin (CnA). In Co-IP experiments CnA could only be immunoprecipitated with 
α-actinin in the presence of FATZ-2 which would suggest that these proteins form a 
trimeric complex (Frey et al., 2000). The C-terminal region (217-240) of FATZ-2 is 
important for the calcineurin binding. FATZ-2 and α-actinin-2 co-localise in the Z-disk 
and calcineurin is also localized in the Z-disk (Frey et al., 2000). Both FATZ-2 and 
FATZ-1 bind to ZASP, telethonin (Frey et al., 2004) and myotilin, (Gontier et al., 
2005). 
FATZ-2 is not required during embryogenesis and development since mice lacking 
FATZ-2 were normal and did not show any abnormalities. However in these mice the 
expression of calcineurin was increased supporting the idea that FATZ-2 negatively 
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modulates the activity of calcineurin. The up-regulation of calcineurin activated a foetal 
gene program associated with cardiac hypertrophy and although the hearts of FATZ-2 
null mice showed no hypertrophy there was a marked induction of the foetal gene 
program genes, ANF and BNP, suggesting that they are regulated by calcineurin (Frey 
et al., 2004). In FATZ-2 deficient mice the Z-disks of the heart appeared fuzzy and 
wider than normal with a significant increase (36%) in diameter. FATZ-1 and FATZ-3 
expression was not upregulated in the heart FATZ-2 null mice therefore they do not 
appear to compensate for the lack of FATZ-2 (Frey et al., 2004). To better understand 
the consequences due to the absence FATZ-2, transgenic mice expressing a 
constitutively active form of calcineurin in heart were bred with FATZ-2 null mice. 
Analyses of progeny hearts showed a high level of cardiac hypertrophy with an almost a 
fourfold increase in heart mass compared with normal mice. In addition calcineurin 
transgenic mice lacking FATZ-2 had a short lifespan and died by the age of 20-28 days 
(Frey et al., 2004). 
Recently mutations in FATZ-2 gene were found to co-segregate with hypertrophic 
cardiomyopathy (HCM). These mutations were a T to C missense which gave rise to a 
S48P substitution in 6 family members affected with HCM and another missense 
mutation A to G giving rise to an I246M substitution. The mutations were only detected 
in individuals with HCM and not in controls and unaffected family members (Osio et 
al., 2007). This linking of FATZ-2 to a genetic cardiomyopathy is very interesting and 
the authors suggest that these FATZ-2 mutations cause HCM by up-regulating 
calcineurin and activating pathways controlled by calcineurin. However these mutations 
are not in the region of FATZ-2 known to bind calcineurin or α-actinin therefore they 
speculate structural changes may occur that affect the interactions. However they also 
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admit that there may be completely different reasons, such as FATZ-2 interacting with 
proteins other than calcineurin to cause this disease. Very recently it has been shown 
that the FATZ-2 transcription is mediated by the transcription factors NF-kB, NFAT 
and MEF2 (Wang et al., 2007). 
 
1.10.3 FATZ-3 (myozenin-3/calsarcin-3) 
Human FATZ-3 is located on chromosome 5 locus 5q31 and contains 7 exons spanning 
19 kb (Frey and Olson, 2002). Two transcripts, one major (~ 3.5 Kb) and one minor (~ 
4k b), were detected by Northern blot analysis in mouse whereas in human there 
appeared to be several transcripts (Frey and Olson, 2002). The gene encodes a protein of 
251 amino acids with a predicted molecular weight of 27.6 kD. In the NCBI database 
there are two other isoforms of FATZ-3 noted; isoforms A and B, respectively 87 and 
205 amino acids. Human and mouse FATZ-3 share a 75% identity at the amino acid 
level. Both in human and the mouse FATZ-3 is specifically expressed in skeletal muscle 
and there is no detectable expression in cardiac muscle. FATZ-3 is expressed in mainly 
in fast-twitch fibres and co-localizes with α-actinin in the Z-disk (Frey and Olson, 
2002).  
FATZ-3 binds to several proteins including calcineurin, α-actinin-2, filamin C, ZASP 
and telethonin. The binding sites of calcineurin, α-actinin-2, ZASP and telethonin map 
to the same region of FATZ-3, an N-terminal region, between amino acids 50 and 67. 
However α-actinin-2 has another binding region between amino acids 186 and 207 and 
filamin C binds to the region between amino acids 67 and 110 (Frey and Olson, 2002). 
FATZ-3 as well as FATZ-1 and FATZ-2 binds both the short (without the LIM 
domains) and the long isoforms (with LIM domains) of ZASP/Cypher (Frey and Olson, 
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2002). It is notable that the FATZ family including FATZ-3 lack known interaction 
domains yet are able to bind so many different proteins. Since the N and C- terminal 
regions of all the FATZ proteins are the most highly conserved regions between the 
family members it is probable that these regions are the main sites of protein-protein 
interaction. 
 
1.11 The Enigma family 
The Enigma family of proteins is comprised of proteins that possess a PDZ domain at 
the N-terminal and one to three LIM domains at the C-terminal and are associated with 
the cytoskeleton and involved in signal transduction pathways. There are two subclasses 
of the Enigma family defined by the number of LIM domains; the Enigma subfamily: 
Enigma, Enigma homology protein (ENH) (Kuroda et al., 1996) and ZASP/Cypher 
(long isoforms have three LIM domains; short isoforms have no LIM domains); the 
ALP subfamily: comprising of RIL (Kiess et al., 1995), CLP36 (Wang et al., 1995), and 
actin-associated LIM protein (ALP) (Xia et al., 1997) have one LIM domain. All 
members have one N-terminal PDZ domain with a high degree of sequence identity, the 
PDZ domains of Enigma and RIL, CLP36, and ALP are 42, 47, and 44% identical (fig 
4). The PDZ domains of the Enigma Family members are distinguished by the amino 
acids P/S and W in place of G and L in the “GLGF” signature sequence of PDZ 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ENIGMA is also known as LIM mineralization protein (LMP), PDZ and LIM domain 
protein 7 (PDLIM7). Enigma is expressed in brain and skeletal muscle, where it 
localizes in the Z-disk (Guy et al., 1999). In cultured cells it is detected in the cytoplasm 
and membrane ruffles rich in actin filaments (Barres et al., 2005; Borrello et al., 2002). 
The Enigma protein is known to interact and co-localize with the short isoform of 
RET/PTC2, a chimeric oncoprotein isolated from papillary thyroid carcinoma and also 
with the short isoform of RET-wt and of its mutants (RET-C634R and RET-M918T) 
that are linked with multiple endocrine neoplasia (MEN2) syndrome. However Enigma 
binds very poorly and does not co-localize with the long isoforms of RET (Borrello et 
al., 2002) 
 
1.11.2 Enigma homologue protein (ENH) 
The name ENH comes from the high level of homology that is shared between the ENH 
and enigma protein, there is a 37% identity between the two proteins (Kuroda et al., 
1996). ENH is expressed in heart and skeletal muscle (Kuroda et al., 1996). It interacts 
with α-actinin through its PDZ domain and colocalizes with it at the Z-disk (Nakagawa 
et al., 2000; Niederlander et al., 2004). The LIM domains of EN bind to protein kinase 
C ß (PKCß) (Nakagawa et al., 2000). ENH is expressed also in various cancer cell lines 
(Nakagawa et al., 2000). 
There are four isoforms of ENH: ENH1, ENH2, ENH3 (Kuroda et al., 1996) and ENH4 
that was discovered later (Niederlander et al., 2004). All four isoforms have an N-
terminal PDZ domain however only ENH1 has three LIM domains at the C-terminal, 
while the other isoforms lack the LIM domains. This is similar to ZASP/Cypher that has 
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isoforms with and without LIM domains. The distribution pattern of different isoforms 
is specific, the short ENH4 isoform  is expressed only in skeletal muscle, the ENH3 
isoform both in skeletal and cardiac muscle, the ENH2 isoform in skeletal and ENH1 
isoform in cardiac muscle (Kotaka et al., 1999; Niederlander et al., 2004).  
 
1.11.3 ALP (Actinin associated LIM protein) 
ALP is a 39kDa muscle protein containing an N-terminal PDZ domain and a C-terminal 
LIM domain. Genetic mapping studies showed that ALP is located at the 4q35 locus on 
chromosome 4. It is found to be highly expressed in differentiated skeletal muscles, 
enriched in smooth muscle tissues such as arteries and a splice isoform is expressed at a 
low level in heart. (Xia et al., 1997). The ALP isoform in skeletal muscle (ALPSK) 
contains a central exon encoding 112 amino acids, which in the heart isoform (ALPH) is 
replaced by an exon encoding only 64 amino acids.The ALP-PDZ domain is 75 amino 
acids and shares a 55 %, 48 % and 45 % amino acid identity with the PDZ domains of 
CLP-36, RIL, and enigma respectively whereas the LIM domain of ALP shares a higher 
homology with the LIM domains of CLP36 and RIL about 67% (Xia et al., 1997). ALP 
also has a third domain which is the ZM motif that is also present in CLP-36 and ZASP 
(Klaavuniemi et al., 2004). Recently a third isoform of ALP has been found in zebrafish 
but this lacks the ZM motif (Te Velthuis et al., 2007). 
Studies using cultured myoblasts showed that the PDZ domain of ALP binds to the 
spectrin-like motifs of α-actinin-2, whereas the ZM motif of ALP was responsible for 
the interaction of ALP with the rod domain of alpha-actinin-2 and its localization at the 
Z-disk (Klaavuniemi et al., 2004). A mutation in the PDZ domain (L78K) abolished the 
binding of the PDZ domain to alpha-actinin (Xia et al., 1997) when the PDZ domain 
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was used alone whereas when the full length ALP protein was used in binding 
experiments this mutation (L78K) only reduced the binding with alpha-actinin-2 to 87% 
(Henderson et al., 2003). Immunostaining of intact myocardium showed that ALP is 
present in the intercalated discs, where it binds to α-actinin and γ-catenin. Disruption of 
the ALP gene causes right ventricular (RV) chamber dilation and dysfunction 
(Pashmforoush et al., 2001). 
 
1.11.4 RIL (Reversion induced protein) 
The reversion induced protein (RIL) was first discovered in mice by (Kiess et al., 1995) 
It is located on human chromosome locus 5q31.1 and has seven exons that code for 330 
amino acid protein. It is expressed in brain and lung and in a variety of cultured cells 
lines but not in muscle (Bashirova et al., 1998; Kiess et al., 1995; Schulz et al., 2004; 
Vallenius et al., 2004). RIL localizes in dendritic spines in cultured neurons (Schulz et 
al., 2004) and along stress fibres (Vallenius et al., 2004). It has an N-terminal PDZ 
domain (4-84 aa) and a C-terminal LIM domain (253-303 aa) (Bashirova et al., 1998; 
Cuppen et al., 1998; Kiess et al., 1995). A remarkable point about RIL is that its PDZ 
can bind to its LIM domain. RIL contains a tyrosine phosphorylation site ([RK]-(2,3)-
[DE]-x(2,3)-Y) within the LIM domain (Y-274), and it has been shown that the LIM 
domain of RIL can be phosphorylated by tyrosine in vitro and in vivo, and can be 
dephosphorylated in vitro by the PTPase domain of protein tyrosine phosphatase (PTP-
BL ) (Cuppen et al., 1998). It is expressed in brain and heart of adult mice. In brain 
there is another isoform of RIL encoded by a transcript lacking exon six, the exon that 
codes for the LIM domain (Bashirova et al., 1998; Kiess et al., 1995). There is a high 
(96%) identity between mouse and human RIL.  
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The C-terminal of RIL can bind to the second and the fourth PDZ domains of PRP-BL 
(which contains five PDZ domains). Surprisingly deleting the last four amino acids of 
RIL did not affect its binding to the PDZ II and PDZ IV domains of PRP-BL. This is an 
unusual characteristic as PDZ domains usually bind the last four amino acids of the C-
terminal their binding proteins (Cuppen et al., 1998). RIL binds to α-actinin and 
localizes to actin stress fibres as does CLP-36 and also enhances the binding of α-
actinin to actin filaments suggesting that RIL has a role in modulating actin stress fibre 
dynamics through its binding to α-actinin (Vallenius et al., 2004). 
RIL has been found to be deleted in patients with myelodysplasia and myeloid leukemia 
(Bashirova et al., 1998). Recently, it was found that RIL was highly methylated in 60% 
of patients (55 out of 92) with acute myeloid leukemia (AML) and colon cancer, 
whereas in normal tissues RIL was not or only poorly methylated. These data lead to the 
speculation that RIL could be a good candidate for a tumour suppressor gene (TSG) 
silenced by hypermethylation (Boumber et al., 2007). 
 
1.11.5 CLP-36 (hCLIM1, Elfin) 
C-terminal LIM domain protein (CLP) (Wang et al., 1995) also known as, human 36-
kDa carboxyl terminal LIM domain protein (hCLIM1) (Kotaka et al., 1999) and Elfin 
(Kotaka et al., 2001), is a 36kD protein first discovered in rat. CLP-36 is highly 
expressed in heart, lung and liver, moderately in spleen and skeletal muscle and at low 
levels in testis and brain tissue (Wang et al., 1995). CLP-36 belongs to the Enigma 
family of proteins, it has an N-terminal PDZ domain (1-89 amino acids) as well a LIM 
domain at the C-terminal region (258-310 amino acids). It also shares an overall identity 
of 41.1%  with the rat RIL protein (Kiess et al., 1995; Wang et al., 1995). 
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The rat CLP-36 shares an 87.8% homology at the amino acid level with the human 
CLP-36 (hCLlM1). FISH and radiation hybrid experiments showed that the human 
HCLIM1 gene maps on chromosome 10, position 10q36 (Kotaka et al., 1999). The 
CLP-36 protein belongs to the ZM motif family, as it contains a central ZM motif 
between the PDZ and the LIM domains (Klaavuniemi et al., 2004). 
In the epithelial cells the LIM domain of CLP-36 binds to C-terminal EF hand region of 
α-actinin-1 and -4. Analyses such as immunoprecipitation and matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry indicate that both α-actinin-1 
and α-actinin-4 form complexes with CLP-36. The CLP36-LIM domain also binds to 
the C-terminal EH-hand region of α -actinin-2; this interaction is localized at the Z-disk 
and is abrogated when the LIM domain is truncated. On the other hand the PDZ domain 
of CLP-36 binds to the spectrin-like repeats of all the α-actinin isoforms (Bauer et al., 
2000; Kotaka et al., 2000; Vallenius et al., 2000). Vallenius and colleagues have shown 
that by deleting the first 24 amino acids of the CLP-36 PDZ domain they can eliminate 
the binding of CLP-36 to α-actinin and consequently its localization to stress fibres 
(Vallenius et al., 2000). Another binding protein of CLP-36 is vinculin; a protein that 
serves as an anchor for actin and actin-binding proteins in the cell membrane. Vinculin 
and CLP-36 colocalize at the intercalated disks that are the specialized regions of the 
plasma membrane that connect the cardiac muscle cells. The interaction and localization 
of CLP-36 and vinculin is thought to be mediated via the interactions of the two 







Z-disk alternatively spliced PDZ motif protein (ZASP) (Faulkner et al., 1999) is also 
known as Cypher (Zhou et al., 1999) or Oracle (Passier et al., 2000) in mice. ZASP is a 
32 kD protein that maps on chromosome 10q22.3-10q23.2. The protein is highly 
expressed in skeletal and to a lesser extent in heart muscles in embryonic and adult 
tissue. Immunostaining experiments showed that ZASP is localized in the Z-disk 
(Faulkner et al., 1999). ZASP belongs to the Enigma family of proteins, the members of 
which all have a N-terminal PDZ domain and one or more LIM domains at the C-
terminal (Te Velthuis et al., 2007). The human ZASP gene consists of 16 exons and has 
several isoforms; to date six isoforms have been found C1/Z1, C/Z2, C/Z3, C/Z4, C/Z5 
and C/Z6. The human isoforms 2 to 5 contain both an N-terminal PDZ and three C-
terminal LIM domains whereas isoforms 1 and 6 contain only the PDZ domain. The 
PDZ domain of ZASP is encoded by exons 1, 2 and 3, while the LIM domains are 
encoded by exons 12-16 (Vatta et al., 2003). The ZASP isoforms containing exon 4 are 
expressed in cardiac muscle, whereas the isoforms containing exon 6 are expressed in 
skeletal muscle (Huang et al., 2003). ZASP also contains a third domain known as the 
ZM motif which is encoded by exons 4 and 6 (Klaavuniemi et al., 2004). 
ZASP interacts with α-actinin in two different regions, the PDZ of ZASP binds to the 
EH-hand region of the C-terminal of α-actinin whereas the ZM motif that binds to the 
rod region of α-actinin. ZASP co-localizes with α-actinin in the Z-disk whereas the LIM 
domains interact with and are phosphorylated by all 6 isoforms of protein kinase C 
(PKC α, ß1, γ, ζ, δ, and ε), and ZASP is by PKC (Klaavuniemi and Ylanne, 2006; Zhou 
et al., 1999).  
Introduction 
50 
ZASP is important for the stability of the Z-disk. In fact, ZASP knockout mice die in the 
first 24 hour after birth from a severe form of congenital myopathy as a result of 
functional failure of striated muscles, these mice also showed symptoms of heart failure. 
The structure of the Z-disk was analyzed in ZASP null mice; contracting skeletal and 
cardiac muscle tissue showed abnormality in the Z-disk, while a normal structure was 
found in the non-contracting embryonic diaphragm muscles. These observations 
suggested that although ZASP may not be required for the formation of protein 
complexes during sarcomerogenesis, it is however essential in maintaining Z-disk 
stability during muscle contraction (Zhou et al., 2001). Mutations in exon 4 of ZASP 
gave rise to mutations in the ZASP protein (T213I and S196L) found in patients with 
isolated non-compaction of the left ventricular myocardium (INLVM) whereas 
mutations in exon 6 resulted in mutations (D117N and K136M) in the ZASP protein 
found in patients with INLVM and DCM. Both sets of mutations were located in the 
region coding for the ZM motif (Klaavuniemi et al., 2004; Vatta et al., 2003). 
The PDZ of ZASP is a classical class I PDZ domain which binds to the C-terminal of 
aα-actinin-2 (calmodulin-like domain/ EF-hand region). The ZASP-PDZ domain 
consists of 85 amino acids and the crystal structure shows a high similarity with the 
third PDZ domain of the human disk large protein (DlgA). The structure of the ZASP 
PDZ domain is similar to other PDZ domains in that it consists of 6 beta sheets and 2 
alpha helices organized as follow (ß1, ß2, ß3, α1, ß4, ß5, α2 and last ß6). ß2 and α2 
form the groove that starts from the conserved ‘PWGF’ loop (residues P9, W10, G11 
and F12) in the PDZ domain of human ZASP and (residues P11, W12, G13 and F14) in 
the PDZ domain of Cypher, the mouse form of ZASP. The ZASP PDZ domain contains 
a unique tryptophan at the N-terminal portion of ß2. This groove is the active site for 
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interaction in PDZ class I and it is the site of the interaction between the α-actinin C-
terminal region and the ZASP-PDZ domain (Au et al., 2004). It has also been shown 
that a mutation in the PDZ of ALP (L78 to K78) abolished its binding with α-actinin 
(Xia et al., 1997). Therefore mutations were made in the PDZ region of Cypher in order 
to study in more detail its interaction with α-actinin; these mutations were G14 to A14, 
F15 to A15 and L76, L77 and L78 to K (Au et al., 2004; Zhou et al., 2001). These 
mutations managed to disrupt the binding of Cypher with α-actinin and hence its 
localization in the Z-disk (Zhou et al., 2001) indicating that the mutations may disrupt 
the folding of the Cypher PDZ domain . 
 
1.12 PDZ domains 
PDZ proteins were first recognized as a group of proteins found at cell-cell junctions 
that had a common structural domain of 80-90 amino acid residues named PDZ for the 
first identified three proteins PSD-95 (a 95 kDa neuronal PDZ protein that associates 
with receptors and cytoskeletal elements at synapses), Dlg (the Drosophila 
melanogaster Discs large protein), and ZO-1 (the zonula occludens 1 protein that is 
involved in maintenance of epithelial polarity) (Cho et al., 1992; Kim et al., 1995; 
Woods and Bryant, 1993) Originally the domain was known as Discs-large homology 
regions (DHRs) or GLGF repeats since there are four highly conserved residues within 
the domain (Gly-Leu-Gly-Phe) (Hung and Sheng, 2002). The PDZ domains have been 
found in a wide variety of proteins from bacteria to mammals, they are usually around 
90 kDa and are involved in protein-protein interactions normally binding proteins 
through their C-terminals (last 4 to 6 amino acids) but in some cases they can also bind 
internal regions of proteins (Bezprozvanny and Maximov, 2001). 
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SMART (a simple modular architecture research tool) database lists about 1,163 PDZ 
domains in 484 human proteins, 259 PDZ domains in 153 Drosophila melanogaster 
proteins, 130 PDZ domains in 95 Caenorhabditis elegans proteins and 26 PDZ domains 
in 23 Arabidopsis thaliana proteins while there are only 3 PDZ-like domains in 
Saccharomyces cerevisiae and 5 in Escherichia coli (Schultz et al., 2000). PDZ domains 
also exists in plants but they are quite rare (Venter et al., 2001) and it has been 
suggested that PDZ-like domains may have entered the plant and bacterial genomes by 
horizontal genetic transfer (Pallen and Ponting, 1997). It is interesting that the PDZ-like 
domains in plants and bacteria share a similar secondary and tertiary structure but have 
different topology (Hung and Sheng, 2002). 
PDZ domains can occur as a single copy within the protein such as (Veli1 and ZASP) or 
as multiple copies, which is the most common form of PDZ containing proteins. The 
number of PDZ copies can reach up to 13 as for example in MUPP1 (multi-PDZ 
domain protein1) (Harris and Lim, 2001). One of the speculations regarding the 
existence of multiple PDZ domains in a single protein, is that this multiplicity can serve 
as a (glue) binding different proteins simultaneously to form supramolecular complexes 
that can serve in cell signalling and protein targeting (Schultz et al., 1998). 
 
1.12.1 Structure and binding characteristics of PDZ domains 
In a review Huang and Sheng, give an overview of X-ray crystallographic studies of 
PDZ domains in complex with their cognate peptide ligands a method that enabled the 
identification of the structural basis for the binding specificity of PDZ domains (Hung 
and Sheng, 2002). The first solved PDZ domain crystal structure was that of the PDZ3 
domain of PSD-95 (Doyle et al., 1996) followed by other PDZ structures, such as PDZ2 
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of PSD-95, the PDZ of CASK, syntrophin, Neuronal nitric oxide synthase. These 
structures of these proteins were solved by x-ray crystallography and/or NMR (Hung 
and Sheng, 2002). The general structure of the PDZ domain consists of six beta sheets 
(ßA- ßB- ßC- ßD- ßE and ßF) and two alpha helices (αA and αB). The six beta sheets 
fold as a beta sandwich domain. The N- and C-terminals of the PDZ domain are close to 
each other in the folded structure, which makes these domains highly modular and 
raises the speculation that these domains could have entered existing proteins without 
any significant structural change during evolution (Harris and Lim, 2001). Both the ßB 
and the αB of the PDZ domain form a groove in which the end of the peptide or the C-
terminal of the protein bind as an anti parallel beta sheet (Fig 5). This mechanism is 
known as beta strand addition (Harrison, 1996). Structural analyses of both the free and 
complexed peptide of the PDZIII of PS D-95 show that both forms are almost identical 
therefore the binding of the peptide does not change the structure of PDZ domains 
(Doyle et al., 1996). Between the ßA and the ßB sheets there is a conserved loop (R/K-
XXX-G-ФGФ or GLGF motif) which creates a hydrophobic cavity that surrounds the 
C-terminal of the binding protein. Studies have shown that in some PDZ domains the 
first glycine of the GLGF motif can be substituted by a threonine or a serine but the 
second glycine is highly conserved (Jelen et al., 2003). 
 
1.12.2 Why do PDZ domains bind specifically to the C-terminal of proteins? 
The PDZ domain structure is folded in a way that is suitable for binding to a free 
carboxylate group at the end of the binding protein or peptide. The ßA and ßB are 
connected to each other through a loop which contains a highly conserved arginine or 
lysine residue (at position 318 in PDZ3 of PSD-95) of the Gly-Leu-Gly-Phe (GLGF) 
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sequence motif, this loop is also known as “carboxylate-binding loop”. Through this 
loop both ßA and ßB form a pocket which has hydrophobic characteristics that 
surrounds the C-terminal of the peptide. The GLGF motif contains three main-chain 
amide protons that form hydrogen bounds with the C-terminal of the binding protein or 
ligand plus the guanidinium group of arginine at position 318 interacts with the 
carboxylate anion via a water molecule (Doyle et al., 1996). “Since a free carboxylate 
binding group only exists at the very end of the polypeptide chain, the interactions 
between the carboxylate-binding loop and the carboxylate oxygens form the structural 
basis for the PDZ recognition of C-terminal peptides” (Sheng and Sala, 2001). The 
pocket that is formed by the ßA and the ßB sheets with the carboxylate binding loop in 
the middle is generally hydrophobic in many PDZ domains, which makes it common 
that most if not all PDZ domains select a peptide with a hydrophobic C-terminal. In the 
case of the PDZ 3 domain of PSD-95, valine is the preferred amino acid at position 0 
the last reside of the peptide (Niethammer et al., 1998). The amino acid at position 0 
varies between different PDZ domains; this is due the differences in the size and 
geometry of the hydrophobic pocket in these domains. Normally valine, leucine, 
isoleucine, phenylalanine or alanine are found at position 0 of the PDZ binding peptide 
(Songyang et al., 1997). However the hydrophobic amino acid at the end of the peptide 
is not always selective as is the case of the PDZ domain of PSD-95, it can bind as well 
to a peptide that ends with an isoleucine or leucine even if the preferred amino acid is 
valine (Cohen et al., 1996; Songyang et al., 1997).  
Not only is position 0 important or crucial for the interaction with PDZ domains, 
position 2 is also very important and plays a big role in the classification of PDZ 
domains. For example the PDZ domains of PSD-95 and some other PDZ proteins select 
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a threonine or serine at position 2. The crystal structure of this domain shows that the 
threonine at position 2 forms strong hydrogen bound with the N-3 nitrogen of histidine-
372, which is in the first position of the αB1. This bond can also occur with the serine at 
position 2 of the peptide. These type of PDZ domains are classified as PDZ class I. 
Proteins containing class II PDZ domains such as LIN-2/CASK and p55 have valine 
instead of histidine at position αB1 which preferentially binds to a phenylalanine or 
tyrosine at position 2 of the peptide (Songyang et al., 1997). For class III PDZ domains 
such as nNOS, the domain contains a tyrosine at the αB1 position that selects for 
negatively charged amino acids at position 2 of the C-terminal of the ligand such as 
aspartate (Stricker et al., 1997; Tochio et al., 1999). Positions 1 and 3 of the PDZ 
binding peptide are predicted to have an influence on the specificity of the PDZ domain 
binding but not as strong as that of positions 0 and 2 (Sheng and Sala, 2001). For 
example; substitution of D for S (–QTSV to –QTDV) at position 1 of the CRIPT C-
terminal protein changed the binding of the peptide from a PDZ III to a PDZ II 
(Niethammer et al., 1998). Position 3 of the CRIPT protein which contains glutamine 
(QTSV) forms hydrogen bounds via its oxygen with the residues Asn-326 ßB2 and Ser-
339 ßC4 in the PDZ domain of PSD-95 (Doyle et al., 1996). Even though the glutamine 
at position 3 interacts with two amino acids on the PDZ domain (Asn-326 ßB2 and Ser-
339 ßC4), position 3 is not as critical as position 2 for binding to PDZ domains 
(Songyang et al., 1997). Not only positions 0, 1, 2 and 3 influence the binding, it has 
also been demonstrated that positions up to 8 can influence the binding of the C-
terminal to PDZ domains (Kozlov et al., 2000; Niethammer et al., 1998; Songyang et 
al., 1997).  
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PDZ domains in some rare cases can bind to internal sequences however this can occur 
only if these sequences form a specific tertiary structure that mimics a chain terminus. 
The best studied example of this is the interaction between the PDZ domain of nNOS 
and the PDZ domain of either syntrophin or PSD-95. The internal sequence of the 
nNOS PDZ domain forms a heterodimer with either the PSD-95 or the syntrophin PDZ 
domain. This occurs because the nNOS PDZ domain contains a 30 residue extension, 
which forms a ß-hairpin structure that can dock inside the peptide binding pocket of the 
syntrophin or the PSD-95 PDZ domain, forming an unusual head-to-tail interaction 
(Christopherson et al., 1999). 
 
1.12.3 Classification of PDZ domains 
PDZ domains can be classified using two different approaches. The first type of 
classification is based on the sequence of the ligand or the C-terminal of the binding 
protein. Through that approach PDZ domains were classified into three different 
classes; PDZ I, II, and III and as mentioned above, position 2 is very important for this 
type of classification. In class I PDZ domain proteins, for example PSD-95, Dlg and 
ZO1, the amino acids serine or threonine are usually found at position 2 and the binding 
peptide sequence is X-[S/T]-X-Ф (where Ф is any hydrophobic amino acid and X is any 
amino acid). Class II PDZ domain proteins, for example PICK2 and CASK 
(calcium/calmodulin-dependent serine protein kinase), usually have a hydrophobic 
residue at position 2 and a common binding peptide sequence of X-Ф-X-Ф (Songyang 
et al., 1997). PDZ class III proteins which include nNOS (neuronal nitric oxide 
synthase) have a preference for a negatively charged residue on the position 2 of the 
binding peptide, the common motif being-X-[D/E/K/R]- Ф (Stricker et al., 1997). In 
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some cases PDZ domains are able to bind to peptides from two different classes 
indicating that these classifications are still far from being perfect. For example 
syntenin, a 32kDa protein that interacts with many cell membrane receptors, contains 
two PDZ domains, the PDZI domain is able to bind peptides from class I and III, while 
the PDZ2 domain is able to bind peptides from classes I and II (Kang et al., 2003). 
The classification used by the Eukaryotic Linear Motif (ELM) resource for predicting 
functional sites in eukaryotic proteins also depends on the last four amino acids of the 
PDZ binding peptide and is quite similar to that outlined above only more precise in 
choosing the sequence of the four amino acids (www.elm.eu.org). This program uses 
the -X-[S/T]-X-[VIL] motif for ligands binding to class I PDZ domains, the -X-[VYF]-
X-[VIL] motif for ligands binding class II PDZ domains and the -X-[DE]-X-[VIL] 
motif for ligands biding to class III PDZ. 
The second approach of classification is based on the two critical positions of the PDZ 
domain; the first position is that of the amino acid immediately following the second ßB 
strand referred to as Pos1 and this is usually a glycine (G). The second critical amino 
acid position is the first position in the second αB helix designated as Pos2; this is 
usually a histidine (H). Based on this approach and by analyzing the PDZ domain 
protein listed in the SMART database (http://smart.embl-heidelberg.de) Bezprozvanny 
and Maximov, classified the PDZ domains into 25 different groups based on the polarity 
and/or bulkiness of these two amino acids (Bezprozvanny and Maximov, 2001). 
However Vacarro and Dente (Vaccaro and Dente, 2002) have shown that this type of 
PDZ domain classification based on only the two conserved amino acids in the 
hydrophobic pocket is difficult, especially since there are other positions involved in the 
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recognition of the binding peptide. Two of the 25 groups did not correspond to any 
known PDZ domains, (G, n) and (a, p) that should have Glycine (Pos1) and a negative 
amino acid (Pos2) and an aromatic amino acid (Pos1) and a polar amino acid (Pos2), 
respectively. Another problem is that of the remaining 23 groups only 9 had known 
ligand sequences. Of these one corresponded to PDZ domain proteins classified as 
binding to class I motifs, this group had G at Pos1 and H at Pos2. Four groups can be 
unified as PDZ class II and one group includes PDZ domains that are known to have 
dual specificity (Vaccaro and Dente, 2002). Vacarro and colleagues have shown 
experimentally that the substitution of the histidine in the crucial position αB (Pos 1) of 
hINADL-7 (class I binding PDZ domain) is not sufficient to change its binding 
specificity and ligand preference (Vaccaro and Dente, 2002). In order to classify PDZ 
domains on the basis of their hydrophobic pocket it is important to consider all the 
positions that are responsible and can influence the binding plus the corresponding 
sequence of the ligands. In conclusion, it would appear that the classification of PDZ 
domains and the specificity of their ligands are still not very clear and it will require 
further experimental and bioinformatics studies to be done. 
 
1.12.4 The effect of phosphorylation on C-terminus binding 
Most ligands that bind PDZ domains have a serine, threonine or tyrosine reside at the 
position 2 or 3 of the peptide. I have mentioned before that these positions are important 
for the interaction between the ligand and the PDZ domain, especially position 2. The 
phosphorylation of the amino acids in these positions can affect the binding positively 
or negatively. For example: PKA kinase phosphorylation of the amino acid at position 2 
of the C-terminus of the inward rectifier K channel (Kir 2.3) protein resulted in 
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disruption of the binding of this protein with the PDZ domain of PSD95 (Cohen et al., 
1996). On the other hand, recent studies demonstrated that phosphorylation can also 
increase the strength of the interaction. Phosphorylation of the C-terminal peptide of the 
mitochondrial ribosomal protein MRP2 increased its binding to the three different PDZ-
containing proteins PDZK1 (PDZ domain containing-protein), IKEPP (intestinal and 
kidney enriched PDZ protein) and EBP50 (ezrin-radixin-moesin binding 
phosphoprotein-50) (Hegedus et al., 2003). Normally in proteins with internal PDZ 
domains either hetero or homo interactions occur usually between PDZ domains of the 
same protein, for example, the PDZ 3 and 4 of INAD can bind to each other and form 
homo-dimers (Xu et al., 1998). 
 
1.12.5 The multiplicity and function of PDZ domains 
As mentioned above, PDZ domains can occur as a single copy as in ZASP, RIL and 
Veli1 or as multiple copies in the same protein normally as tandem repeats one after the 
other. It has been shown that 18% of the human PDZ-domain containing proteins have 
three or more PDZ domains in the same protein, the highest number being in the 
MUPP1 protein that contains 13 PDZ domains. PDZ containing proteins can also 
contain other domains in the same protein such as LIM domains as in the Enigma 
family of proteins (Harris and Lim, 2001) (Fig 6).  
Based on experimental data several hypotheses have been made regarding the frequency 
of PDZ domains. For example, syntenin that has two PDZ domains in tandem needs 
both for binding other proteins. The PDZ2 domain of syntenin can bind the C-terminal 
of syndecan, neurexin, and ephrin-B1 but only with the help of PDZ1 or another copy of 
PDZ2 but not alone (Grootjans et al., 2000). In this case it appears that multiplicity is 
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crucial for binding. Another study showed that some PDZ domains can play a role in 
influencing the folding of an adjacent PDZ domain. For example, nuclear magnetic 
resonance (NMR) and circular dichroism spectroscopy (CD) experiments showed that 
when alone the PDZ5 domain of GRIP was unstructured and lost its binding with 
GluR2. However when PDZ5 was connected with the PDZ4 domain of GRIP it became 
highly structured and the binding with GluR2 was restored (Zhang et al., 2001). It has 
been suggested that multiple PDZ domains can allow a protein to bind several other 
proteins simultaneously, thereby assembling large proteins complexes (Harris and Lim, 
2001; Sheng and Sala, 2001). PDZ-based complexes are often localized to specific 
subcellular compartments where PDZ-based scaffolds have been shown to organize 
signal transduction pathways. For example, the photo-transduction pathway in 
Drosophila, where ion channels and signalling molecules are co-assembled by the 
multi-PDZ protein InaD (Montell, 1998; Tsunoda and Zuker, 1999). The first human 
disease related to a mutation in a PDZ domain was the Usher syndrome type 1C, an 
autosomal recessive disorder characterized by congenital sensorineural deafness, 
vestibular dysfunction, and blindness (Montell, 2000; Verpy et al., 2000). In a very 
recent study it was found that the over expression of the PDZ domains of syntenin (2 
PDZ domains) increased cancer cell invasion in vitro. Therefore syntenin could be a 
potential biomarker and drug target for breast, gastric and melanoma cancer 
(Meerschaert et al., 2007). An in vitro study on the ZASP/Cypher protein showed that 
mutations (G14A, F15A and L78K) in its PDZ domain blocked its binding with α-
actinin 2 therefore it was no longer able to co-localize in the Z-disk with α actinin 2 but 
rather showed a diffused pattern inside the cell. This demonstrates the role of PDZ 
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domains in binding and localizing proteins to different subcellular regions (Zhou et al., 
2001).  
PDZ domain proteins can also contain other domains such as LIM, SAM, SH3, CaM, 
GUK and ankyrin repeats (Jelen et al., 2003). A recent study on PDZ/LIM family 
proteins noted that there are ten mammalian PDZ proteins that contain both PDZ and 
several LIM-domains. These proteins are members of the Enigma family proteins [ALP, 
RIL, Elfin (CLP36), Mystique, Enigma (LMP-1), enigma homologue (ENH), ZASP 
(Cypher/ Oracle)], LMO7 and the two LIM domain kinases (LIMK1 and LIMK2) (Te 
Velthuis et al., 2007). It has been suggested that cytoskeletal proteins belonging to the 
PDZ-LIM family serve as adapters for direct binding of LIM- proteins to the 
cytoskeleton (Vallenius et al., 2000). The precise function of PDZ domains is still not 
clear and also their classification needs to be better defined. Studies to-date on PDZ 
proteins definitely show that they have an important role in multiple protein-protein and 
















Figure 5. The structure of a PDZ domain complexed with a C-terminal peptide ligand, 
based on PDZ3 of PSD-95 complexed with CRIPT (Doyle1996; Niethammer 1998). 
The ribbon diagram of the PDZ domain (gray) is shown bound to the peptide ligand 
(yellow). The structures in A and B are slightly rotated relative to each other to show 
particular sets of interactions. A. The free carboxylate group (orange) of the C-terminal 
residue (0 position) of the peptide interacts with the conserved amino acids (Arg-318 
and G-L-G-F) of the carboxylate binding loop (red). The side chain of the -3 residue 
(glutamine; light green) interacts with βB2 (asparagines, red) and βC4 (serine; dark 
green). B. The hydroxyl group of the -2 residue (threonine; light blue) interacts with the 
side chain of αB1 (histidine; dark blue). The side chain of the -1 residue (serine; light 
purple) of the CRIPT peptide shows no interactions with the PDZ domain. However, 
¯ B2 and ¯ C5 residues (dark purple) are likely to influence selectivity at the -1 position 









Figure 6. Modified figure showing the modular organization of PDZ-containing proteins. 












AlphaScreen is an Amplified Luminescent Proximity Homogeneous Assay that is non-
radioactive, homogeneous proximity assay that relies on hydrogel coated Donor and 
Acceptor beads providing functional groups for conjugation to biomolecules. In the 
AlphaScreen assays, a signal is generated when a donor and an acceptor bead are 
brought into proximity by an interaction between the two conjugated biomolecules. The 
laser excitation at 680 nm of a photosensitiser (phthalocyanine) present on the Donor 
bead results in the production of singlet oxygen. The short lifetime of singlet oxygen in 
aqueous solution (~4 µsec) allows diffusion over a distance up to ~200 nm. The singlet 
oxygen migrates to react with a thioxene derivative in the Acceptor bead generating 
chemiluminescence at 370 nm that further activates fluorophores contained on the same 
bead emitting light at 520− 620 nm. This reaction cascade results in amplification of the 
signal that can be detected at the attomolar level. In the absence of a specific biological 
interaction, the singlet state oxygen molecules gave a very low background signal. The 
half-life of the decay reaction is 0.3 sec, which allows the technology to operate in a 
time-resolved mode ensuring a reduced background by minimizing the effect of auto-
fluorescence. Also a long excitation wavelength of 680 nm combined with a shorter 
emission wavelength of 520−620 nm reduces interference from biological or assay 
components.  




The AlphaScreen method was used to evaluate the strength of protein-protein bindings, 
to study the interactions occurring when more than one binding partner of a protein is 
present and also to eliminate the suspicion that there is an intermediary protein present 
as can be the case in experiments using cell lysates and in vitro transcripted translated 
protein. The AlphaScreen was done in collaboration with the Genome Research Group, 
CRIBI, University of Padua. This group has a Fusion-alpha microplate analyzer 
(Packard Bioscience) which is a universal multiplate analyzer designed to measure top 
and bottom fluorescence intensity, time-resolved, fluorescence, absorbance and 
luminescence. At present the protocol used is to biotinylate the protein to be used as 
Donor (usually a His tagged protein) and bind it to Streptavidin-Donor beads. The 
proteins used as Acceptors (Glutathione S-transferase [GST]-tagged proteins) are bound 
to the Glutathione-Acceptor beads, the opposite combination is also possible as both 
GST and His detection kits are available. 
2.1.1 AlphaScreen Experiments 
Alphascreen experiments were performed using His tagged proteins, GST fusion 
proteins or peptides. Experiments were done using 384-well plates (OptiPlate-384 white 
opaque, Packard BioScience) in a final volume of 25 µl per well. Both the GST 
detection and the His detection Kits for AlphaScreen were used according to the 
manufacturer’s specifications (Perkin Elmer). The acceptor and donor beads were used 
at a concentration of 0.02 µg/µl (6.5 pM). First the protein to be tested was added to the 
wells and the acceptor beads were immediately added. The following steps were done in 
the dark. The plate was incubated for 30 minutes at RT before adding the donor beads 
and incubated for 3 hours, then kept for 15 minutes at 28 ˚C to equilibrate the 
temperature before reading. The signal was read at 28°C using a Fusion 




AlphaTMMultilabel Reader (PerkinElmerTM) at 300 ms excitation, 700 ms emission.3. 
When testing a protein for binding it was titrated against the partner protein in order to 
establish the concentration of both proteins that resulted in a significant value for the 
ratio of the signal(S) to noise (N), normally in the range of S/N 8-50. In every 
experiment negative controls without one or both proteins were used to measure the 
background (noise) level. The experiments were repeated at least 3 times, to reduce the 
possibility of false results. Also biotinylated GST (0.5nM) or biotinylated His (1nM) 
were used as internal controls to normalize the signal readings. In competition 
experiments the binding proteins were first added to the wells at a fixed concentration 
that would result in binding in the absence of a competitor. Then the protein used as 
competitor was added at decreasing concentrations. 
The Ratio is calculated as the mean of the normalized Signal divided by the mean of the 
normalised Noise ie 
Nm
Sm
R =  
The confidence of the ratio is calculated from the standard deviation of the Signal and 






















Sm = normalized signal mean;  dSm= mean standard deviation of normalized signal 
Nm = normalized noise mean;  dNm= mean standard deviation of normalized noise 
 
For competition experiments using AlphaScreen the concentration at which both 
proteins gave good binding was kept fixed and the possible competitor protein was 
added at variable concentrations. The result was plotted as the ratio obtained by dividing 
the signal in the presence of the competitor by that of the signal in the absence of the 




competitor. The experiments were repeated at least three times and the values for the 
mean as well as the standard deviation from the mean of the samples were plotted. 
 
2.2 Antibodies 
2.2.1 Primary Antibodies 
The following antibodies were obtained commercially. 
Anti-c-myc mouse monoclonal clone 9E10, ascites fluid (M5546, SIGMA)  
Anti-FLAG M2 mouse monoclonal antibody (F 2426, SIGMA) 
Anti-HA (F-7) mouse monoclonal antibody (sc-7392, Santa Cruz Biotechnology) 
Anti-GFP polyclonal antibody (46-0092, Invitrogen) 
Anti-GST polyclonal antibody made in goat (27457701, GE Healthcare): 
Anti-6xHis monoclonal antibody albumin free (631212, BD Biosciences) 
Anti-GFP HRP conjugated polyclonal antibody made in goat (66633-100, Abcam), 
allows the detection of the GFP fusion protein without the detection of the heavy and 
light chain of the IgG. 
The following antibodies were produced in house by Dr. G Faulkner, MMB, ICGEB. 
The antibodies were made in mouse to the respective human muscle proteins. 
Anti-FATZ-1 polyclonal antibody made in mouse: this antibody was raised against a 
recombinant His tagged human full length FATZ-1 (1-299 aa) protein. 
Anti-FATZ-2 polyclonal antibody made in mouse: this antibody was raised against 
the human recombinant His tagged human full length FATZ-1 (1-264 aa). 
Anti-ZASP polyclonal antibody made in mouse: this antibody was raised against the 
human recombinant His tagged human full length ZASP-1 (1-283 aa). 




Anti-Ankrd2 polyclonal antibody made in mouse: this antibody was raised against 
the human recombinant His tagged human partial full length Ankrd2 (5-333 aa). 
Anti-Ankrd2 monoclonal antibody clone 2F10 (ascites fluid): the monoclonal 
antibody was produced using the Ankrd2 C-terminal (297-333 aa) protein. The position 
of the epitope was pin-pointed to the last 20 amino acids of the C-terminal of Ankrd2 
using GST fusion proteins for different regions of the Ankrd2 protein. 
2.2.2 Secondary antibodies 
These antibodies were obtained commercially. 
 
Anti-mouse IgG AP-conjugated antibody (Sigma, A3562) 
Anti-rabbit IgG AP-conjugated antibody (Sigma, A3687) 
Anti-goat IgG AP-conjugated antibody (Sigma, A4187) 
Anti-mouse conjugated to fluorescein isothiocyanate (FITC) antibody (Sigma, 
F4018) 
Anti-goat Alexa 546 antibody (Molecular Probes, A21085): anti-goat IgG conjugated 
to the fluorescent dye Alexa 546 that absorbs light at 556 nm and emits light at 573 nm. 
Anti-mouse HRP conjugated antibody: anti mouse immunoglobulins conjugated with 
horseradish peroxidase was used for chemiluminescence detection (A-9044, GE 
Healthcare Biosciences). 
 
2.3 Bacterial strains and growth media 
The following E.Coli strains were used for this work: 
DH5α recA1
-
 strain (F-, recA1-, endA1, gyrA96, thi-1, hsdR17 (rk-, mk+), supE44, 
elA1) for the propagation of eukaryotic expression vectors; the K-12 derived E.Coli 
strain 




M15[pREP4] (NalS, StrS, rifS, lac-, ara-, gal-, mtl-, F-, recA+, uvr+)  for the expression 
and purification of His tag recombinant proteins. 
BL21 (DE3) pLys S strain (F-, ompT, hsdSB (rB
- mB
-), dcm, gal, (DE3), pLysS, Cmr) 
(Promega) for the expression and purification of Glutathione-S-transferase (GST) 
recombinant proteins. Both the M15 and the BL21 strains allow high levels of 
expression of recombinant proteins after Isopropyl-β-D-thiogalactoside (IPTG) 
induction. 
BL21-CodonPlus-RIL straina: E. coli B F– ompT hsdS(rB– mB–) dcm+ Tet
r gal endA 
Hte [argU ileY leuW Camr], this strain is mainly used if the protein sequence contains a 
high percentage of arginine, isoleucine and leucine. 
BL21-CodonPlus-RP straina: E. coli B F– ompT hsdS (rB– mB–) dcm+ Tet
r gal endA 
Hte [argU proL Camr], this strain is normally used when the protein sequence is rich in 
proline and arginine.  
The bacterial cultures were grown in one of the following media: 
Luria Broth (LB): 10 g bactotryptone, 5 g yeast extract, 5 g NaCl (for 1 L). 
Terrific Broth (TB): 12 g bactotryptone, 24 g yeast extract, 4 ml glycerol (for 1 L). 
Before use KH2PO4 at 17mM final concentration and K2HPO4 at 72 mM final 
concentration should be added. 
 
2.4 Baculovirus expression system 
Baculovirus expressing the human muscle protein FATZ-3 was made using the Bac-to-
Bac baculovirus expression system (Invitrogen). The Spodoptera frugiperda (Sf9) 
insect cell line was used for baculovirus transfection and infection. 




Steps of baculovirus preparation: Human FATZ-3 cDNA was inserted into the 
pFastBacHT vector at the BamHI-HindIII restriction site. The pFastBacHT vector 
contains Tn7R and Tn7L which are two sequences homologous with the mini-attTn7 
sequence that is present in the baculovirus shuttle vector (bacmid 136 kb), and allow 
homologous recombination transposition of the gene of interest and into the bacmid. In 
order to allow the homologous transposition of FATZ-3 into the bacmid genome FATZ-
3 pFastBacHT was transformed into the E. coli strain DH10Bac that contains the 
bacmid genome. Transformed DH10Bac cells were incubated for 48 hr at 37 °C. After 
48 hr white and blue colonies were grown, selection was for the white colonies (positive 
colonies). White colonies were analysed further by PCR in order to confirm the 
presence of FATZ-3 in the bacmid genome. This bacmid DNA was then purified using 
a high purity plasmid miniprep kit (Marligen Biosciences). The bacmid containing 
FATZ-3 (1 ug of DNA) was transfected into Sf9 cells on 35 mm dishes (9x105 cells). 
Cells were then incubated at 27°C for 72 hr or until signs of viral infection started to 
appear. Then the virus (P1) was harvested from the cell culture medium. The virus from 
the P1 stock was amplified by infecting Sf9 cells with a multiplicity of infection (MOI) 
ranging from 0.05 to 0.1 pfu per cell; the amount of the P1 virus required for this 
amplification was calculated according to the formula:  
 
MOI (pfu / cell)   x   number of cells
titer of viral stock (pfu / ml)
Inoculum required (ml) =
 
 
The amplified virus (P2) was harvested from the media after 48 hr. and the efficiency of 
the P2 stock virus was tested by infecting a constant number of Sf9 cells (2x106 in a 
35mm dish) with different amounts of the virus (5, 50, 150 and 500ul). The amount of 




virus giving the optimum protein expression was noted and a time course experiment 
made using this fixed amount of the P2 virus to infect same number of Sf9 cells in 4 
different 60mm plates to determine when the virus starts to express the recombinant 
protein. One plate was harvested every 24 hours until 96 hr (24, 48, 72, 96hr). The 
results of these experiments are detailed in chapter 3 (Results). 
 
2.5 Cell culture 
2.5.1 C2C12 cells 
C2C12 are mouse myoblasts that on the addition of differentiating medium or at 
confluency differentiate rapidly, forming contractile myotubes. Growth conditions: 
DMEM supplemented with 10 % v/v Foetal Calf Serum and 50 µg/ml gentamycin. 
Differentiation conditions: DMEM supplemented with 0.4 % Ultroser G and 50 µg/ml 
gentamycin. 
2.5.2 COS-7 cell line 
The COS-7 cell line is derived from CV-1, a simian cell line (cercopithecus aethiops), 
by transformation with an origin-defective mutant of SV-40. Growth conditions: 
DMEM supplemented with 10 % Foetal Calf Serum and 50 µg/ml gentamycin.  
2.5.3 Sf9 cell line 
The Sf9 cell line was derived from pupal ovarian tissue of the Spodoptera frugiperda. 
The Sf9 cell line is highly susceptible to infection with Autographa california nuclear 
polyhedrosis virus (AcNPV baculovirus), and can be used with all baculovirus 
expression vectors. Sf9 cells are commonly used to isolate and propagate recombinant 
baculoviral stocks and to produce recombinant proteins. Growth conditions: Grace’s 




insect medium (Invitrogen Corporation) supplemented with 10 % Foetal Calf Serum 
and 50 µg/ml gentamycin. 
 
2.6 Gene amplification and cloning 
2.6.1 Amplification and cloning of full length FATZ-3 
Human full length FATZ-3 was amplified from human skeletal muscle mRNA 
(Invitrogen) using the “OnestepRT-PCR” Kit (QIAGEN). Primers were designed with a 
BamHI restriction site on the forward primer and a HindIII restriction site on the reverse 
primer, to allow cloning in other vectors with the same restriction sites. The 
concentration of primers and mRNA was optimized and the final amplification 
conditions were as follows: 50 °C for 30 min, 95 °C for 15 min, followed by 40 cycles 
of 94 °C for 1 min., 62 °C for 1 min., 72 °C min for 1 min. then 72 °C for 10 min. The 
PCR product separated on a 1% agarose gel, the band of DNA corresponding to FATZ-
3 was cut from the gel and then purified using the QIAEX purification Kit (QIAGEN). 
This FATZ-3 DNA was digested with enzymes for 3 hr at 37 °C, and then purified 
again using the QIAEX purification Kit (QIAGEN) ready for cloning into a variety of 
vectors. 
N-terminal eukaryotic expression vectors: The full-length cDNA of human FATZ-3 
was cloned into in the BamHI-HindIII restriction sites in the following the eukaryotic 
expression vectors. 
pCMV-tag-3B (Stratagene): contains an N-terminal c-myc (EQKLISEEDL) tag  
pCMV-tag-2B (Stratagene): contains an N-terminal FLAG (DYKDDDK) tag.  
pFastBacHT FATZ-3: contains an N-terminal 6His tag used to express FATZ-3 in Sf9 
insect cells. 




pcDNA3-HA: FATZ-3 cDNA was cloned into the BamHI-EcoR1 restriction sites in a 
modified pcDNA3 vector (Invitrogen) with a N-terminal HA tag (YPYDVPDYA). 
pEGFP-C1 FATZ-3: FATZ-3 cDNA was cloned into in the BglII-HindIII restriction 
sites. The FATZ-3 was digested BamHI-HindIII and inserted into the BglII-HindIII site 
of the vector. 
C-terminal eukaryotic expression vectors: The full-length cDNA of human FATZ-3 
was cloned into in the BamHI-HindIII restriction sites in the following eukaryotic 
expression vectors. 
pCMV-tag-5A (Stratagene): contains a C-terminal c-myc (EQKLISEEDL) tag 
pCMV-tag-4A (Stratagene): contains a C-terminal FLAG (DYKDDDK) tag. 
Bacterial expression vectors: The full-length cDNA of human FATZ-3 was cloned 
into the BamHI-HindIII restriction sites in the following bacterial vectors. 
pGEX-6PH-3: contains a N-terminalGST tag. The vector is a modified form of the 
pGEX-6P-3 vector (GE Healthcare) containing BamHI-HindIII restriction sites. 
pQE30-FATZ-3 (QIAGEN): contains a N-terminal six histidine (6xHis) tag 
pPROEXHTa contains a N-terminal six histidine (6xHis) tag with a TEV protease 
cleave site (leu, tyr, phe, gln) for removing the 6His tag.  
2.6.2 Amplification and cloning of regions of FATZ-3 
Regions of FATZ-3 cDNA were amplified by PCR using the full length FATZ-3 cDNA 
as template and with a BamHI restriction site on the forward primer and HindIII on the 
reverse primer. They were then cloned into the various expression vectors noted above 
using these restriction sites. Three regions were chosen based on a theoretical prediction 
of the secondary structure of FATZ-3 obtained using the Predictprotein program 




(PredictProtein: B Rost, G Yachdav and J Liu (2004) The PredictProtein Server. 
Nucleic Acids Research 32(Web Server issue):W321-W326). 
FATZ-3 (1-240 bp) expressing the protein F ATZ-3 mutant sN (1-80 aa) 
FATZ-3 (241-540 bp) expressing the protein FATZ-3 mutant Cen (81-180 aa) 
FATZ-3 (541-753 bp) expressing the protein FATZ-3 mutant sC (181-250 aa) 
In order to obtain better protein expression FATZ-3 was divided into two main regions. 
FATZ-3 (1- 240 bp) expressing the protein F ATZ-3 mutant LN (1-180 aa) 
FATZ-3 (240-753 bp) expressing the protein F ATZ-3 C terminal (80-251 aa) 
FATZ-3 (198-753 bp) expressing protein FATZ-3 P (66-139 aa). This region of 
FATZ-3 was cloned and expressed as a His tag recombinant protein to be used for 
antibody production. It was specifically chosen because it had low homology with other 
members of the FATZ family. 
FATZ-3 (196-251aa): primers where designed to amplify the last 168 bp of FATZ-3 
with the addition of the BamHI-HindIII restriction sites at the ends. The amplified DNA 
was cloned into pGEX-6PH vector which was used to express an N-terminal GST 
FATZ-3 (196-251 aa) fusion protein. This deletion mutant containing the last 56 aa of 
FATZ-3 was sent to our collaborator Prof. Olli Carpen (Helsinki) for use in in vitro 
phosphorylation studies. 
Eight of the FATZ-3 deletion mutants published by Frey and Olson (Frey and Olson, 
2002) were amplified by PCR with BamHI-HindIII restriction sites and then cloned into 
the various expression vectors noted above. These FATZ-3 deletion mutants encode the 
following FATZ-3 partial proteins F1 (1-110 aa), F2 (37-110 aa), F3 (109-251 aa), F4 
(109-207 aa), F5 (73-251 aa), F6 (50-251 aa), F7 (50-186 aa) and F8 (50-110 aa). Since 
there were difficulties expressing the smaller deletion mutants in vivo, probably due to 




their size and susceptibility to degradation it was decided to use a larger tag. The DNA’s 
of the deletion mutants were cloned into the BiglII-HindIII site of the eukaryotic 
expression vector pEGFP-C1. The GFP is 27 kDa alone and these FATZ-3 fusion 
proteins expressed with the GFP tag ranged from 33.7 to 48.7 kDa. 
2.6.3 Myotilin 
Myotilin deletion mutants, M1 (1-250 aa) and M2 (185-498 aa) were designed by our 
collaborator Prof. Olli Carpen, Turku, Finland. The DNA encoding these deletion 
mutants of myotilin were amplified by PCR in order to insert suitable restriction sites, 
BamHI-HindIII and BamHI-EcoRI respectively, for cloning in the pCMV-tag-2B-FLAG 
vector. These constructs were produced in vivo for binding studies.  
2.6.4 Amplification and cloning of FATZ-1, -2, -3 and myotilin lacking last 15 bp 
Primers were designed to produce FATZ-1, -2, -3 , myotilin and a myotilin deletion 
mutant (M2) without the last 15 bp corresponding to the last 5 amino acids of the 
protein. The amplified DNA was cloned into the pGEX-6PH vector for the production 
of GST protein and also into the eukaryotic expression vector pCMV-tag 3B. These 
constructs were produced in order to study the binding of the FATZ-1, -2-, -3 and 
myotilin proteins without the last 5 amino acids to the ZASP, ALP and CLP PDZ. The 
full length human myotilin cDNA was kindly supplied by our collaborator Prof. Olli 
Carpen (University of Turku, Finland). Primers were designed in order to amplify the 
full length myotilin with BamHI-EcoRI restriction sites. The gene was then digested by 
BamHI-EcoRI restriction enzyme and inserted in the eukaryotic vector pCMV-tag-2B-
FLAG through its restriction BamHI-EcoRI, in order to study protein-protein interaction 
in vivo. 
 




2.6.6 PDZ-ZASP pPROEXHTa 
The PDZ (1-85aa) region of ZASP had been cloned previously into expression vectors 
in our laboratory. PDZ-ZASP was cut by BamHI-HindIII and cloned in the prokaryotic 
vector pPROEXHTa, that allows the production of the protein with a 6His tag and a 
TEV protease cleavage site (leu, tyr, phe, gln). This PDZ-ZASP pPROEXHTa vector 
was sent to our collaborator Prof. Olli Carpen (University of Turku, Finland) for 
structural studies. 
2.6.7 PDZ-ZM-ALP pGEX-6P 
Primers were designed with BamHI-HindIII restriction sites to amplify the first 501 bp 
of ALP encoding amino acids 1-167aa that contain both the PDZ domain and the ZM 
motif. The PDZ-ZM-ALP was amplified, digested and cloned into the pGEX-6PH 
vector for the expression and purification of an N-terminal GST tag fusion protein for 
use in vitro studies such as AlphaScreen.  
 
2.7 In vitro binding  
Equal amounts of GST (GST and GST-PDZ-ZASP) proteins bound to glutathione-
Sepharose 4B resin were incubated for three hours at RT with in vitro transcribed and 
translated (IVTT) 35S labelled proteins: FATZ-3, FATZ-3 lacking the last 5 amino 
acids. The resins were briefly centrifuged and washed several times before being 
subjected to SDS-PAGE as was the IVTT protein, 30 % of the total amount used in each 
of the binding reactions. The gels were dried and exposed either to BioMax 
autoradiography film or to SR Packard phosphor screens; the analysis was done using a 
Packard Cyclone Phosphor Imager (Packard Instrument Co). 
 




2.8 In vitro transcription and translation  
The TNT Coupled Reticulocyte Lysate System (Promega) was used to produce IVTT 
proteins such as full length human FATZ-1, human FATZ-1 lacking the last 5 amino 
acids, full length human FATZ-2, human FATZ-2 lacking the last 5 amino acids, full 
length human FATZ-3, human FATZ-3 lacking the last 5 amino acids, human myotilin 
full length and the myotilin mutant lacking the last 5 amino acids. This system allows 
the production of both radioactive and non-radioactive proteins. 
Each transcription/translation reaction was performed using 25 µl of TNT Rabbit 
Reticulocyte Lysate, 2 µl of TNT Reaction buffer, 1 µl of T7 RNA polymerase, 2-5 µl 
of the appropriate radiolabeled aminoacid was used (Pro-mix [35S] cell labelling mix, 
GE Healthcare Biosciences), 1 µl of the amino acid mixture minus methionine/cysteine, 
1 µl of RNasin ribonuclease inhibitor, DNA template (0.5-1 µg) and nuclease free water 
to a final volume of 50 µl. The reaction was performed at 30°C for 90 minutes. Samples 
were tested for the presence of the desired protein by SDS-PAGE and then the gel was 
dried, exposed either to BioMax autoradiography film or to SR Packard phosphor 
screens. The analysis was done using a Packard Cyclone Phosphor Imager (Packard 
Instrument Co). 
 
2.9 PDZ Array  
The PDZ array membranes (Panomics) were used according to the protocols in the 
manufacturer’s handbook. The array membranes have a notch at the top right hand 
corner for orientation purposes. When biotinylated peptides were used as ligands 1.5 µg 
of the peptide was mixed with 15 µl of Streptavidin-HRP (DAKO) and incubated at 4°C 
for 30 min before adding to 5 ml of Blocking Buffer (Panomics CS7660) and kept at 




4°C until ready to use. When a His –tagged purified protein was used instead of a 
biotinylated peptide as ligand it was diluted in blocking buffer to obtain a protein 
concentration of 15 µg/ml. The membranes were incubated for 1 hr at room temperature 
(RT) in blocking buffer and then rinsed with wash buffer before adding the peptide or 
the purified protein. They were then incubated with gentle shaking for 1-2 hr at RT and 
washed three times with wash buffer for 10 min (each wash) at RT. When His –tagged 
purified protein was used the membrane was incubated with anti-histidine HRP 
conjugate diluted in wash buffer and incubated for 1-2 hr at RT. After incubation the 
membranes were washed three times in wash buffer at RT then treated with the 
provided solutions for chemiluminescence and after incubation for 5 min at RT the 
membranes were exposed to Hyperfilm for ECL (Amersham). 
 
2.10 Peptides 
Peptides were produced in the Protein Structure and Bioinformatics laboratory, ICGEB. 
The peptides, corresponding to the last 5 residues of the FATZ family of proteins and 
myopalladin, were synthesized on solid phase (Fmoc/t-Bu chemistry). The synthesis 
was automatically performed on a 0.05 mmol scale with a Gilson AspecXl Solid Phase 
Extraction instrument modified in-house. Biotin was manually added at the peptide N-
terminus as a Biotin 4-nitrophenyl ester at the end of the synthesis. After cleavage from 
the resin the peptides were precipitated with diethyl ether, washed and freeze-dried. The 
peptides were purified by RP-HPLC on a Zorbax 300SB-C18 column (Agilent) using a 
linear gradient from Eluent A (0.1% trifluoroacetic acid in water) to Eluent B (0.1% 
trifluoroacetic acid in acetonitrile) using UV monitoring at 214 nm. The collected 




fractions were analyzed by ESI-MS on a API150EX single quadrupole mass 
spectrometer (Applied Biosystems), pooled and freeze-dried. 
List of peptides: The following peptides where used for both AlphaScreen studies and 
the TransSignal PDZ array domains experiments. 
Biotin-GABA-GABA-EpSEEE; -ESEEE, -EpSEEL; -ESEEL; -EpTEEL; -ETEEL; -
EpSEDL;-ESEDL; -EpSEDL; -ESDEL and –EpSDEL. For competition experiments the 
same peptides without biotin but with GABA were used. 
 
2.11 Protein Production 
2.11.1 Production and purification of native 6His-tagged proteins  
The pQE30 (QIAGEN) and the pPROEXHT (Life Technologies) vectors were used for 
the expression of His-tagged proteins. The difference between these vectors is that the 
pPROEXHT contains a TEV protease cleavage site, whereas the pQE30 does not. His 
tagged proteins required for structural studies such as C-terminal FATZ-3 (81-251 aa) 
and the PDZ-ZASP (1-85 aa) were produced using the pPROEXHT vector that had a 
cleavable 6His tag. The protocols used for production and purification were the same 
for both vectors. The E. coli strain M15(pREP4) was transformed and after induction 
colonies were screened for expression of the recombinant His tag protein. A fresh 
colony expressing FATZ-3 was inoculated into LB (500ml), grown overnight at 37°C 
with shaking and the next day this culture was used to inoculate LB (500 ml) with 
ampicillin (100 µg/ml) and kanamycin (30 µg/ml) selection and grown at 37°C with 
shaking until an OD600 of 0.6. At this point the 1-2 mM IPTG was added for induction 
of the recombinant protein and the culture was grown at 37°C or at room temperature 
(native protein protocol) for 4-5 hours. Then cells were harvested by centrifugation at 




6,000 rpm for 15 minutes, the pellet resuspended in the lysis buffer ( Tris 50mM, NaCl 
300mM, Imidazole 10mM pH8) and kept on ice for 45 minutes. The suspension was 
sonicated and then centrifuged 10 minutes at 14000 rpm to remove cellular debris. The 
supernatant was transferred to a fresh tube, mixed with 1 ml of Ni-NTA (QIAGEN) 
resin and incubated for 1 hour at 4°C with gentle mixing. The Ni-NTA (nitriltriacetic 
acid) resin is a metal chelant adsorbent attached to Sepharose CL-6B which binds with 
high affinity to the 6xHis tag. The resin was washed three times for 10 minutes in wash 
buffer (Tris 50mM, NaCl 300mM, imidazole 20mM pH8). The recombinant protein was 
eluted by the addition of 1 ml of the elution buffer (Tris 50mM, NaCl 300mM, 
imidazole 250mM pH8). Protein levels and purity were checked by SDS-PAGE 
followed by Coomassie Blue staining. The proteins produced were used for 
AlphaScreen or structural studies. 
List of 6His tagged fusion proteins produced and purified for the project  
1) Full length FATZ-3 (1-251 aa) 
2) C-terminal FATZ-3 (81-251 aa) 
3) C-terminal FATZ-3 (81-251 aa) the His tag of this protein could be cleaved 
using the TEV protease 
4) PDZ-ZASP (1-85 aa) the His tag of this protein could be cleaved using the 
TEV protease 
5) alpha-actinin-2 (1-894 aa) 
 
2.11.2 Production and purification of GST recombinant proteins  
GST-recombinant proteins were produced and purified using the Glutathione S-
transferase Gene Fusion System (GE Healthcare) for the expression, purification and 
detection of fusion proteins produced in E.Coli. The pGEX plasmids are designed for 




inducible, high-level intracellular expression of genes or gene fragments as GST fusion 
proteins. cDNA of different proteins were inserted into pGEX plasmids, these vectors 
were then transformed in the E.Coli strain BL21 (DE3)-pLys S (Promega) that is 
engineered to contain the pLys plasmid encoding the T7 lysozyme. RIL, RP or RLP 
variants of BL21 (DE3)-pLys S (Promega) containing extra codons were used when the 
protein to be expressed was rich in arginine (R), isoleucine (I), leucine (L) or proline 
(P). Colonies were screened for expression of the recombinant protein. A positive 
colony was grown in LB in the presence of ampicillin (100 µg/ml) (SIGMA) at 37°C 
with shaking overnight until the bacterial culture reached the OD600 of 0.6. At this point 
the GST-recombinant protein expression was induced by the addition of 0.5-1 mM 
IPTG and the bacteria grown for a further 3-4 hours with mixing at room temperature or 
at 37°C. Then the cells were collected by centrifugation at 6,000 rpm for 15 minutes, 
resuspended in lysis buffer (Hepes 25mM pH 7.6, NaCl 300mM, EDTA 1mM, DTT 
1mM, Lysozyme, protease inhibitor cocktail Roche, Triton 100, 0.5%) and kept on ice 
for 20 minutes. The composition of the lysis buffer varied depending on the protein to 
be purified. At this point the suspension was sonicated, and then centrifuged at 
maximum speed to remove cell debris. The supernatant was recovered and incubated for 
1 hour with Glutathione Sepharose-4B beads (GE Healthcare), at 4°C with mixing. 
During this step the recombinant GST proteins should bind to the glutathione 
conjugated beads. Then the solution was briefly centrifuged and the recovered resin was 
washed three times with lysis buffer for five minutes with mixing at 4°C. After a final 
wash in PBS (Phosphate buffered saline), the GST-recombinant proteins were eluted 
from the beads by the addition of 200 µl of 20 mM Glutathione (SIGMA) for 10 
minutes at room temperature. As an alternative, proteins can be kept bound to the resin 




for use in GST pull down experiments. The amount and purity of the proteins was 
determined by SDS-PAGE and subsequent staining with Coomassie Brilliant Blue R 
(Coomassie Blue 0.4%, Acetic Acid 10%, and Methanol 40%). Native GST fusion 
proteins were used for GST pull-down assays and AlphaScreen experiments. 
List of GST fusion proteins produced and purified for the project 
1)  Full length human FATZ-3 (1-251 aa)  
2)  Human FATZ-3 mutant (81-251 aa)  
3)  Human mutant FATZ-3 lacking the last 5 amino acids (1-246 aa) 
4)  Human full length FATZ-1 (1-299 aa)   
5)  Human FATZ-1 lacking the last 5 amino acids (1-294 aa) 
6)  Human full length FATZ-2 (1-264 aa) 
7)  Human FATZ-1 lacking the last 5 amino acids (1-259 aa)  
8) Human full length myotilin (1-498 aa)  
9)  Human myotilin mutant lacking the last 5 amino acids (1-493aa)  
10)  Human myotilin deletion (1-250 aa)  
11)  Human myotilin deletion (185-498 aa)  
12)  Human myotilin mutant lacking the last 5 amino acids (185-493 aa)  
13) Human myotilin deletion (441-493 aa),  
14)  Human palladin (716-772 aa)  
14) Human PDZ-ZASP (1-85 aa)  
15)  Human PDZ-ALP (1-80 aa)  
16)  Human PDZ-ZM-ALP (1-167 aa).  
 
 




2.12 Structural Biology Protocols 
2.12.1 Production and purification of the C-terminal FATZ-3 (81-251aa) for protein 
crystallization: Small scale production and purification 
The C-terminal region of FATZ-3 in the pPROEXHT vector was used to transform 
BL21 (DES) RIL bacteria. A fresh colony was picked the next day, inoculated into 50 
ml of LB media containing 100ug/ml ampicillin (Sigma) and grown overnight at 37 °C. 
The 50 ml culture was used to inoculate a 500 ml culture to an optical density of 0.10 at 
600 nm, the culture was incubated with shaking at 37 °C until the OD600 reached 0.60, 
and then IPTG was added to a final concentration of 1mM. The culture was incubated at 
RT for 5 hr and then the cells were collected by centrifugation at 6,000 rpm for 15 min. 
These cells were resuspended in a 1/10th of the culture volume with lysis buffer (20mM 
Tris pH 8, 50mM NaCl, 10mM imidazole and complete EDTA-free protease inhibitor 
cocktail, Roche) and left on ice for 1hr. Cells were disrupted by sonication on ice, and 
the soluble phase was separated from the inclusion bodies and cellular debris by 
centrifugation at 12,000rpm for 15 min.  
The protein purification was made in three steps: 
Affinity purification: The supernatant was transferred to a fresh tube, mixed with 1 ml of 
Ni-NTA resin (QIAGEN) and incubated for 1 hour at 4°C with gentle mixing. Then the 
resin was centrifuged and washed three times for 10 minutes in wash buffer (Tris 
50mM, NaCl 300mM, imidazole 20mM pH8). The concentration of imidazole in the 
wash buffer varied depending on the stability of the protein binding to the Ni-NTA 
resin. The recombinant protein was eluted in 5 fractions by adding 1 ml of elution buffer 
(Tris 50mM, NaCl 300mM, Imidazole 250mM pH8) for each fraction. Protein level and 
purity were checked by SDS-PAGE followed by Coomassie Blue staining. The 




concentration of the protein was measured by UV at wave length 280nm. The protein 
was dialyzed against (20mM Tris pH8, 75 mM KCl) buffer to remove imidazole. 
Dialysis was done overnight at 4°C, and then the protein was centrifuged to remove 
precipitates formed during dialysis. Any precipitated material was checked by SDS-
PAGE to control if there was purified protein present. To cleave the 6His tag from the 
protein the supernatant containing purified protein was treated with Ac-TEV protease 
(Invitrogen) with an enzyme/substrate ratio of 10U for 100ug of protein, the reaction 
was made overnight at 4°C, then the protein before and after cleavage was checked by 
SDS-PAGE to confirm the removal of the His tag. 
Ion exchange chromatography: In order to achieve the highest purification level and to 
remove the protease, anion exchange chromatography was used. The sample was loaded 
on a MonoQ HR 5/5 column (Amersham Biosciences), containing a matrix (10 μm 
hydrophilic polymer particles) covalently bound to a quaternary amino group that is a 
strong anion exchanger. Elution was performed with a 20 CV linear gradient from 0% 
to 100% of Elution Buffer (20 mM Tris pH 7.5,1 M KCl). Peak fractions obtained from 
elution were analyzed by SDS-PAGE (12%). Fractions containing pure C-terminal 
FATZ-3 were pooled, and concentrated using a Vivaspin 5 ml concentrator (VIVA 
Science). 
Gel filtration chromatography: The molecular weight of native proteins and their 
aggregation state can be determined by size exclusion chromatography. Compounds of 
similar molecular shape and density like globular proteins are related by a sigmoidal 
relationship existing between their distribution coefficient (Kd) and the logarithms of 
their molecular weights.  
 




Kd of each gel filtration column is defined as: 
 






Where Ve, Vt and Vo represent the elution, total and void column volume respectively. 
The elution position of the C-terminal FATZ-3 protein relative to proteins of known 
molecular mass was determined using 10/30 Superdex200 HR gel filtration 
chromatography (Amersham Biosciences). The column was eluted at a flow rate of 0.5 
ml/min with 20 mM Tris pH 7.4 and 500 mM NaCl. The Kd was determined from the 
chromatogram for pre-mixed standard proteins of known molecular mass (Gel Filtration 
Calibration Kits HMW and LMW, Amersham Biosciences) and for the samples. It was 
then plotted against the logarithm of the molecular mass of the standard proteins. The 
standard curve obtained was used to calculate the apparent molecular mass of the C-
terminal FATZ-3 protein and showed that this behaved as a dimer. The purified protein 
was then concentrated using the Vivaspin concentrator(VIVA Science) and its 
concentration was measured by UV at 280 nm. The protein (50ul) had a concentration 
of 0.5 mg/ml. 
2.12.2 Large scale production and purification of C-terminal FATZ-3 protein 
Several scale-up trials were made to optimize suitable buffer conditions, since the 
buffers and the purification protocols that worked when using small scale conditions did 
not work when using large scale conditions. The protocol was similar to that for the 
small scale except for the volumes and the use of a French Press for disruption of the 
cells. A 12 L culture of BL21 (DES) RIL bacteria transformed with the pPROEXHT 




containing C-terminal FATZ-3 vector was grown to an OD600 of 0.1 at 37°C. The 12 L 
culture was then incubated at 25°C until the OD600 was 0 6, then induced by adding 
IPTG (1mM) and incubating with shaking for a further 5 hours at 25°C. Cells were 
centrifuged at 6,000 rpm and resuspended in 1/10th of the volume with lysis buffer 
containing 50 mM MES pH6, 300 mM NaCl, 10 mM imidazole and complete EDTA-
free protease inhibitor cocktail (Roche). The lysate was left on ice for 1 hour and then 
disrupted using a French Press, a very efficient method of disruption, and then 
centrifuged at 12,000 rpm for 20 mins.  
Protein purification in three steps:  
Affinity purification. Supernatant was mixed with 12 ml of Ni-NTA (QIAGEN) resin 
and incubated for 1 hour at 4°C with mixing. Then washed three times with 200ml 
washing buffer MES 50mM pH6, NaCl 300mM, Imidazole 15mM. The recombinant 
protein was eluted in 50 ml elution buffer (MES 50mM pH6, NaCl 300mM, Imidazole 
250mM). Protein levels and purity were checked by SDS-PAGE followed by 
Coomassie Blue staining. Samples then were dialysed against MES pH 5, KCl 75mM. 
Cation exchange chromatography. The C-terminal FATZ-3 protein was stable in the 
MES buffer at pH6 for this reason we used cation exchange as the second step in the 
purification since there were problems using ion exchange chromatography with Tris 
pH6 in the scale-up experiments. The sample was loaded on a Source 15S column 
(Amersham Biosciences). Elution was performed with a 20 CV linear gradient from 0% 
to 100% of elution buffer (20 mM Tris pH 7.5, 1 M KCl). Peak fractions from the 
elution were analyzed using 12% SDS-PAGE. Fractions containing purified C-terminal 
FATZ-3 protein were pooled, and concentrated using a Vivaspin 5 ml concentrator 
(VIVA Science). 




Size exclusion chromatography. The purified protein from the cation exchange column 
was further purified by Gel filtration using a Superdex 200HR 16/60 column 
(Amersham Biosciences) equilibrated with a buffer containing 20 mM MES pH 6 and 
75 mM KCl. Peak fractions were collected, concentrated with a Vivaspin 5 ml 
concentrator, and then analyzed using 12% SDS-PAGE. The purified protein 
concentration was measured at 280 nm, the final concentration was about 10 mg/ml in a 
volume of 120 µl. 
2.12.3 Dynamic light scattering (DLS) 
Dynamic light scattering measurement is a powerful method to analyze the quaternary 
structure of a protein and to evaluate its aggregation state. In DLS experiments, the 
radius (R) of a particle is calculated from its diffusion coefficient (D) via the Stokes-
Einstein equation reported below, where kB is the Boltzmann constant, T the 
temperature, η the solvent viscosity, and f = 6πηR the frictional coefficient for a 
compact sphere in a viscous medium. 
                                                               
                                                                
In the above equation, R is the radius of an hypothetical hard sphere that diffuses with 
the same strength as the particle under examination. Its value is derived from the 
diffusional properties and it is considered indicative for the apparent size of the dynamic 
hydrated particle. In a typical DLS experiment, the photons scattered from the randomly 
oriented molecules in solution are detected with a single photon counting device. The 
intensity of the scattering signal is dependent on the molecular weight, density, shape, 




concentration of the particles, viscosity, and refractive index of the medium, the 
magnitude of the particle-particle and solvent-particle interactions. The correlation 
between the scattering intensities measured during small time increments can be 
described with an intensity correlation curve. The scattering intensity at the detector is 
dependent upon the position of the particles relative to the detector that, in the absence 
of any different forces, is driven by the Brownian motion. The measured intensity 
correlation curve bears an indirect measurement of the particle’s diffusion coefficient D. 
Moreover an appropriate analysis of the autocorrelation function can also provide useful 
data regarding sample polydispersity, the technique being sensitive to aggregation. DLS 
measurements were carried out using a DynaPro MS/X instrument (Protein Solutions, 
Inc.), scanning different temperatures in the range between 4 °C and 22 °C with a 
protein concentration of 10mg/ml. The use of quartz microcuvettes allowed the use of 
very small sample volumes (12 μl or 45 μl), which could be almost completely 
recovered. DLS measurements were preceded by sample centrifugation at 20,000 g for 
30 min to reduce the presence of dust or other particulates, which could interfere with 
the scattering of photons by the protein molecules. The DLS instrument is provided with 
the DYNAMICS v6 software for controlling parameters such as temperature, 
acquisition time and photon flux. Moreover the software calculates an autocorrelation 
function to fit the measurements to either monomodal or bimodal distribution and gives 
as output the graphical profiles of this fit, the sum of squares differences between the 
measured correlation curve and the best fit curve using the cumulants method of 
analysis (B. J. Frisken, 2001). The numerical values obtained from the fitting included 
the hydrodynamic radius, the percentage of polydispersity, and the molecular weight of 
the sample, estimated using a calibration curve prepared from globular protein 




standards. Furthermore, the degree of polydispersity obtained from DLS measurements 
of a protein sample was related to the probability to obtain crystals (Ferre-D’Amare and 
Burley, 1994). There is a higher probability of obtaining a crystal from a protein 
solution, which shows a low degree of polydispersity (below 20%). 
2.12.4 Circular dichroism (CD) 
Circular dichroism spectroscopy is a form of light absorption spectroscopy that 
measures the difference in absorbance of right- and left-circularly polarized light (rather 
than the commonly used absorbance of isotropic light) by a substance. It has been 
shown that the CD spectra between 260 and approximately 180 nm can be analyzed for 
the different secondary structural types: alpha helix, parallel and antiparallel beta sheet, 
turn, and other secondary structure formations. The concentration of the C-terminal of 
FATZ-3 (81-251 aa) was measured at 280nm then this value was divided by the 
extension coefficient of the protein. CD measurements were performed on a Pistar-180 
spectrometer (Applied photo physics) using a 0.5mm path length cuvette (QS) with a 
protein concentration of 3.6 µM. Wavelength spectra were obtained by averaging five 
scans at 20oC recorded at 0.5nm intervals from 180 to 360 nm at a rate of 45 nm min-1 
and a bandwidth of 2.0 nm. (number of samples 50,000; sample period 25.0 
microseconds). Using 23 reference proteins, quantitative determination of secondary 
structure elements was achieved using the CDNN (CD Spectroscopy Deconvolution) 
program. 
2.12.5 Stura Footprint screens  
“Stura footprint screen” is a simple test that defines the individual pattern of solubility 
for a given protein with a range of precipitants, the method was described by Enrico 
Stura (Stura et al., 1994). The methodology of the test depends on mixing different 




concentrations of the desired protein with different concentrations of precipitants, then 
checking at which conditions the protein will start to precipitate. The condition where 
the protein will start to precipitate gives an indication of the optimum crystallization 
conditions. The stura footprint screening kit used was obtained from Molecular 
Dimensions. C-term FATZ-3 (81-251aa) was used at a concentration of 10mg/ml with 6 
different conditions of the kit. These were the recommended starting conditions, 
especially if the protein sample was limited (as was the case the C-terminal FATZ-3 
protein). The 6 recommended precipitants were used with the C-terminal FATZ-3 (81-
251aa) protein by mixing 1ul of each precipitant with 1ul of the protein (10mg/ml), then 
immediately checking under the microscope for the formation of any precipitates. The 
best condition was obtained using PEG plus 0.2M imidazole malate pH 7. 
2.12.6 Protein crystallization 
The protein crystallization was performed by the “sitting drop technique” using three 
commercial crystallization kits The JCSG+ Suite (QIAGEN), the JBScreen 1, 2, 3 and 4 
(JENA BIOSCINCE) and the PACT premier-HT96 MD1-36 (Molecular Dimension 
Limited). The mixing of the protein-precipitants was performed using the nanodrop 
robot. Two different concentrations of the protein were mixed with each concentration 
of the precipitant (0.1 ul and 0.2 ul of the protein with 0.1 ul of the precipitant). 
Approximately 300 conditions were used and the drops were then incubated at 22°C.  
 
2.13 Transfections and co-immunoprecipitations 
Sub-confluent COS-7 cells (7.5 x 105 cells) were seeded onto 100 mm plates (Falcon) 
and transfected with the following expression vectors (2 µg) Ankrd2-c-myc-pCMV, 
pcDNA3 and FATZ-3-FLAG-pCMV  using the FuGENE 6 reagent (Roche) as 




described in the manufacturer’s protocol. Then 48 hr after transfection cells were 
harvested and lysed in 300 µl of E1A buffer (50 mM Hepes pH 7, 250 mM NaCl, 0.1 % 
v/v NP40 and protease inhibitors (Complete-EDTA free, Roche). Samples were briefly 
sonicated (10 seconds) at maximum power and then centrifuged for 10 minutes at 
14,000 rpm at 4°C to remove cell debris. Supernatants were recovered and the protein 
concentration determined using the Biorad Protein Assay (Biorad). Extracts were 
subjected to SDS-PAGE and blotted onto a PDVF membrane to be tested for the 
presence of the desired protein products, using appropriate antibodies. Tagged proteins 
were immunoprecipitated from the extracts by the addition of specific antibodies for 2 
hours at 4°C. Then protein A-Sepharose (GE Healthcare) was added and samples kept 
in agitation for 1 hour at 4°C. After five washings in E1A buffer the beads were 
centrifuged and following the addition of protein sample buffer, boiled 5 min and 
subjected to SDS-PAGE and then western blotting. The antibodies used for 
immunoprecipitation were anti c-myc clone 9E10 mouse monoclonal ascites fluid 
(M5546, SIGMA) and anti FLAG (M2), F3165 mouse monoclonal antibody (SIGMA).  
2.14 Western blotting  
Protein extracts or complexes from immunoprecipitations were separated by SDS-
PAGE and then blotted onto Immobilon-P membrane (Millipore) to perform western 
blotting. The transfer of protein samples from the gel onto the membrane was done in a 
blotting apparatus using a constant voltage of 20 V overnight, the transfer buffer 
contained 20 % methanol and 10 % Tris-glycine. 
The membrane was blocked for at least 1 hour in a solution of 10 % low fat milk in PBS 
containing 0.05 % Tween-20. The primary antibodies were diluted in 5 % low fat milk 
in PBS with 0.05 % Tween-20 and incubated for at least 90 minutes with gentle mixing. 




The secondary antibodies were diluted in 5% low fat milk in PBS with 0.05% Tween 20 
and incubated 45 minutes with agitation. Both Alkaline Phosphatase (AP)- and 
Horseradish Peroxidase (HRP)- conjugated secondary antibodies were used, according 
to the detection method employed, NBT/BCIP colorimetric assay or ECL respectively. 
 
2.15 Primers used for this study: 
 
FATZ-3 primers 
Primer name  Primer sequnce  TM  
Rcen-FATZ-3 TATAAGCTTCTAATCGCTCTGGTAGTC 62.8°C 
Rev Ab FATZ-3  TATAAGCTTCTACAGGGCGCTGGGGCTG 76°C 
For Ab FATZ-3  TATGGATCCATGTTAGCAGCCAGCCAGC 76.4°C 
FATZ3 F Olson 1 TATGGATCCATGATCCCCAAGGAGCAG 75.2°C 
FATZ3 F Olson 2 TATGGATCCATGATGGAGGAGCTGTCAC 73.9°C 
FATZ3 F Olson 3,4,5 TATGGATCCTTCCCGGCCTCACCC  76.5°C 
FATZ3 F Olson 6 TATGGATCCATGCTGGCCGGAAGC  76.7°C 
FATZ3 F Olson 7 TATGGATCCGCAGCCAGCCAGC 75.9°C 
FATZ3 F Olson 8,9,10 TATGGATCCCTCCTCTTCCAGAAGAGG 71.5°C 
FATZ3 R Olson 1,2,10 TATAAGCTTCGGGAAGATGTGGAGCTC 70.4°C 
FATZ3 R Olson 3,6,8 TATAAGCTTCTACAGCTCCTCGGACTC 66.5°C 
FATZ3 R Olson 5,7,9 TATAAGCTTGGGGGTGTGACTTCG 68.6°C 
FATZ3 R Olson 4 TATAAGCTTCCCCACGAGGGGTCCTC 73.5°C 
FATZ3 -5 R TATAAGCTTTGGGAGGTTACGGACC 67.4°C 
FATZ-3 FOR C56 GTAGGATCCATGAAGACCCCGGTGCCA 78.4°C 
FATZ-3 REV C56 TAAAAGCTTCTACAGCTCCTCGGACTC 68.9°C 
FATZ3F  GTTAACAAGCGGAAGCTACCA 62.9°C 
FATZ3R  GTCTTGGCTCCGGATGTTACC 66.6°C 
FATZ3ORFF  TATGGATCCATGATCCCCAAGGAGCAGA 76.2°C 
FATZ3ORFR  TATAAGCTTCTACAGCTCCTCGGACTC 66.5°C 
FATZ-3 ORF-F2  TATGGATCCATGATCCCCAAGGAGCA  75°C 
FATZ-3 ORF-NSR TATAAGCTTCAGCTCCTCGGACTCTGGC 73°C 
FN-FATZ-3 TATGGATCCATGATCCCCAAGGAGCAGA 76.2°C 
RN-FATZ-3 TATAAGCTTCTACCTCCTGGCGCTTCC 71°C 
FC-FATZ-3 TATGGATCCATGGGCCGAAGTCACACC 77.6°C 
RC-FATZ-3 TATAAGCTTCTACAGCTCCTCGGAC  64.6°C 
Fcen-FATZ-3 TATGGATCCATGAAGGTGACTGGAAC 69.5°C 





Primer name  Primer sequnce  TM  
FATZ-1 FOR C56 GTTGGATTCATGAAGTTTGACCTGG 68.2°C 
FATZ-1 REV C56 GTTAAGCTTTCACAGCTCCTCTGTTTG 67.7°C 
FATZ-1 ORF-F  TATGGATCCATGCCGCTCTCAGGAACCCC  80.5°C 
FATZ-1 ORF-NSR TATAAGCTTCAGCTCCTCTGTTTCTC 63.9°C 
FATZ1 -5 F TATGGATCCATGCCGCTCTCAGGAACC 76.9°C 




Primer name  Primer sequnce  TM  
FATZ-2 FOR C56 GTTGGATCCATGTTTGAGCTATTGC 68.1°C 
FATZ-2 REV C56 GCCAAGCTTTCATAGGTCTTCTGATTCTGGTA 72°C 
FATZ-2 ORF-F  TATGGATCCATGCTCTCACATAATACT 64.3°C 
FATZ-2 ORF-NSR TATAAGCTTTAGGTCTTCTGATTCTGG 62.6°C 
FATZ2 -5 F TATGGATCCATGCTATCACATAATAC 61.5°C 




Primer name  Primer sequnce  TM  
Myotilin R Rest  TATGAATTCTTAAAGTTCTTCACTTTC 58.9°C 
Myotilin F Rest  TATGGATCCATGTTTAACTACGAACG  65.3°C 
Myotilin F  ATGTTTAACTACGAACGTCC 55.7°C 
Myotilin R  TTAAAGTTCTTCACTTCATAG  50.4°C 
Myotilin F part 1  TATGGATCCATGGCTCGCAGATTGC 74.9°C 
Myotilin R part 2 TATGAATTCTGGTGGGTAAAATTTC  62.6°C 
Myotilin -5 R TATAAGCTTATAGAGTCCAGATTGAG 57.9°C 
MyT 973 For GGGCTTATGCATGTGTTGCCAAGAATAGAGCAGG 78.9°C 
MyT 973 Rev  CCTGCTCTATTCTTGGCAACACATGCATAAGCCC 78.9°C 
 
 





Primer name  Primer sequnce  TM  
ALP HindIII primer REV TATAAGCTTTAAGAATGAGACCCCGCA  68.6°C 
F PDZ-ZASP Bgl II TATAGATCTTATGTCTTACAGTGTGACC 59.5°C 
R PDZ-ZASP EcoRV  TATGATATCTACGCTTTGATTTCTGCAG 65.8°C 
M13 CAGGAAACAGCTATGAC 50.6°C 







Chapter 3 RESULTS 
 
3.1 Amplification, cloning and expression of FATZ-3 
The FATZ-1 and FATZ-2 genes had previously been cloned in our laboratory (Faulkner 
et al., 2000). My project was to study the function of the FATZ-3 gene. The human 
FATZ-3 gene had previously been shown to map at locus 5q31 and contain 7 exons 
spanning a 19kb region. It codes for a 251 amino acid protein having a high homology 
to the N- and C-termini of FATZ-1 and FATZ-2 (Frey and Olson, 2002).  
In order to study FATZ-3 its cDNA was amplified by RT-PCR from human skeletal 





Figure 7. FATZ-3 cDNA amplified from skeletal muscle mRNA by RT-PCR and run 
on an agarose gel (1%). Lane 1, molecular weight marker, 1 kb plus ladder (Invitrogen); 




This amplified cDNA was then sequenced and I found no discrepancies between this 
sequence and the sequence of FATZ-3 in the NCBI database. The primers used to 
amplify the FATZ-3 cDNA had restriction sites which facilitated the cloning of this 
cDNA into a variety of expression vectors both prokaryotic and eukaryotic. To check 
the level of expression of FATZ-3 in eukaryotic cells, COS-7 cells were transfected 
with FATZ-3 vectors expressing either c-myc or FLAG tagged recombinant proteins 
(respectively pCMV-3B, pCMV-2B). The proteins from transfected cell lysates were 
separated by SDS-PAGE, immunoblotted and detected with antibodies against c-myc 
(Fig. 8 a) and FLAG (Fig 8 b). 
 
 
    
 
Figure 8. (a) and (b): Western blots showing the recombinant FATZ-3 protein 
expressed in COS-7 cells and detected respectively, by anti c-myc and anti-FLAG 
monoclonal antibodies. 15 µg of cell lysate was loaded on the SDS PAGE gel and 
detected with anti-c-myc monoclonal antibody diluted 1:1000 (M5546, SIGMA) a, and 







3.2 The FATZ family, myotilin, palladin and myopalladin share high 
similarity at their extreme C-termini (last 5 amino acids) 
Together with Prof. Olli Carpen, University of Turku, Finland, we noted that the 
terminal 5 amino acids of FATZ-1 (ETEEL), FATZ-2 (ESEDL), FATZ-3 (ESEEL), 
myotilin (ESEEL), myopalladin (ESDEL) and palladin (ESEDL) share high similarity 
(Fig. 9). Notably those of FATZ-3 and myotilin are identical (ESEEL) as are those of 
FATZ-2 and palladin (ESEDL). This high similarity raised the question of whether 
these proteins could interact via their C-terminal with the same protein or proteins as 
well as the possibility that the C-terminal final five amino acids may represent a new 




Figure 9. A schematic diagram showing the proteins of myopalladin, palladin and 
myotilin with their IGc2 and IG-like domains and the FATZ family of proteins. All six 
proteins share high homology at the last 5 amino acids of their C-terminal. 
 
To verify if this putative binding motif was shared by other proteins a program was 
written by Prof. G. Valle, Genome Research Group, CRIBI, University of Padova, to 




E[ST][DE][DE]L. The last 5 amino acids were given the following weightings: position 
0 L = 2, position 1 E or D = 1, position 2 E or D = 1, position 3 S or T = 1 and position 
4 E = 1. A score of 6 is given when all the criteria are met. The program was used to 
check the UniProt Knowledgebase Release 11.3 (UniProtKB/Swiss-Prot Release 53.3 of 
10-Jul-2007 and the UniProtKB/TrEMBL Release 36.3 of 10-Jul-2007). The 
E[ST][DE][DE]L motif was found to be restricted in Vertebrates to the proteins of the 
FATZ family, myotilin, myopalladin and palladin with the exception of histidine 
ammonia lyase that has the final C-terminal amino acids the same as FATZ-2 and 
palladin (ESEDL). The data is reported in Table 1 is only for the proteins with a score 
of 6 corresponding to exact matches for the motif E[ST][DE][DE]L. It is notable that 
there are very few proteins that have exact matches: FATZ-1 (myozenin-1/ calsarcin-2), 
FATZ-2 (myozenin-2/calsarcin-1), FATZ-3 (myozenin-3/ calsarcin-3), myopalladin, 
palladin and histidine ammonia lyase. All of these proteins except histidine ammonia 
lyase and palladin are localized in the Z-disc of striated muscle. Palladin is an actin-
binding protein involved in cytoskeletal organization in a variety of cell types and has a 
high identity with myopalladin which is found in the Z-disc. Therefore, with the 
exception of histidine ammonia lyase the proteins conserving the E[ST][DE][DE]L 
motif have a role in muscle or cytoskeletal structure and/or function. L-Histidine 
ammonia-lyase is a cytosolic enzyme catalyzing the first reaction in histidine 
catabolism, the nonoxidative deamination of L-histidine to trans-urocanic acid. Genetic 
deficiency of the enzyme, transmitted as an autosomal recessive trait, causes 
histidinaemia which is characterized by increased histidine and histamine as well as 
decreased urocanic acid in body fluids.  Histidine ammonia lyase has been reported to 




It had previously been shown that the FATZ family of proteins bound ZASP 
(Cypher/Oracle) however these interactions had not been mapped either on ZASP or on 
the FATZ family members (Frey and Olson, 2002). Recently in the laboratory of Prof. 
Olli Carpen (personal communication, unpublished results) as a result of yeast–two-
hybrid experiments it was found that myotilin binds to ZASP through its C-terminal and 
that they co-localize in the Z-disk. Based on this data and our observations we 
speculated that the last 5 amino acids of the C-terminal of myotilin, myopalladin, 
palladin and the FATZ family could have a role in the interaction with ZASP. This 
hypothesis was further strengthened by the information obtained using the ELM 
program (a resource for predicting functional sites in eukaryotic proteins, (Puntervoll et 
al., 2003) which predicted that the terminal four amino acids of myotilin, myopalladin, 
palladin and the FATZ family constituted a binding motif for class III PDZ domain 
proteins: X[DE]X[IVL], where X is any amino acid. 
 










    
6 LDGETEEL Q9NP98 MYOZ1_HUMAN FATZ-1  (Myozenin-1/Calsarcin-2) 
6 LDGETEEL Q1AG03 Q1AG03_CANFA Calsarcin 2 - Canis familiaris (Dog) 
6 LDGETEEL Q8SQ24 MYOZ1_BOVIN Myozenin-1 - Bos taurus (Bovine) 
6 LDGETEEL Q0IIE1 Q0IIE1_BOVIN MYOZ1 protein - Bos taurus (Bovine) 
6 LDGETEEL Q4PS85 MYOZ1_PIG Myozenin-1 - Sus scrofa (Pig) 
6 LDGETEEL Q1AG04 Q1AG04_PIG Calsarcin 2 - Sus scrofa (Pig) 
6 LDGETEEL Q1AG02 Q1AG02_RABIT Calsarcin 2 - Oryctolagus cuniculus (Rabbit). 
6 LDGETEEL Q9JK37 MYOZ1_MOUSE Myozenin-1 - Mus musculus (Mouse) 
6 VDGETEEL Q6DIU0 Q6DIU0_XENTR Myozenin 1 - Xenopus tropicalis  
6 VDGETEEL Q7ZYN8 Q7ZYN8_XENLA MGC53296 protein - Xenopus laevis 
6 MDGETEEL Q7SYY0 Q7SYY0_XENLA Myoz1-prov protein - Xenopus laevis 
6 FDGETDDL Q6DHF0 Q6DHF0_DANRE Zgc:92347 - Danio rerio (Zebrafish). 
6 FDGETDDL Q6P0T8 Q6P0T8_DANRE Zgc:77785 - Danio rerio (Zebrafish) 
6 SSEETDDL Q1JQ62 Q1JQ62_DANRE Si:ch211-238e6.5 - Danio rerio (H-L-H protein) 




6 FDGETDEL Q4SQM4 Q4SQM4_TETNG Chromosome 17 SCAF14532, Calsarcin rel. 
6 FDGETDDL Q4SV47 TETNG Chromosome undetermined SCAF13803 calsarcin rel. 
    
6 TVPESEDL Q9NPC6 MYOZ2_HUMAN FATZ-2 (Myozenin-2/Calsarcin-1) 
6 TVPESEDL Q5R6I2 MYOZ2_PONPY Myozenin-2 - Pongo pygmaeus (Orangutan) 
6 TIPESEDL Q5E9V3 MYOZ2_BOVIN Myozenin-2 - Bos taurus (Bovine) 
6 TIPESDDL Q1AG08 Q1AG08_PIG Calsarcin 1 - Sus scrofa (Pig) 
6 TVPESDDL Q9JJW5 MYOZ2_MOUSE Myozenin-2 - Mus musculus (Mouse) 
6 TIPESDDL Q8CE60 Q8CE60_MOUSE 10 days neonate skin cDNA, RIKEN. 
6 TIPESDDL Q9D3I5 Q9D3I5_MOUSE 6 days neonate head cDNA, RIKEN 
6 EIPESDDL Q8AVF9 Q8AVF9_XENLA Myoz2-prov protein - Xenopus laevis. 
6 EIPESDDL Q63ZK4 Q63ZK4_XENLA LOC494787 protein - Xenopus laevis  
6 EIPESDDL Q5I0T4 Q5I0T4_XENTR Myozenin 2 - Xenopus tropicalis 
6 EIPESDDL Q6P5L6 Q6P5L6_DANRE Zgc:77703 - Danio rerio (Zebrafish) 
6 FIPESDDL Q6P2T2 Q6P2T2_DANRE Myozenin 2 - Danio rerio (Zebrafish) 
    
6 ALVESEDL Q7L3E0 Q7L3E0_HUMAN Palladin protein - Homo sapiens  
6 ALVESEDL Q7L8P5 Q7L8P5_HUMAN Hypothetical protein DKFZp586L0518  
6 ALVESEDL Q9Y3E9 Q9Y3E9_HUMAN CGI-151 protein - Homo sapiens (Human) 
6 ALVESEDL Q9UQF5 Q9UQF5_HUMAN SIH002 - Homo sapiens (Human) 
6 ALVESEDL Q9Y2J6 Q9Y2J6_HUMAN KIAA0992 protein - Homo sapiens (Human) 
6 ALVESEDL Q4R5Y9 Q4R5Y9_MACFA Testis cDNA, clone: QtsA-19723 
6 GLVESEDL Q3MHW8 Q3MHW8_BOVIN PALLD protein - Bos taurus (Bovine) 
6 GLVESEDL Q6DFX7 Q6DFX7_MOUSE Palld protein - Mus musculus (Mouse) 
6 GLVESEDL A0JNZ3 A0JNZ3_MOUSE Palld protein - Mus musculus (Mouse) 
6 GLVESEDL Q9ET54 Q9ET54_MOUSE Actin-associated protein palladin  
6 GLVESEDL Q9CWW1 Q9CWW1_MOUSE ES cells cDNA, RIKEN full-length 
6 GLVESEDL Q69ZT7 Q69ZT7_MOUSE MKIAA0992 protein - Mus musculus (Mouse) 
6 GLVESDDL Q4RKT9 Q4RKT9_TETNG Chromosome 1 SCAF15025, whole genome 
    
6 KIPESEDL Q4VB93 Q4VB93_HUMAN Histidine ammonia-lyase - Homo sapiens  
6 TIPESDDL P35492 HUTH_MOUSE Histidine ammonia-lyase - Mus musculus 
6 TIPESDDL P21213 HUTH_RAT Histidine ammonia-lyase - Rattus norvegicus. 
6 TIPESDDL >Q76N86 Q76N86_RAT Histidase - Rattus norvegicus (Rat) 
    
6 SVVESDEL Q86TC9 MYPN_HUMAN Myopalladin - Homo sapiens 
6 SVVESDEL Q5DTJ9 MYPN_MOUSE Myopalladin - Mus musculus (Mouse) 
6 SVVESDEL Q86TC92 MYPN_HUMAN Isoform 2 of Q86TC9 - Homo sapiens (Human) 
    
6 NLPESEEL Q8TDC0 MYOZ3_HUMAN FATZ-3 (Myozenin-3/Calsarcin-3) 
6 NLPESEEL Q8TDC02 MYOZ3_HUMAN Isoform 2 of Q8TDC0 - Homo sapiens  
6 NLPESEEL Q08DI7 Q08DI7_BOVIN Myozenin 3 - Bos taurus (Bovine) 
6 NLPESEEL Q1AG05 Q1AG05_PIG Calsarcin 3 - Sus scrofa (Pig) 
6 KLPESEEL Q8R4E4 MYOZ3_MOUSE Myozenin-3 - Mus musculus (Mouse) 
6 KLPESEEL Q9Z3272 SYNPO_RAT Isoform 2 of Q9Z327 - Rattus norvegicus  
    
6 GLYESEEL Q9UBF9 MYOTI_HUMAN Myotilin - Homo sapiens  
6 GLYESEEL Q0VCX9 Q0VCX9_BOVIN Similar to titin immunoglobulin domain protein 
6 GLYESEEL Q9JIF9 MYOTI_MOUSE Myotilin - Mus musculus (Mouse) 




3.3 Preparation of native protein for use in AlphaScreen Experiments 
In collaboration with the groups of Prof. Olli Carpen and Prof. Giorgio Valle we 
undertook a variety of experiments in order to test the hypothesis that the PDZ domain 
of the Enigma proteins ZASP, ALP and CLP-36 interact with the FATZ family of 
proteins, myotilin, palladin and myopalladin. One method used to detect binding was 
the AlphaScreen technique; the experiments were done in conjunction with our 
collaborators at CRIBI, University of Padova. This is an in vitro binding technique that 
can detect the interaction between two or more proteins with high level of sensitivity 
(Fig 10). The method is described in detail in the Material and Methods section. 
 
                      
 
Figure 10. Diagram showing the principles of the AlphaScreen technique. When the 
donor beads are excited at a wavelength of 680 nm there are two possible outcomes: (a); 
there is no signal since the two proteins do not interact. (b); the two proteins interact 
and the distance between them is less than 200nm. This allows the transfer of singlet 
oxygen from the donor to the acceptor beads, resulting in emission from the acceptor 
beads at 520-620 nm (the diagrams are reproduced from the Pakard BioScience booklet 




I amplified and cloned the cDNA of the PDZ domains of ZASP, CLP-36 and ALP into 
prokaryotic vectors that express a His tagged recombinant protein. Figure 11 show the 
SDS-PAGE gel of the purification of ZASP native N-terminal His tagged PDZ protein 
used in the AlphaScreen, ALP and CLP-36 native His-tagged protein purifications were 
similar. 
Also for AlphaScreen experiments I cloned, expressed and purified the native GST 
tagged full-length and truncated (lacking the terminal 5 amino acids) proteins of FATZ-







Figure 11. SDS-PAGE gel (15 %) stained with Coomassie blue showing the 
purification of the ZASP His-PDZ protein. 1) before induction with IPTG, 2) pellet 
(insoluble protein), 3) supernatant (soluble protein), 4) and 5) first and second washes, 






          
 
Figure 12. A schematic diagram showing the native GST tagged full-length and 
truncated (lacking the terminal 5 amino acids) proteins of FATZ-1, FATZ-2, FATZ-3 
and myotilin produced for AlphaScreen experiments. The bands (taken from SDS-
PAGE gels) close to each model show the native GST protein obtained after purification 
elution from glutathione resin. 
 
 
3.4 The C-terminal (last 5 amino acids) of the FATZ family and myotilin 
bind the PDZ domains of ZASP, ALP and CLP-36 proteins 
PDZ domains commonly bind the C-terminal of their interacting proteins. Therefore in 
order to check if the terminal 5 amino acids of the FATZ family, myotilin, palladin and 
myopalladin bind to the PDZ domains of ZASP, CLP-36 and ALP we performed 
binding experiments using both full-length and truncated (minus C-terminal 5 aa’s) 
protein. The His-tagged PDZ domain proteins were bound to the donor beads and the 
GST tagged ligand bearing proteins to the acceptor beads. Since the proteins used in 







Figure 13. A schematic representation of four of the proteins of the enigma family 
ZASP, ALP, CLP-36 and RIL, with their different binding domains. All four proteins 
have a PDZ domain at their N-terminal and one or three LIM domains at the C-terminal 
of the protein. ZASP, ALP and CLP-36 have in common another binding motif called 
ZM. The ZASP-1 isoform of ZASP that lacks the LIM domains at the C-terminal was 
used in all of the experiments reported in this thesis. 
 
 
A schematic diagram of the PDZ proteins studied can be found in Figure 13 showing 
that all of the proteins had single N-terminal PDZ domains and ALP, CLP-36 and RIL 
had single LIM domains towards the C-terminus. RIL was not used in AlphaScreen 
experiments but is a member of the Enigma family and detected in PDZ array 
experiments. The ZASP-1 isoform of ZASP was used in these experiments as it was the 
form detected by yeast-two- hybrid experiments to bind to myotilin (personal 
communication from Prof. Olli Carpen, unpublished data). All of the PDZ proteins used 










Figure 14. Results obtained from the AlphaScreen experiments using native His tagged 
PDZ proteins (ZASP, CLP and ALP) attached to the donor beads and native full length 
and truncated (minus the C-terminal 5 amino acids) GST proteins of FATZ-1, FATZ-2, 
FATZ-3, myotilin and α-actinin2 (ACTN2) attached to the acceptor beads. The 
concentration of the donor and acceptor proteins was 50 nM. The experiment was 
repeated at least three times and the standard deviations of the means are shown as bars 
at the top of the histograms. 
 
From the results of the AlphaScreen experiments (fig 14) it is clear that all of the 
proteins studied (FATZ-1, FATZ-2, FATZ-3, myotilin and α-actinin2) with the 




CLP-36). Truncated protein was produced for each of the proteins and tested but only 
the result for the truncated FATZ-2 protein is shown in the interests of clarity in Figure 
14. All of the truncated proteins tested did not bind the PDZ domains studied. In Figure 
14 it can be seen that although all of the PDZ domains were able to bind the proteins 
tested there was variability.  
The PDZ domain of ZASP showed much stronger binding to the ligand proteins than 
the PDZ domains of ALP or CLP-36 with the exception of α-actinin2 had stronger 
binding to the PDZ domain of CLP-36. The best ligand protein for overall binding was 
FATZ-2 whereas FATZ-3 bound poorly to the three PDZ domains studied. 
 
 
3.5 The PDZ domain of ZASP binds the IVTT full-length FATZ-3 but 
not truncated FATZ-3 (minus C-terminal 5 aa’s)  
 
The proteins used in the GST pulldown experiment are shown schematically in Figure 
15a. In order to confirm the AlphaScreen result that FATZ-3 truncated protein is unable 
to bind the PDZ domain of ZASP I performed a GST pulldown in vitro binding assay. I 
used IVTT [35S]-labeled FATZ-3 both full-length (251 aa) and truncated (1-246 aa) to 
pull down GST PDZ-ZASP and GST alone. As expected the full-length FATZ-3 but not 
the truncated FATZ-3 pulled down the GST PSZ-ZASP (Fig 15b). Neither protein 












Figure 15. a). A schematic figure showing the FATZ-3 proteins both the full-length 
(251 aa) and the truncated minus the C-terminal 5 amino acids (246 aa). b) An 
autoradiograph of a GST pull down experiment showing that IVTT FATZ-3 full-length 
(wt) protein (251 aa’s) binds to ZASP GST-PDZ (GST-PDZ-Z) protein whereas the 
FATZ-3 truncated C-terminal protein (246 aa’s) does not. Neither protein bound 
strongly to GST alone. The first two columns show the input (50 %) of the IVTT 
proteins. The bottom row shows lanes from a SDS-PAGE gel stained with Coomassie 
blue. The lanes show the loading of the GST proteins confirming that equal amounts of 






3.6 Peptides of the C-terminal amino acids of the FATZ family, myotilin, 
palladin and myopalladin bind to the PDZ domains of ZASP, ALP and 
CLP proteins 
 
We designed peptides corresponding to the last 5 amino acids of the C-terminals of the 
proteins to be tested linked to two gamma-butyric acid (GABA) molecules that were 
used as non-hydrophobic linkers and biotin. These peptides were ETEEL (FATZ-1), 
ESEDL (FATZ-2 and palladin), ESEEL (FATZ-3 and myotilin) and ESDEL 
(myopalladin). It is known that the type of amino acid at position 0 is important for the 
binding between the ligand and the PDZ domain as changing this amino acid can either 
destroy or alter the binding. Therefore a peptide was designed ESEEE with the last 
amino acid changed from leucine (L) to glutamic acid (E) to test the specificity of 
binding. 
The biotinylated peptides were bound to the donor beads and the His tagged PDZ 
proteins for ZASP, CLP-36 and ALP were bound to the acceptor beads, the experiment 
was performed as detailed in the Material and Methods. The PDZ domain proteins were 
used at a concentration of 50nM whereas the peptides were used at a concentration of 
10 nM with the exceptions of ESEEE and ESDEL that were used at concentrations of 
25 and 50 nm respectively. Therefore the binding seen for these peptides when 











Figure 16. Results obtained from the AlphaScreen experiments using biotinylated 
peptides (donor) and His tagged PDZ proteins (acceptor). The peptides which 
correspond to last 5 amino acids of the C-terminals of FATZ-1, FATZ-2/palladin, 
FATZ-3/myotilin, myopalladin as well as the mutated peptide with the L changed to E 
were tested for binding to the PDZ domains of ZASP (Z), CLP-36 (C) and ALP (A). 
The experiment was repeated at least three times and the standard deviations of the 
mean are shown as bars at the top of the histograms. 
 
 
From the results of the AlphaScreen experiments shown in Figure 16 it can be seen that 
all of the peptides bind to the different PDZ domain proteins with the exception of the 
mutated peptide (ESEEE) with the last amino acid L substituted with E. Therefore the 
last amino acid is crucial for the interaction with the PDZ motif of ZASP, CLP-36 and 
ALP. These results confirm the computer prediction that the last four amino acids of the 




The variation in binding is dependent both on the peptide and the PDZ domain studied. 
The FATZ-1 peptide would seem to bind better to the PDZ domain of ZASP whereas 
the FATZ-2/palladin peptide binds equally well to the PDZ domain of CLP36 and 
ZASP. FATZ-3/myotilin and myopalladin both bind better to the PDZ domain of CLP-
36. It should be noted that both the peptides and the proteins are non-phosphorylated 
(fig 16). 
 
3.7 Phosphorylation affects the binding activity of the C-terminal amino 
acid peptides to the PDZ domains of ZASP, CLP-36 and ALP: 
To determine the influence of phosphorylation on the binding between the biotinylated 
peptides and the PDZ domains; peptides were designed phosphorylated on either the 
serine (EpSEEL, EpSEDL, EpSDEL, EpSEEE) or the Threonine (EpTEEL) residues. 
These phosphorylated peptides were tested for binding activity with the PDZ domains 
of ZASP, CLP-36 or ALP using AlphaScreen. The phosphorylated peptides were bound 
to the donor beads and the native His tagged PDZ domain proteins were bound to the 
acceptor beads. There was a significant difference in the strength of the binding between 
different phosphorylated peptides to the PDZ domains (fig 17) 
Although there is variation in the strength of binding all the phosphorylated peptides 
bind well with the PDZ domain of ZASP. The strongest binding being that of the 
FATZ-3/myotilin peptide followed in order of decreasing strength by that of FATZ-
2/palladin, FATZ-1, myopalladin respectively. The peptide mutated EpSEEE did not 
show any appreciable binding to the three PDZ domains used in these experiments. 
Only the FATZ-3/myotilin and the FATZ-2/palladin phosphorylated peptides showed 




PDZ domain was particularly weak since 5 times more peptide was used in these 
binding experiments than in the others. If the same concentration was used (ie 10 nM) 




Figure 17. Results from AlphaScreen experiments showing the binding of the 
phosphorylated peptides with the PDZ domains of ZASP (Z), CLP (C) and ALP (A). 
The His tagged PDZ domain proteins were used at a concentration of 50 nM whereas 
the phosphorylated peptides were used at a concentration of 10 nM the exceptions to 
this were ESEDL and ESEEE that were used at 50 nM. The experiment was repeated at 
least three times and the standard deviations of the means are shown as bars at the top of 
the histograms. 
 
Seen in Figure 18 is a composite diagram showing results of the AlphaScreen binding 
experiments for both the non-phosphorylated peptides (fig 16) and the phosphorylated 
peptides (fig 17). The results show the binding between the peptides and the PDZ 




between peptides and also PDZ domains. The mutated peptide phosphorylated 
(EpSEEE) or not (ESEEE) showed no binding with any of the PDZ domains. This result 
is in keeping with the known literature on PDZ domain interactions, namely that the last 
amino acid of the C-terminal ligand is crucial for the binding. Therefore we can 
conclude that this observation is also true for the binding of the E[ST][DE][DE]L 
ligand to the PDZ domains of ZASP, CLP-36 and ALP (fig 18). Previously, it was not 
known that the FATZ family, myotilin, palladin and myopalladin could bind to CLP-36 
and ALP. 
 
 Mutated peptides (ESEEE, EpSEEE): Both the phosphorylated and non 
phosphorylated peptide showed no binding with the PDZ domains of ZASP, CLP-36 
and ALP (Fig. 18).  
 FATZ-1 (ETEEL, EpTEEL): The phosphorylated peptide showed stronger binding to 
the ZASP-PDZ domain than to the PDZ domains of CLP-36 and ALP and this was also 
true for the non phosphorylated peptide. Therefore for the FATZ-1 ligand 
phosphorylation would appear to be an advantage at least for binding the PDZ domain 
of ZASP (fig. 18). The binding to CLP-36 although weak did not change due to 
phosphorylation. 
 FATZ-2/palladin (ESEDL, EpSEDL): The phosphorylated peptide showed stronger 
binding to the ZASP-PDZ domain than to the PDZ domains of CLP-36 and ALP. The 
non phosphorylated peptide showed the strongest binding to the CLP-36 PDZ domain. 
For the FATZ-2/palladin ligand phosphorylation would appear to be an advantage at 
least for binding the PDZ domain of ZASP (fig. 18). The binding to CLP-36 did not 
change due to phosphorylation. However it is notable that only the phosphorylated 






































































































































































































































































































































































































































FATZ-3/ myotilin (ESEEL, EpSEEL): The phosphorylated peptide showed stronger 
binding to all three PDZ domains than the non phosphorylated peptide. It is interesting 
that also in this case only the phosphorylated peptide was able to bind the ALP PDZ 
domain. Therefore for FATZ-3/myotilin phosphorylation had positive effect on the 
interactions with the PDZ domains of ZASP, CLP-36 and ALP (Fig. 18).  
Myopalladin (ESDEL, EpSDEL): The phosphorylated peptide showed stronger 
binding to the ZASP PDZ domain than the non-phosphorylated peptide. On the other 
hand the non-phosphorylated peptide showed stronger binding to the CLP-36 PDZ 
domain than the phosphorylated peptide. There was only very weak binding of the 
phosphorylated peptide to the ALP PDZ domain and none with the non-phosphorylated 
peptide. In the case of myopalladin phosphorylation had positive effect on the 
interaction with the PDZ domains of ZASP and ALP and negative effect on that of 
CLP-36 (Fig. 18). 
 
 
3.8 The C-terminal FATZ-1 (CD2) competes with the binding between 
the phosphorylated and non phosphorylated peptides of FATZ-3/myotilin 
and the ZASP-1 protein: 
One of the advantageous of the AlphaScreen technique is that it can be used for 
performing competition studies. In this competition experiment we used the C-terminal 
domain of the FATZ-1 protein (CD2) as competitor for the binding between the 
peptides phosphorylated and non-phosphorylated of FATZ-3/myotilin and the ZASP-1 






         
 
Figure 19. Results of the AlphaScreen competition assay. The phosphorylated 
(EpSEEL) and non-phosphorylated (ESEEL) FATZ-3/myotilin peptides were used at a 
concentration of 50 nM and the ZASP-1 protein at 100 nM. The strength of binding of 
these peptides to the ZASP-1 protein was taken as 100 % when measured without the 
addition of the competitor. Increasing amounts of the competitor (the C-terminal 
domain of the FATZ-1-CD2 protein) were added to the interaction. The standard 
deviation of the means were added as lines either side of the points denoting the 
Signal/Noise ratio. 
 
The CD2 region of FATZ-1 is the C-terminal part of the protein comprising of amino 
acids 171 to 299 (Faulkner et al., 2000). The non-phosphorylated native His tagged C-
terminal FATZ-1 protein (CD2) was able to compete better with the binding between 
the non-phosphorylated peptide and the native ZASP-1 protein than with the binding 
between the phosphorylated peptide and the ZASP-1. It required 10 nM of the 
competitor protein to knockdown 50 % of the binding strength in the case of the non-
phosphorylated peptide and 100 nM in the case of the phosphorylated peptide. This 




phosphorylated and non-phosphorylated FATZ-3/myotilin peptides with the PDZ 
domain pf ZASP noted in the previous experiments (fig 18) since that of the 
phosphorylated peptide was stronger. Therefore this result confirms that the 
AlphaScreen can measure qualitatively the strength of binding of an interaction and that 
the full-length protein behaves in a similar manner to the PDZ domain alone. A 
schematic model of the AlphaScreen interactions can be seen in Figure20.  
                 
 
 
Figure 20. Schematic diagrams depicting the competition by the native His tagged 
FATZ-1 protein of the binding between the native ZASP-1 protein and the a) 




3.9 The ACTN2 protein competes with the binding between the 
phosphorylated and non-phosphorylated peptides of FATZ-3/myotilin 
and the ZASP-1 protein. 
It is known that α-actinin2 (ACTN2) binds the PDZ domain of ZASP (Zhou et al., 
1999). The final four amino acids of the C-terminal of ACTN2 constitute a binding 
motif for class I PDZ domain proteins: X[ST]X[VIL] where X is any amino acid. In 




type I PDZ domain however we have shown that it can also be classified as a type III 
PDZ domain. Therefore we wanted to check if ACTN2 was capable of competing the 
binding between the ZASP-1 protein and the phosphorylated and non-phosphorylated 
peptides of FATZ-3/myotilin that is an interaction with a type III ligand (fig 21). 
 
                  
 
Figure 21.  The competition of ACTN2 for the binding of non-phosphorylated and 
phosphorylated peptides of FATZ-3/myotilin with ZASP-1 protein detected using the 
AlphaScreen technique.  
 
Although the difference was not as striking as with the FATZ-1 CD2 protein the non-
phosphorylated native His tagged ACTN2 was able to compete better with the binding 
between the native ZASP-1 protein and the non phosphorylated FATZ-3/myotilin. Until 
a concentration 10 nM of this competitor protein there was no appreciable reduction in 
the binding strength. In the case of the non-phosphorylated peptide binding ZASP-1 at 




the case of the phosphorylated the decrease was approximately 60 % (fig 20). Therefore 
the ACTN2 protein is capable of interfering with the binding between a class III PDZ 
domain ligand and ZASP-1. A schematic model of the AlphaScreen interactions can be 





Figure 22. Schematic diagrams depicting the competition by the native His tagged 
ACTN2 protein of the binding between the native ZASP-1 protein and the a) 














3.10 PDZ array experiments 
It was important to know if the E[ST][DE][DE]L motif was specific for a set of PDZ 
domain proteins or if it bound ubiquitously to any PDZ domain therefore as a way of 
testing several PDZ domains for binding to this ligand a commercial array of PDZ 
proteins was used (Panomics PDZ Array I). There are 28 different GST tagged PDZ 
domain proteins spotted in duplicate on the blot as well as positive and negative control 
proteins (fig 23).  
 
 
Figure 23. Schematic diagram of the TranSignal PDZ Domain Array I. The proteins on 
the array are spotted in duplicate at 100 ng. Positive controls (Histidine tagged ligands) 
are spotted along the row E and the columns 17 and 18, a negative control (GST 
protein) was spotted at position D 9 and 10 (Panomics) 
. 
In the PDZ array experiments I used the same biotinylated phosphorylated and non-
phosphorylated peptides that we had previously used for the AlphaScreen experiments 
but at a concentration of 0.3 µg/ml, as well as native His tagged C-terminal FATZ-3 
(81-251 aa) protein at a concentration of 15 µg. The results with the various peptides are 
detailed below. 
 
3.10.1 FATZ-1 peptides bind to the PDZ domain of hCLIMI (CLP-36) and RIL 
Both the phosphorylated (EpTEEL) and the non-phosphorylated (ETEEL) peptides 




membranes in order to check for interactions with PDZ domain proteins. The strength of 
the binding of the biotinylated ligand to the GST PDZ protein roughly correlates with 
the intensity of the signal detected. The phosphorylated peptide had a stronger binding 
to the PDZ domain of hCLIM1 (CLP-36) than the non-phosphorylated peptide (fig 24) 
which confirms with the result obtained using the AlphaScreen technique (fig 18). Also 
both peptides bound to a new PDZ domain protein, RIL (fig 24). As can be seen in 
Figure 24 the binding with RIL was strong and phosphorylated peptide bound better 




Figure 24. PDZ Array blots showing the interactions of the phosphorylated (EpTEEL) 
and non-phosphorylated (ETEEL) FATZ-1 peptides with the GST PDZ domain proteins 
on the blot. The only PDZ domain proteins positive in both blots were hCLIMI (CLP-
36) and RIL.  
 
3.10.2 FATZ-2/palladin peptides bind to the PDZ domain of hCLIMI (CLP-36) and 
RIL 
The phosphorylated (EpSEDL) and non-phosphorylated (ESEDL) peptides of FATZ-
2/palladin were individually incubated with the two membranes.  
Both peptides showed interactions with the PDZ domain of hCLIM1 (CLP-36) and RIL 









Figure 25. PDZ array blots showing the interaction of the non-phosphorylated (ESEDL) 
and phosphorylated (EpSEDL) FATZ-2/palladin peptides with the PDZ domain of 
hCLIM1 (CLP-36) and RIL.  
 
3.10.3 FATZ-3/myotilin peptides bind to the PDZ domain of CLP and RIL 
The phosphorylated (EpSEEL) and non-phosphorylated (ESEEL) peptides 
corresponding to the last 5 amino acids of FATZ-3/myotilin were incubated with two 
different membranes and showed binding to the PDZ domain proteins of hCLIM1 
(CLP-36) and RIL (fig 26). In this instance the non-phosphorylated peptide bound 
stronger to the RIL PDZ domain protein than the phosphorylated peptide. 
However inexplicably the non-phosphorylated peptide bound stronger to the hCLIM1 
(CLP-36) protein this is in contradiction to the results found using the AlphaScreen. The 
amount of protein blotted can vary therefore the PDZ Array is less precise than the 







Figure 26. PDZ Array blots showing the interaction of the non-phosphorylated 
(ESEEL) and phosphorylated (EpSEEL) FATZ-3/myotilin peptides with the PDZ 
domain proteins hCLIM1 (CLP-36) and RIL.  
 
 
3.10.4 Myopalladin peptides bind to the PDZ domain of CLP and RIL 
The non-phosphorylated (ESDEL) myopalladin peptide bound stronger to the PDZ 
domain proteins hCLIM1 (CLP-36) and RIL than the phosphorylated peptide (EpSDEL) 
(fig 27). This result confirms that of the AlphaScreen for the non-phosphorylated 




Figure 27. PDZ Array blots showing the interaction of the non-phosphorylated 
(ESDEL) and phosphorylated (EpSDEL) myopalladin peptides with the PDZ domain of 




3.10.5 The mutated peptides do not bind to the PDZ domains of hCLIM1 (CLP-36) 
and RIL 
The phosphorylated (EpSEEE) and non-phosphorylated (ESEEE) mutated peptides 
were both tested for binding to the GST PDZ domain proteins. As expected both of 
these peptides did not show any binding with hCLIM1 (CLP-36) and RIL. However the 
phosphorylated peptide did interact with another the PDZ domain protein, Dlg4-D3. 
Thus showing that by changing the amino acid at position 0 you can destroy its binding 






Figure 28. PDZ Array blots showing that the non-phosphorylated (ESEEE) and 
phosphorylated (EpSEEE) mutated peptides did not interact with the PDZ domain 
proteins hCLIM1 (CLP-36) and RIL. The non-phosphorylated peptide ESEEE bound to 










3.10.6 The C-terminal FATZ-3 protein behaves as the non-phosphorylated FATZ-
3/myotilin peptide 
I produced and purified native His tagged protein of the C-terminal of FATZ-3 (81-251 
aa) to check if this protein could show the same binding activity as the non- 
phosphorylated peptide (ESEEL). As can be seen in Figure 29 the C-terminal protein 
binds well to the PDZ domains of hCLIM1 (CLP-36) and RIL. The FATZ-3 protein and 
peptide both showed the same binding activity with these PDZ domain proteins (fig 29). 
This confirms that the biotinylated 5 amino acid peptides behave in a similar manner to 
the native His tagged protein in binding experiments. 
 
 
           
 
Figure 29. PDZ Array blot, showing that the native His tagged FATZ-3 C-terminal 



































































































































































































































































































































































































































































































It can be seen in figure 30 that all of the peptides with the exception of the mutated 
peptides bind to the PDZ domain proteins of hCLIM1 (CLP-36) and RIL. The non-
phosphorylated mutated peptide interacts with the PDZ domain of Dlg4-D3 protein. 
Unfortunately the proteins for ALP and ZASP were not present in these commercial 
Arrays therefore only the results for CLP-36 can be directly compared with the 
AlphaScreen results. The poor binding of the phosphorylated myopalladin peptide to 
CLP-36 confirms our AlphaScreen findings, as does the FATZ-2/palladin binding 
which was the same for both the phosphorylated and non-phosphorylated peptides. In 
contrast the binding of the FATZ-1 non-phosphorylated peptide was weaker in the blot 
than that seen by AlphaScreen were both the phosphorylated and non-phosphorylated 
peptides showed equal binding. The binding with the FATZ-3/myotilin peptide is also 
in contrast to the AlphaScreen result as the phosphorylated peptide did not bind well. 
The binding of RIL to the FATZ family, myotilin , palladin and myopalladin was 
previously unknown although it is in keeping with the fact that the RIL belongs to the 















3.11 FATZ-3 interacts with Ankrd2 
During a search for new binding partners for FATZ-3 I found that Ankrd2 could bind 
FATZ-3. I confirmed this by co-immunoprecipitation experiments in COS-7 cells. In 
these experiments COS-7 cells were transfected with FLAG-tagged FATZ-3 alone or 
with c-myc-tagged full length Ankrd2. Cell lysates from transfected cells and non-
transfected cells were immonuprecipitated with antibody against the c-myc tag, the cell 
lysate was subjected to SDS-PAGE, immunoblotted and then probed with antibody 
against the FLAG-tag. A positive band was detected in the double transfections 
indicating that FATZ-3 interacts with Ankrd2 since it could be detected by co-
immunoprecipitation (Fig 31). 
 
                           
 
Figure 31. Co-IP of Ankrd2 and FATZ-3 transfected COS-7 cell lysates (100 µg). The 
cell lysates were immunoprecipitated with anti-c-myc monoclonal antibody separated 
by SDS-PAGE, immunoblotted and detected with anti-FLAG monoclonal antibody. 
Lane 1, cell lysates from non-transfected COS-7 cells; lane 2; cell lysates from COS-7 
transfected with pCMV-FLAG-FATZ-3 and with pCMV-cmyc Ankrd2; lane 3, 
transfected with pCMV-FLAG-FATZ-3 alone; lane 4, cell lysates from COS-7 





3.11.1 The N-terminal FATZ-3 binds Ankrd2  
In order to determine region of FATZ-3 interacting with Ankrd2 I made two constructs 
of the FATZ-3 gene; an N-terminal (1-540 bp) which encodes a (1-180aa) protein and a 
C-terminal (241-753bp) which encodes a (81-251aa) protein. Both constructs share an 
overlap of 300 bp which encodes for a central region (81-180aa) of the FATZ-3 protein 
(fig 32a). COS-7 cells were transfected with N-terminal FLAG-tagged constructs of 
FATZ-3 full-length (as positive control), N-term-FATZ (1-180 aa), C-term-FATZ-3 
(81-251 aa) and a c-myc tagged Ankrd2 construct as well as the vectors without inserts 
(negative controls). Cell lysates (70 ug) were immonuprecipitated with antibody against 
c-myc the then separated by SDS-PAGE, immunoblotted and probed with anti-FLAG 
antibody. Both full length and N-terminal FATZ-3 were able to bind to Ankrd2 as it co-
immunoprecipitated with them. There was no binding of Ankrd2 with the C-terminal of 
FATZ-3. Therefore the binding region for Ankrd2 is the first 180 amino acids of the N-
terminal of FATZ-3 (fig 32b). Western blots of cell lysates show the amount of proteins 
expressed in transfected cells and that there was no cross reaction of the cmyc antibody 



















Figure 32. a) schematic diagram showing the full length FATZ-3 and the N- and C-
terminal regions of FATZ-3. b) Co-IP of COS-7 cells transfected with pCMV-FLAG-
FATZ-3, pCMV-FLAG-N-term-FATZ-3, pCMV-FLAG-C-term-FATZ-3 and pCMV-c-








3.12 Expression and purification of FATZ-3 protein 
The FATZ family of proteins is interesting in that apart from the motif their C-terminal 
that we are proposing as a PDZ domain ligand there are no other binding motifs known 
for these proteins. They have been shown to bind to a large variety of proteins; filamins, 
ACTN2, telethonin, calcineurin, myotilin, ZASP and now as demonstrated by the work 
in this thesis, to ALP, CLP-36 and RIL. Therefore it would be very useful to know the 
tertiary structure of members of this family to understand their protein-protein 
interactions. Therefore I undertook as part of my PhD project to obtain information on 
the tertiary structure of FATZ-3 and for this structural project we choose to use the 
approach of crystallization FATZ-3. These studies were done in collaboration with the 
laboratory of Prof. Kristina Carugo, University of Vienna, Austria. I prepared the 
purified protein and initial tests in Trieste and then went to her laboratory for 3 months 
to do large scale production and purification of the protein as well as the crystallization 
procedures outlines below. The crystals obtained were examined at the European 
Synchrotron Radiation Laboratory, Grenoble, France. 
In order to crystallize a protein it is necessary to obtain a high concentration of purified 
protein (5-10 mg/ml). I spent a lot of time and effort in setting up the conditions and 
system for protein expression and purification mainly due to the difficulty of expressing 
high amounts of soluble full length FATZ-3 protein. I tried to express FATZ-3 the full 
length protein first as a His tagged protein and then as a GST recombinant protein using 
both bacterial and the Baculovirus expression systems. The protein purification trials 





3.12.1 Expression and purification of His tagged FATZ-3 full-length protein in 
Bacteria 
The cDNA of FATZ-3 was cloned into the prokaryotic expression vector pQE30 
(Qiagen) which allows the expression of a protein with a 6XHis tag at the N-terminal. 
E. coli M15 [pREP4] cells were transformed with the His-FATZ-3 construct and used 
for protein expression after induction with IPTG. 
I made several protein production and purification trials with different all at room 
temperature with different concentrations of IPTG and different buffers however protein 
was very low. Figure 33 shows an example of a the amount of FATZ-3 obtained from 
purification from of a 500 ml culture of M15 cells induce with 1mM IPTG. 
 
                        
 
Figure 33. SDS-PAGE of His tagged FATZ-3 protein obtained from M15 cells (500ml 
culture) induce with 1mM IPTG: Lane1, M15 cell lysate before induction with IPTG; 
Lane2, pellet after induction (insoluble proteins); Lane 3, supernatant after induction 
(soluble proteins); Lane4, flow-through from column; Lanes 5-7, three washes; Lane8, 
the eluted His-FATZ-3 showing two bands, one at  ~28  kD (FATZ-3) and one at ~10 




3.12.2 Protein expression and purification of recombinant GST-FATZ-3 full length 
protein in Bacteria 
Since I had difficulties expressing and purifying FATZ-3 full-length protein with an N-
terminal His tag, I decided to produce FATZ-3 as a GST fusion (N-terminal) protein to 
try to enhance solubility. The GST-FATZ-3 construct was used to transform BL21 
(DE3) pLys S bacterial cells and induced by IPTG. I made several trials with different 
concentrations of IPTG and different buffers; shown in Figure 34 is an example of three 
protein purifications with different IPTG concentrations (0.1, 0.5 and 1 mM). There was 
no significant difference between the three concentrations of IPTG. I obtained higher 
expression and solubility when FATZ-3 was expressed as a GST fusion protein. 
However the amount obtained was still not sufficient for protein crystallization trials 
(fig 34). 
 
            
 
Figure 34. SDS-PAGE of the different purification trials for GST-FATZ-3. The 
different concentrations of IPTG used were 0.1, 0.5 and 1 mM. The GST-FATZ-3 
protein was detected as a 54 kD band after SDS-PAGE. Only the eluted proteins and 




3.12.3 Protein expression and production of full-length His tagged FATZ-3 protein 
using the Baculovirus expression system 
Since I had difficulties expressing and producing FATZ-3 in bacteria, I decided to 
express the protein in eukaryotic cells by using the Baculovirus expression system 
(Invitrogen). Full-length FATZ-3 cDNA was cloned into the pFastBacHT vector which 
expresses an N-terminal 6XHis tag recombinant protein. The pFastBacHT vector 
contains Tn7R and Tn7L which are two sequences homologous with the mini-attTn7 
sequence, that is present in the baculovirus shuttle vector (bacmid 136 kb), and allows 
homologous recombination and thus transposition of the gene of interest into the 
bacmid. In order to allow the transposition of His tagged FATZ-3 into the bacmid 
genome the FATZ-3 pFastBacHT construct was transformed into the E. coli strain 
DH10Bac that contains the bacmid genome. After His tagged FATZ-3 was inserted into 
the bacmid genome, the bacmid containing FATZ-3 (1ug) was produced and then 
transfected into Sf9 insect cells (2 x 106/ml). 
The baculovirus virus containing FATZ-3 (P1) was then amplified by infection in Sf9 
cells (2 x 106/ml, MOI 0.1 to obtain a higher amount of the virus (P2). The efficiency of 
infection of the virus and the expression of FATZ-3 was checked by viral dose and time 









3.12.3.1 Dose efficiency experiment for the P2 virus expressing His-FATZ-3 full-
length protein 
I performed experiments to check the efficiency of infection of the virus producing 
FATZ-3 and to determine the optimum amount of virus needed for protein expression.  
 




Figure 35. a) A schematic figure outlining the dose efficiency experiment. Sf9 cells 
were plated at 2x106 cells per dish and infected with different amounts of the 
baculovirus expressing the full-length FATZ-3 protein. b) infected cell lysates (from the 
5 different plates) separated by SDS-PAGE, immunoblotted and detected with 
monoclonal antibody to the His tag and a polyclonal antibody to FATZ-3 (a mixture of 
polyclonal antibody to FATZ-1 and FATZ-2 that can detect FATZ-3) to check the 
expression of the protein. The lane numbers correspond to the numbers in Figure 34a 
showing the different amounts of virus used for infection. Lane 4 shows the optimum 




Sf9 cells (2 x 106 cells) were seeded in dishes (60 mm) and infected with different 
amounts of the virus (5, 50, 150 and 500 ul) plus a uninfected cells as a control 
(schematic diagram, fig 35a). Cells were harvested after 4 days and cell lysates were 
separated on two SDS-PAGE gels, blotted onto membranes and detected with 
antibodies against the His tag and FATZ-3 (in this case a mixture of FATZ-1 and 
FATZ-2 antibodies were used) to check the expression of the protein. In lane 5 the 
amount of the FATZ-3 protein was approximately double that in lane 4 but this result 
was obtained using at least 3 times more virus (500 µl of P2 virus stock) for the 
infection (fig 35b). Therefore the optimum amount of virus needed for good virus 
infection and 6XHis FATZ-3 recombinant protein production was 150 µl of the P2 
stock for infection of 2x106 Sf9 insect cells. 
 
3.12.3.2 Time course experiment for the P2 virus expressing full-length His-FATZ-3 
protein  
I made a time course experiment to determine the best time for the expression of the His 
tag FATZ-3 recombinant protein. The experiment was performed by infecting Sf9 cells 
(2x106  cell for a 60 mm dish)  with the previously determined optimum amount of 
baculovirus expressing FATZ-3 (150 ul) and harvesting one dish a day (schematic 
diagram, fig 36a). The cell lysates were then run on a SDS-PAGE gel, blotted onto a 
PDVF membrane and detected with anti-His antibody. I found that the optimum time of 








                 
 
                          
 
Figure 36. a) A schematic diagram outlining the time course experiment. Sf9 cells were 
plated at 2x106 cells per dish, the cells were infected with 150ul of baculovirus and a 
dish was harvested every 24 hours. b) Sf9 cell lysates from the dishes harvested at 
different times were separated by SDS-PAGE, immunoblotted and detected using 
monoclonal anti-His antibody. The optimum expression of His tagged FATZ-3 was 96 
hours or longer. 
 
 
3.12.3.3  Purification of native FATZ-3 protein expressed by baculovirus in Sf9 cells  
From the previous experiments (does and time course) I knew the optimum amount of 
virus (150ul) needed for expressing FATZ-3 and the best time to harvest the Sf9 cells 
(at least 4 days after infection). Therefore I started to produce the His-FATZ-3 full-




of this thesis. Briefly Sf9 cells to (200 ml, 2x106 /ml) were grown in spinner flasks and 
infected the cells with the optimum amount of virus.  
The cells lysates were lysed with buffer containing lysozyme, centrifuged, incubated 
with Ni-NTA resin for 2 hours at 4 °C, then washed and eluted with elution buffer 
containing 250 mM imidazole. The eluates were run on a SDS-PAGE gel which was 
then stained with Coomassie blue. In the Baculovirus system the amount of soluble 
native His–FATZ-3 protein obtained was higher than that obtained from bacterial 
expression, however still not enough for further purification for crystallization 
experiments (fig 37). We tried scaling up the culture volume to 1 L culture and we tried 
as well scaling up in bottles but both ways didn’t of scaling up didn’t give the right 
expected amount of proteins plus we faced difficulties dealing with Sf9 cells in large 
scales. 
 
      
 
Figure 37. A SDS-PAGE gel showing His-FATZ-3 protein production and purification 
from a 200 ml culture of Sf9 cells. Lane 1, total cell lysate; lane 2, pellet (insoluble 
proteins); lane 3, flow-through from column; lanes 4-5 two different washes, lanes 6-7 




3.13 Expression and purification of C-terminal FATZ-3 protein in 
bacteria 
Since I had a lot of difficulties expressing and producing soluble full-length FATZ-3 
using both bacterial and Baculovirus systems I decided to try a different approach, 
namely express a shorter form rather than the full-length of the FATZ-3 protein. I found 
using computer predictions for FATZ-3 that by removing the first 80 amino acids the 
isolectric point (PI) of the protein dropped from 9.4 to 7.3. Therefore I decided to use 
this truncated version of the FATZ-3 protein. 
 
3.13.1 Comparison of the expression and purification of GST and His tagged C-
terminal FATZ-3  
Primers were designed to amplify the last 516 bp of the FATZ-3 cDNA with restriction 
sites for cloning. The DNA corresponding to the C-terminal FATZ-3 was amplified by 
PCR and then after confirming there were no changes in the sequence it was cloned into 
the following prokaryotic vectors; pPROEXHTa which expresses recombinant proteins 
with a N-terminal His tag and contains a TEV protease cleavage site for cutting the His 
tag and pGEX-6P-3 which expresses a N-terminal GST protein containing a thrombin 
site for removing GST that can be cleaved by a prescission protease specific for 
thrombin. The amplified PCR fragment encodes the final 171 amino acids of the C-
terminal of FATZ-3. I was interested in this C-terminal region of FATZ-3 since the C-
terminal is important for the interactions with PDZ domain proteins. I used both vectors 
to transform the E. coli strain BL21-Codon Plus-RP cells. Codon bias can be a 
significant obstacle for efficient expression of heterologous genes in E. coli hosts. In 




proline codon (CCC) most frequently affect bacterial gene expression. BL21-
CodonPlus-RP cells contain a ColE1-compatible vector with extra copies of the argU 
and  proL Camr tRNA genes which recognize arginine and proline codons, respectively. 
The C-terminal of FATZ is high in proline 15.7 %. In order to compare the 
pPROEXHTa and pGEX-6P-3 vectors I expressed the truncated FATZ-3 protein from 
both. I used a 200 ml culture of bacteria and induced with 1 mM for 4 hours at room 
temperature. On comparing the results of the purifications of the truncated FATZ-3 
protein with those of the full-length FATZ-3 protein produced in bacteria I could see 
that the C-terminal FATZ-3 is expressed better and is more soluble than the full-length 
FATZ-3. However comparing the two vectors, pPROEXHTa (fig 38a) and pGEX-6P-3 
(fig 38b), there was no great difference in the production of C-terminal FATZ-3. As 
there was no difference between the vectors I decided to use pPROEXHTa since the His 
tag is very small and if necessary I could used the C-terminal FATZ-3 without removing 
the His tag. The His tag is less likely to interfere in structural studies of the protein than 
GST, since the GST is approximately 26 kD. It may be better not to cleave the tag as 
any cleavage involves loss of protein and the amount of soluble C-terminal FATZ-3 is 










            
 
Figure 38 a) SDS-PAGE showing production of GST C-term-FATZ-3 obtained from 
BL21-Codon Plus-RP cells (200ml culture). Lane 1; lysate of cells before the induction 
with IPTG; lane 2; pellet ( insoluble proteins); lane3, supernatant (soluble proteins); 
lane4, flow-through from column, lanes 5-6 two washes; lanes 7-8 first and second 
elutions respectively; lane 9, GST alone (for comparison). b) SDS-PAGE showing 
production of His C-term-FATZ-3 obtained from BL21-Codon Plus-RP cells (200ml 
culture); lane 1, lysate of cells before induction with IPTG; lane,2, supernatant (soluble 
protein), lane3, flow-through from column; lanes 4-5, two different washes; lanes 6-8, 
first, second and third elutions of His C-terminal FATZ-3. 
 
 
3.13.2 Optimization of the purification of C-terminal FATZ-3 protein: 
In order to obtain the best level of purity of native soluble C-terminal FATZ-3 I tried 
several different buffers for the affinity purification step varying salt and imidazole 
concentrations. The best concentration of salt was around 300mM NaCl in the lysis, 
wash and elution buffers. To find the optimum concentration of imidazole I needed to 




lysis and wash buffers in order to reach the highest purity obtainable from affinity 
purification with the minimum loss of protein. 
Four small scale protein purification experiments were made with different 
concentrations of imidazole: First purification, in both lysis and wash buffers I used no 
imidazole; Second purification, in the lysis and wash buffers I used 3 mM and 5 mM of 
imidazole respectively; Third purification, in the lysis and wash buffers I used 5 mM 
and 10 mM of imidazole respectively; Fourth purification, in the lysis and wash buffers 
I used 10 mM and 20 mM of imidazole respectively. I found that the third condition 
(10mM imidazole lysis buffer and 20 mM in the wash buffer) was the best to obtain a 
good level of affinity purification for the amount of protein obtained (fig 39a). 
 I performed a small scale experiment to cleave the His tag from the His tag C-terminal 
FATZ-3 protein in order to determine the behaviour of the protein without the His tag 
(fig 39a). I used about 60 µg of the purified C-terminal FATZ-3 protein with 30 Units of 
the TEV enzyme with the addition of DTT (70 mM) in the reaction buffer, incubated 





                   
 
 
Figure 39. a) SDS-PAGE showing four different purifications using different 
concentrations of imidazole in the lysis and wash buffers, two elutions from each 
purification were loaded on the gel. Lanes 1-2, 1st and 2nd elutions from the purification 
using no imidazole in the lysis and wash buffers; lanes 3-4, 1st and 2nd elutions from the 
purification using 3 mM and 5 mM imidazole in the lysis and wash buffers respectively; 
lanes 4-5, 1st and 2nd elutions from the purification using 5 mM and 10 mM imidazole in 
the lysis and wash buffers respectively; lanes 7-8, 1st and 2nd elutions from the 
purification using 10 mM and 20 mM imidazole in the lysis and wash buffers 
respectively. b) SDS-PAGE the C-terminal FATZ-3 protein after cleavage of the His 
tag. Lane 1, His-C-terminal FATZ-3 before cleavage; lane 2, the C-terminal-FATZ-3 









3.14 Medium scale production and purification of C-terminal FATZ-3 
protein 
Previous purification trials were made with small scale culture, volumes of 50 ml and 
200 ml. I was interested to achieve a high level of protein purity and concentration for 
crystallization experiments therefore I increased the bacterial culture volume to 500ml. I 
induced the protein by adding IPTG 1 mM and incubating the culture at room 
temperature for 4 hours. The cells were harvested and resuspended in lysis buffer with 
the optimum concentrations of salt (300mM NaCl) and imidazole (10 mM), incubated 
on ice for 45 min. and then I purified the C-terminal FATZ-3 protein using three steps: 
 
1 Affinity purification: after centrifuging the cell lysate, the supernatant was 
incubated with Ni-NTA resin for 2 hours at 4°C and then washed several times 
with washing buffer containing 20 mM imidazole. The protein then was eluted 
using an elution buffer containing 250 mM imidazole. Elutions were run on a 
SDS-PAGE gel and then this was stained with Coomassie to see the first level of 
purity. 
2 Ion Exchange Chromatography: The eluted protein (after the first step) was 
dialysed against a buffer (KCl 75mM, TRIS 20 mM, pH 8.2) before being used 
in Ion exchange chromatography. The samples were then run on the mono Q 
column and eluted by linear gradient elution in 20 column volumes with the 
buffer (KCl 1M, TRIS 20 mM, pH 8.2).  
 
Fractions were then run on a SDS-PAGE gel and stained with Coomassie blue in 




3 Analytical gel filtration chromatography: Chosen fractions were concentrated 
and run on a Superdex 200 26/60 column for further purification. The protein 
eluted from the column at a molecular weight around 38 kD demonstrating that 
the C-terminal FATZ-3 behaves as a dimer (fig 40a). The level of purity of the 
C-terminal FATZ-3 was very good (fig 40 b) but the amount of protein obtained 
was not very high therefore I needed to scale up the protein production and 
purification. 
 
                           
 
 
Figure 40 a) The curve of the analytical gel filtration purification, the second peak of 
the curve is the dimer of C-terminal FATZ-3 eluting at a molecular weight of ~38 kD. 
b; SDS-PAGE showing the protein after the three steps purification (Affinity 
purification, Ion Exchange Chromatography and Analytical gel filtration 
chromatography), the major band represents the C-terminal FATZ-3 protein after the 





3.15 Large scale production and purification of C-terminal FATZ-3 
protein 
In order to obtain the optimum amount and concentration needed for protein 
crystallization experiments I had to scale up the protein production and purification. 
This part of work was done by me at laboratory of Professor Kristina Carugo, Vienna, 
Austria. I made several scale up trials starting from 5 L to 12 L. I faced a lot of 
difficulties with the protein purification when I scaled up. I tried different buffer 
conditions in the purification trials, until I obtained a good protocol. I had to use 
cationic exchange instead of ion exchange therefore I had to change the buffer from 
TRIS pH 8 to MES pH 6 in order to purify the protein by cationic exchange. For protein 
production I used a 12 L culture of bacteria induced with IPTG for 4 hours at 25°C, the 
cells were then harvested by centrifugation, resuspended in lysis buffer, disrupted using 
a French press and then centrifuged. The supernatant was then incubated with Ni-NTA 
resin for 2 hours, washed several times with washing buffer and eluted with elution 
buffer. 
The eluted protein was run on a SDS-PAGE gel and stained with Coomassie blue in 
order to see the purity of the first step purification (fig 41 a). Eluted samples were 
dialysed against a buffer (KCl 1M, MES 20 mM, pH 6) before being further purified by 
Cation Exchange Chromatography using a Source 15S column. Fractions were run on a 
SDS-PAGE gel and stained with Coomassie blue in order to chose the fractions 
containing the best purified protein (fig 41 b). The chosen fractions where then further 
purified by gel size exclusion chromatography using a Superdex 200HR 16/60 column. 
The fractions corresponding to the molecular weight of the protein were then run on a 




the amount of protein obtained (Fig 41 c). The fractions were then concentrated and 
after concentration checked by UV at 280 nm. The amount of C-terminal FATZ-3 
protein obtained was reasonable for protein crystallization trials (120 µl of protein at 10 
mg/ml) (fig 41 d). 
      
 
 
Figure 41. SDS-PAGE of the three different purification steps for the C-terminal 
FATZ-3 protein. a) M, molecular weight marker; lanes 1-4, different elutions obtained 
from the Affinity purification; b) M, molecular weight marker; lanes 1-9, chosen 
fractions from the cation exchange purification (eluted at the expected IP); c) M, 
molecular weight marker; lanes 1-9, chosen fractions from size exclusion 
chromatography (eluted at the expected molecular weight of the protein); d) the C-
terminal FATZ-3 protein after combining together all the fractions obtained from the 
size exclusion chromatography purification. The concentration of the purified C-





3.16 Circular Dichroism (CD) shows high percentage of random coil for 
the C-terminal FATZ-3 (81-251aa) protein 
 
The purified protein C-terminal FATZ-3 (81-251 aa) protein was used at a concentration 
of 3.6 µM for circular dichroism (CD) studies. These studies were done in order to gain 
information about the secondary structure of the protein. The data I obtained from the 
CD spectra showed that the protein contains 42.6% of random coil, 24.3 % of α-helix, 
17% anti-parallel and 5.7% parallel ß-sheets. This could mean that the protein may not 




Figure 42 Circular Dichroism (CD) results showing that the C-terminal FATZ-3 protein 





3.17 Dynamic light scattering (DLS) shows a low percentage of protein 
polydispersity  
 
In order to have information about the monodispersity of the protein in solution I used 
the purified C-terminal FATZ-3 protein at a concentration of 10mg/ml for DLS spectra.  
 
 
Figure 43 a). Graph of the results 
obtained from the Dynamic light 
scattering (DLS) experiment done at 22 
°C showing that the C-terminal FATZ-3 
protein had 17.7% of polydispersity.  
 
                                                                                                             
 
 
Figure 43 b). Graph of the results obtained from the 
Dynamic light scattering (DLS) experiment done at 4 °C 




I tested the protein sample at two different temperatures 22 °C (fig 43a) and at 4 °C (fig 
43 b) in order to see the behavior of the protein at different temperatures.  
The data I obtained from both temperatures showed that the protein contained a low 
percentage of polydispersity 17% and 16.6%, at 22 °C and 4 °C respectively: This 
means that the protein is homogenous in the solution. 
 
 
3.18 Stura footprint screen experiment 
 
A stura footprint screen kit was used to determine the optimum precipitants for 
crystallization studies and check if the concentration of the C-terminal FATZ-3 (81-
251aa) protein was the best concentration for the crystallization trials. I tried eight 
different conditions (highlighted in Table 2) which were recommended in the kit if there 
was a shortage of protein. I mixed 1 ul of each precipitant with 1 ul of the C-terminal 
FATZ-3 protein (10mg/ml) and checked under the microscope to detect if any protein 
precipitates formed. I saw that the C-terminal FATZ-3 protein precipitated immediately 
after mixing with 0.2M imidazole malate pH 7.0, PEG4K 15% (Table 2, 2B). Therefore 













 1 2 3 4 5 6 
 PEG 600 PEG 4K PEG 10K A.S. PO4 Citrate 
A 15% 10% 7.5% 0.75M 0.8M 0.75M 
B 24% 15% 12.5% 1.0M 1.32M 1.0M 
C 33% 20% 17.5% 1.5M 1.6M 1.2M 






























3.19 Crystallization trials 
 
Based on the results obtained from the stura footprint screen, I chose three 
crystallization kits to check the possibility of obtaining C-terminal FATZ-3 protein 
crystals. These kits were the JCSG+ Suite (QIAGEN), the JBScreen 1, 2, 3 and 4 
(JENA BIOSCINCE) and the PACT premier-HT96 MD1-36 (Molecular Dimension 
Limited). 
I tried around 300 crystallization conditions using the three kits. I used the vapor 
diffusion technique that uses sitting drops by mixing two different amounts of proteins 
0.1 µl and 0.2 µl with two different amounts of the precipitants then the protein drops 
were then incubated at 22 °C.  
The protein drops were made by a robot that forms nano drops. I started to obtain 
crystals after one month from the formation of the protein drops. Four crystallization 
conditions gave crystals from the three different kits that I used (JCSG+ Suite 




HT96 MD1-36). Figure 44 shows the crystals obtained from the four different 
conditions. PACT F2 (0.2M Sodium bromide, 0.1M Bis Tris propane pH 6.5, 20% w/v 
PEG 3350), JENA SCREEN E2 (20% w/v PEG 4000 10% w/v 2-Propanol 100 mM 
HEPES Sodium Salt pH 7.5), JCSG E6 (0.2 M Zinc acetate 0.1 M Imidazole pH 8 20% 
w/v PEG 3000) and JCSG E2a (0.2 M Sodium chloride 0.1 M Sodium cacodylate pH 
6.5 2 M Ammonium sulfate). The crystals were checked by X-ray at 0.91 Å at the 
European Synchrotron Radiation Laboratory, Grenoble, France, unfortunately the 






Figure 44 shows the crystals obtained from four different crystallization conditions 
PACT F2, JENA SCREEN E2, JCSG E6 and JCSG E2a 
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The sarcomere is the repeating contractile unit of striated muscle. Muscle contraction 
occurs when actin filaments (thin filaments) slide past myosin filaments (thick 
filaments) towards the centre of the sarcomere. ATP plays an important role in this 
interaction; the binding of ATP to myosin heads reduces their affinity of binding, while 
the hydrolysis of ATP enhances the interaction. The contractile force of the thin and 
think filaments is controlled and registered by the Z-disk, which is the border line 
between sarcomeres. The Z-disk is an important structure of the sarcomere (Hoshijima, 
2006), and is a complex of many proteins for example actin, alpha-actinin, titin, ZASP, 
the FATZ family, and telethonin to mention just a few. Most of the proteins that localize 
to the Z-disk interact with each other and mutations in Z-disk proteins can give rise to 
various pathological conditions such as cardiomyopathies and muscular dystrophies. 
Sometimes direct pathological effects can be seen as a result of the absence or alteration 
of proteins affecting the structure of the Z-disk. In the case of ZASP knockout mice this 
absence results in an unstructured Z-disk and the knock-out mice die in the first 24 
hours after birth suffering from a severe congenital myopathy (Zhou et al., 2001). 
Several Z-disk proteins bind to other non-muscle proteins involved in cell signalling 
suggesting a role for the Z-disk other than purely structural. 
The FATZ/Calsarcin/Myozenin family of proteins (Faulkner et al., 2000) consists of 3 




different tissue specific expression. FATZ-1 and FATZ-3 are highly expressed in 
skeletal muscle fast-twitch fibres, while FATZ-2 is highly expressed in heart and slow-
twitch fibres (Faulkner et al., 2000; Frey and Olson, 2002; Frey et al., 2000; Takada et 
al., 2001). The proteins share high homology at their N- and C-terminal and low 
homology in the intervening region. FATZ-3 protein shares 29% homology with FATZ-
1 and shares 34% homology with FATZ-2. The members of the FATZ family of 
proteins interact with the same muscle proteins, such as γ-filamin, telethonin, α-actinin-
2, ZASP and calcineurin (Faulkner et al., 2000; Frey and Olson, 2002; Frey et al., 2000; 
Takada et al., 2001) demonstrating that the FATZ family of proteins are very interactive 
towards other muscle proteins. All of the FATZ family members inhibit the activity of 
calcineurin in vitro and mice lacking FATZ-2 (Calsarcin-1/myozenin-2) showed a high 
expression of calcineurin (Frey et al., 2004; Frey and Olson, 2002; Frey et al., 2000) 
indicating that these proteins may be involved in modulating cell signalling. Also it is 
worth noting that mutations in FATZ-2 have been associated with hypertrophic 
cardiomyopathy (Osio et al., 2007).  
Here in this thesis I report research done as part of an ongoing study on the FATZ 
family of proteins in order to discover the role of this family in striated muscle. The 
main finding of this thesis is the identification of a group of mainly striated muscle 
proteins, consisting of the FATZ family, myotilin, palladin and myopalladin, that 
selectively interact via a C-terminal motif with the PDZ domains of several Enigma 
proteins, ZASP, CLP-36 and ALP. These interactions were verified by several methods 
such as GST pulldown, in vitro binding using the AlphaScreen technique and PDZ 
Arrays. The interaction of these proteins with the Enigma family members is highly 




peptide ligands will bind when given the opportunity. In fact only 2 of the 28 PDZ 
domain proteins on the Array bound to the peptide ligands, interestingly these were the 
only two Enigma family members on the Array; RIL and CLP-36 (hCLIM1). Before 
performing these array experiments we did not know that RIL could interact with 
members of the FATZ family, myotilin, palladin and myopalladin therefore RIL is 
another binding partner of these proteins. 
Based on the work presented in this thesis we propose that the FATZ family, myotilin, 
palladin and myopalladin bind to members of the Enigma family of PDZ proteins via a 
C-terminal class III type PDZ ligand. This ligand [ST][DE][DE]L falls into the category 
of a class III PDZ domain binding motif (fig 45). 
 
 
-X - [S/T] -X- [VIL]
P0P1P2P3
Class I
-X - [VYF] -X- [VIL]
P0P1P2P3
Class II
-X - [DE] -X- [VIL]
P0P1P2P3
Class III
FATZ-1:         ETEEL
FATZ-2:         ESEDL
FATZ-3:         ESEEL
Myotilin:        ESEEL
Palladin:         ESEDL
Myopalladin:  ESDEL
P4   P3     P2     P1     P0





Figure 45. Showing the three motifs that represents the three classes of PDZ domains 
class I, class II and class III, and the last 5 amino of the FATZ family, myotilin, palladin 





Initially we and our collaborators observed that the C-terminal last 5 amino acids of 
FATZ-3 and myotilin are identical (ESEEL), also those of FATZ-2 and palladin 
(ESEDL) whilst these amino acids in FATZ-1 (ETEEL) and myopalladin (ESDEL) 
show high similarity to those of the other members of the group. This high similarity 
raised the question of whether these proteins could interact with proteins via this C-
terminal ligand. As mentioned in the Results section using a program written by Prof. G 
Valle we scanned UniProt Knowledgebase Release 11.3 for any protein having as the 
final amino acids of their C-terminal the motif E[ST][DE][DE]L. The amino acids were 
given equal weightings with the exception of the final amino acid which was given a 
higher weighting since it has been shown that this is the most important amino acid for 
the binding between PDZ domains and their ligands. We found that this motif is 
restricted in Vertebrates to the FATZ family, myotilin, myopalladin and palladin with 
the exception of histidine ammonia lyase that has the final C-terminal amino acids 
(ESEDL) identical to FATZ-2 and palladin (Table 2). Histidine ammonia lyase is a 
cytosolic involved in histidine catabolism which has been reported in striated muscle. It 
most probably is able to bind the PDZ domain Enigma family members but whether it 
does so in reality would depend on its localization whereas the FATZ family, myotilin 
and myopalladin are located in the Z-disk in proximity to ZASP, CLP-36 and ALP. 
However interactions between FATZ family, myotilin and myopalladin and RIL are 
unlikely to occur at least in the Z-disc since RIL is located in the brain and lung but not 
muscle. As the number of proteins known to interact with each other increases and 
multiple binding partners is the norm rather than the exception it is important to define 




primarily localized in smooth muscle and non-muscle cells such as colon where it may 
well interact with CLP-36. 
It is important to remember that these proteins can also interact with numerous other 
proteins forming a vast interconnecting network. A major protein hub in this network is 
α-actinin. All of these proteins can bind α-actinin for example; some like RIL can bind 
the non-muscle isoforms of actinin, 1 and 4 whilst all the striated muscle proteins 
ZASP, the FATZ family, myopalladin, myotilin, ALP, CLP-36 and ZASP can bind the 
muscle isoforms of α-actinin. All of the Enigma family members binds to α-actinin 
through their PDZ domains or in some cases through their PDZ and LIM domain as in 
the case of CLP (Vallenius et al., 2000). It has been found that a mutation in the ALP-
PDZ domain (L78K) abolishes the binding of the PDZ domain to α-actinin (Xia et al., 
1997). Several mutations have also been made in the conserved sequence (PWGF) of 
the PDZ domain of ZASP in order to study its interaction with α-actinin. These 
mutations managed to disrupt the binding of the PDZ domain of ZASP to α-actinin, and 
its localization in the Z-disk (Zhou et al., 2001). 
Since it is vital to understand what happens when several of these proteins meet at the 
same site we studied the effect of phosphorylation on binding and also did some 
competition experiments using the AlphaScreen technique. For the competition 
experiments we studied at the interaction between the ZASP-1 full-length protein and 
the FATZ-3/myotilin ligand both phosphorylated (EpSEEL) and not (ESEEL). We 
found that this PDZ class III binding could be competed by the addition of the C-
terminal of FATZ-1, another ligand (class III) for the PDZ of ZASP. There was also 
competition when the α-actinin-2 was used as competitor but in this case much higher 




FATZ-1. Possibly due to the fact that the C-terminal ligand of α-actinin-2 (GESDL) 
involved in binding PDZ domains is classified as class I with the motif X[ST]X[VIL]. I 
have shown the last 5 amino acids instead of the last four amino acids, which is the 
canonical PDZ ligand motif, because we used peptides composed of 5 amino acids and 
we believe that the E at position 4 is not casual since it is conserved by the group of 
proteins (FATZ family, myotilin, palladin and myopalladin) that we are studying as 
ligands for PDZ binding. The PDZ ligand motifs used by the ELM program when 
scanning for functional sites in proteins are: class I (X[ST]X[VIL]), class II 
(X[VYF]X[VIL]) and class III (X[DE]X[IVL]). We confirmed the importance of the 
amino acid at position 0 by mutating L to E and thus eliminating the binding to the PDZ 
domain of the members of the Enigma family (ZASP, CLP-36 and ALP) that we 
studied. 
The effect of phosphorylation on binding of the PDZ domain and ligand varied 
depending on which PDZ domain was used and which ligand. It was clear from 
experiments using the PDZ domain of ZASP that phosphorylation enhanced the binding 
of all of the ligands to this domain. The strongest binding was seen between the PDZ of 
ZASP and the phosphorylated peptide for FATZ-3/myotilin, then that for FATZ-1, 
myopalladin and lastly FATZ-2/palladin, in decreasing order of binding. This pattern 
may reflect the affinity of these ligands to bind the PDZ domain of ZASP. The effect of 
phosphorylation was more variable on the interactions between the PDZ domains of 
ALP and CLP-36. For CLP-36 the effect of phosphorylation varied greatly depending 
on the ligand, the phosphorylated FATZ-3/myotilin ligand (ESEEL, EpSEEL) bound 
better than the non-phosphorylated. There was no difference in the binding of CLP-36 




whether they were phosphorylated or not whereas the non-phosphorylated myopalladin 
(ESDEL, EpSDEL) and bound better than the phosphorylated. In fact it is quite striking 
that the phosphorylated myopalladin showed very poor binding. The ALP PDZ domain 
behaved in a similar way to the ZASP in that phosphorylation enhanced the binding to 
the ligands however only FATZ-2/palladin and FATZ-3/myotilin showed any 
appreciable binding. In our hands the PDZ ALP did not bind the non-phosphorylated 
peptide ligands this data are in contrast to the data with the full length proteins where 
binding was seen. PDZ domains can recognize very short C-terminal sequence motifs 
and the basis of this binding has been shown by X-ray crystallographic studies to be due 
to specific side chain interactions between the amino acids of the ligand and those of the 
hydrophobic pocket at the surface of the PDZ domain (Doyle et al., 1996). The four 
residues that reside in the carboxylate-binding loop of the Dlg PDZ domains are GLGF, 
in fact PDZ domains were originally named GLGF repeats (Cho et al., 1992). It is 
notable that all of the Enigma family members with the exception of ALP have PWGF 
as these four residues whereas ALP has SWGF therefore it is possible that this slight 
difference in binding loop residues may confer slightly different binding properties. 
As a way of looking at the specificity of our C-terminal motif (E[ST][DE][DE]L) I used 
commercial PDZ Arrays as mentioned above. The results from these experiments 
showed that the interactions of our motif and the Enigma family members were specific 
and reflected the results obtained using the AlphaScreen experiments; the only protein 
common to both systems was CLP-36 (hCLIM1 in the arrays). Both phosphorylated and 
non-phosphorylated peptides were used as probes in the Arrays and in agreement with 
the AlphaScreen results the phosphorylated myopalladin peptide binds poorly to CLP-




binding the results obtained in both systems were the similar. The main contrast was the 
binding with the FATZ-3/myotilin peptide as the phosphorylated peptide did not bind 
well. This discrepancy could be due to variability in the amount of protein spotted 
which could vary from array to array although the company try to keep this type of 
variation to the minimum. Also in the Arrays the proteins spotted are GST fusion 
proteins therefore we are comparing bindings between peptides and on the one hand 
GST PDZ proteins on the other His tagged PDZ domain proteins. The binding of RIL to 
the FATZ family, myotilin , palladin and myopalladin was previously unknown 
although it is in keeping with the fact that the RIL belongs to the Enigma family of 
proteins which includes ZASP, CLP-36 and ALP. In theses Array experiments I also 
used the mutated peptide ESEEE that has the last amino acid changed from L to E. As 
expected the phosphorylated peptide (EpSEEE) did not bind to any of the proteins on 
the Array instead surprising the non-phosphorylated mutated peptide interacted with the 
PDZ domain of Dlg4-D3 protein. This finding confirms that changing the position 0 
amino acid of the motif affects the binding. In fact the results also confirm out 
AlphaScreen findings that changing L to E destroys the binding to the Enigma family 
members as binding to both RIL and CLP-36 could not be detected. 
I was also able to show by co-immunoprecipitation experiments another new binding 
partner for FATZ-3, namely Ankrd2. This is an interesting protein that is present both in 
the I–band and the nucleus (Kojic et al., 2004); it is a member of the MARP family and 
is thought to be involved in muscle stress response pathways. In a recent paper 
(Tsukamoto et al., 2007) histological studies on the gastrocnemius muscle were done to 
determine whether nuclear accumulation of Ankrd2 occurs on muscle injury, in this 




found that Ankrd2 accumulated in the nuclei of my fibres adjacent to severely damaged 
myofibres after muscle injury. They also found that Ankrd2 localized in euchromatin 
where genes are transcriptionally activated further confirming the hypothesis of Kojic 
and colleagues (Kojic et al., 2004) that Ankrd2 may translocate from the I-band to the 
nucleus in response to muscle damage and may participate in the regulation of gene 
expression. This opens up a lot of interesting questions and future experiments since I 
was able to map the binding of Ankrd2 to the N-terminal region of FATZ-3 (1-180 aa). 
This region of FATZ-3 is the known binding site for calcineurin, γ-filamin, α-actinin 
and telethonin (Frey and Olson, 2002). 
In parallel with the project that I was involved in on the FATZ family, myotilin and 
myopalladin studying their interactions with other proteins I was also trying different 
approaches to express and purify FATZ-3 protein for crystallization experiments in 
order to get some structural information about that protein. As can be seen in the Results 
section of this thesis I faced a lot of difficulties expressing and producing FATZ-3 full-
length protein in bacteria. Difficulties expressing and producing human proteins in 
bacteria are quite common and can be due to codon difference between human and 
bacterial proteins. For this reason I tried to produce and purify the FATZ-3 full-length 
protein in the Baculovirus system. In this system the expression and production of the 
protein was better but the yield was still not enough for crystallization studies. I tried 
scaling up the protein production in Sf9 insect cells but the amount of protein obtained 
was not sufficient. I also faced problems due to the inherent difficulties of working with 
large volumes of eukaryotic cells. Trying a different approach I managed to get higher 
amounts of His tagged protein expressed and purified when I removed the first 80 




(80-251 aa) in bacteria. I then went to the laboratory of Prof. Kristina Carugo at the 
University of Vienna where I was able to do large scale production of the truncated 
FATZ-3 protein as detailed in the Results section.  
When I obtained the purified protein I undertook some preliminary experiments such as 
circular dichroism and dynamic light scattering to obtain information on FATZ-3. The 
circular dichroism data I obtained showed that the purified C-terminal region of the 
FATZ-3 has a high percentage (42%) of random coil meaning that the protein may not 
be well folded and that this may case problems preventing crystallization. Nevertheless 
the dynamic light scattering showed that the percentage of polydispersity was low, 
which indicated that the protein was homogenous in solution, this could help to obtain a 
better quality of crystals. 
The purified protein was spotted using a nanodroper robot. This method gives the 
possibility of trying many different conditions that were very good in my case since I 
had a small amount of the purified protein (120ul) with a concentration of 10 mg/ml. I 
started to obtain crystals 1 month after setting up the protein drops, unfortunately all the 
crystals I obtained where too small to give good diffraction. Despite the fact that the 
crystals obtained did not give good diffraction, I managed to find the right conditions 
for crystallizing the C-terminal of the FATZ-3 protein. Although the C-terminal of 
FATZ-3 contained a high percentage of random coils, this percentage did not prevent 
the protein from crystallizing. Studies on this part of the project are still on going and it 
should be possible to obtain larger crystals by spotting bigger drops using the conditions 





Another approach would be to co-transform the bacterial cells with two vectors; one is 
expressing the FATZ-3 protein and the other expressing the PDZ domain of the ZASP 
protein. This should allow us to build a complex between both proteins and to try to 
crystallize that complex in order to have more information about how the FATZ-3 
protein binds to the PDZ domain. It is known from previous studies how the a ligand 
interacts with the PDZ domain of ZASP (Au et al., 2004) therefore working with a 
complex of full-length and/or C-terminal FATZ-3 with ZASP-1 full-length or only its 
PDZ domain could give more information about the general structure of the proteins 
and what if any structural changes occur when they interact. This is one of a future 
project that I would like to do. 
The results that I and my collaborators obtained from these studies gave us more 
information about the FATZ family, myotilin and myopalladin. Even though the FATZ 
family members interact with the same proteins, their sites of interaction vary from one 
protein to another; for example FATZ-1 and FATZ-2 bind to α-actinin in a region close 
to the C-terminal (Faulkner et al., 2000; Frey et al., 2000) instead the FATZ-3 has two 
binding sites for α-actinin one close to the N-terminal (50-67 aa) and the other is close 
to the C-terminal (186-207 aa) (Frey and Olson, 2002). As noted the FATZ family 
members bind several different proteins however this PDZ motif is the first canonical 
binding motif reported for the family. 
PDZ domains were first classified by (Songyang et al., 1997), the classification 
depended on the sequence of the ligand or the last amino acids of the polypeptide; 
position 0 and position 2 play a very important role in this classification. Depending on 
the ligand sequence there are three classes of PDZ domains. Class I which binds to 




amino acid), class II which binds to ligand sequence (Songyang et al., 1997) and class 
III which binds to ligand sequence -X-[D/E/K/R]- Ф (Stricker et al., 1997). The motif 
that the FATZ family, myotilin, palladin and myopalladin shares is E[ST][DE][DE]L, 
which based on the classification of (Songyang et al., 1997) belongs to the PDZ domain 
class III. We have demonstrated that this motif binds to the PDZ domain of four 
proteins from the Enigma family ZASP, ALP, CLP-36 and RIL. Surprisingly, since the 
PDZ domain of ZASP is a typical class I PDZ domain (Au et al., 2004), here our motif 
is classified as class III but still binds to the class I PDZ domain of ZASP. This has been 
found previously with the syntenin protein, a 32kDa protein that interacts with many 
cell membrane receptors and contains two PDZ domains, the PDZI domain is able to 
bind peptides from class I and III, while the PDZ2 domain is able to bind peptides from 
classes I and II (Kang et al., 2003). We have a class III motif and that binds to the class 
I PDZ domain of ZASP which taken with the data on syntenin would suggest that the 
classification of the PDZ domains still needs further studies in order to be more defined 
and precise. It is known that ligands which bind to PDZ domains can contain a serine, 
threonine or tyrosine at the position 2 or 3 of the ligand (Cohen et al., 1996); we have a 
serine at the position 3 of the peptide(E[ST][DE][DE]L. The phosphorylated peptides 
showed stronger binding to the ZASP PDZ domain than the non-phosphorylated 
indicating that the phosphorylation had a positive effect on the binding with the PDZ 
domains. It is known that phosphorylation can reduce the binding affinity or even block 
binding between two proteins, for example phosphorylation of the myosin heads 
reduces the binding affinity of myosin towards actin which helps it slide along actin. 
Also phosphorylation by the PKA kinase of the amino acid at position 2 of the C-




binding of this protein with the PDZ domain of PSD95 (Cohen et al., 1996). On the 
other hand it has also been noted that phosphorylation can increase the binding of the 
ligand to the PDZ domains, an example of this is the phosphorylation of the C-terminal 
peptide of the mitochondrial ribosomal protein, MRP2, increased its binding to the three 
different PDZ-containing proteins PDZK1 (PDZ domain containing-protein), IKEPP 
(intestinal and kidney enriched PDZ protein) and EBP50 (ezrin-radixin-moesin binding 
phosphoprotein-50) (Hegedus et al., 2003). This is what happens in the interactions of 
the phosphorylated peptides (FATZ family, myotilin, palladin and myopalladin) with 
the PDZ domain of ZASP, phosphorylation enhances the binding. 
It is known that ligands which bind to PDZ domains can contain a serine, threonine or 
tyrosine at the position 2 or 3 of the ligand (Cohen et al., 1996); we have a serine at the 
position 3 of the peptide(E[ST][DE][DE]L. The phosphorylated peptides showed 
stronger binding to the ZASP PDZ domain than the non-phosphorylated indicating that 
the phosphorylation had a positive effect on the binding with the PDZ domains. 
A personal view and a very speculative hypothesis of mine is the following. The 
E[ST][DE][DE] motif common to the last 5 amino acids of the C-terminal of the 
proteins of the FATZ family, myotilin, palladin and myopalladin can allow them to be 
classified as a group of PDZ binding proteins which specifically bind to the PDZ 
domains of the Enigma family; phosphorylation of the serine or threonine at the third 
position of the peptide affected the binding to these PDZ domains. It is known that 
phosphorylation can reduce the affinity of interactions; a common example of this is the 
phosphorylation of the myosin heads which results in a reduction in the binding strength 
of the myosin head to actin leading to movement of the myosin head along actin. The 




interaction; in the case of myosin it is needed to release the myosin in order to achieve 
movements which results in the contraction. In the case of the binding of the FATZ 
family, myotilin and myopalladin to ZASP, phosphorylation may be needed to 
strengthen their interactions to obtain higher stability of the Z-disk during contraction of 
the sarcomere. These proteins can still bind without phosphorylation, the 
phosphorylation only increases the binding so maybe these proteins only get 
phosphorylated when the sarcomere is contracting and dephosphorylated when the 
muscle is relaxed. 
PDZ domains usually work as adaptors in connecting proteins together and localizing 
signalling proteins to different locations in the cell, they also play an important role in 
cell signalling which means that the FATZ family, myosin and myopalladin may act not 
only as muscle proteins involved in Z-disk structure but they may also be indirectly 
involved in cell signalling. This is not so strange since the FATZ family members have 





Chapter 5 CONCLUSIONS 
 
The main finding of this thesis is the identification of a group of mainly striated muscle 
proteins, consisting of the FATZ family, myotilin, palladin and myopalladin, that 
selectively interact via a C-terminal motif with the PDZ domains of several Enigma 
proteins, ZASP, CLP-36 and ALP. These interactions were verified by several methods 
such as Co-IP, in vitro binding using the AlphaScreen technique and PDZ Arrays. The 
interaction of these proteins with the Enigma family members is highly specific as 
verified by the restricted number of PDZ domain proteins with which their peptide 
ligands will bind when given the opportunity. In fact only 2 of the 28 PDZ domain 
proteins on the Array bound to the peptide ligands, interestingly these were the only two 
Enigma family members on the Array; RIL and CLP-36 (hCLIM1). Therefore based on 
the results of the PDZ Array experiments RIL would appear to be a binding partner for 
proteins of the FATZ family, myotilin, palladin and myopalladin. Based on the work 
presented in this thesis we propose that the FATZ family, myotilin, palladin and 
myopalladin bind to members of the Enigma family of PDZ proteins via a C-terminal 
class III type PDZ ligand. This ligand motif [ST][DE][DE]L falls into the category of a 
class III PDZ domain binding motif. 
I was also able to find another new binding partner for FATZ-3, namely Ankrd2, and 
also map its binding site to the N-terminal that is the region of FATZ-3 known to bind 
calcineurin, γ-filamin, α-actinin and telethonin. This is an interesting finding since 
Ankrd2 protein is thought to be involved in muscle stress response pathways and 




striated muscle cells and accumulates in the euchromatin in the nuclei of myofibres on 
muscle injury.  
Another important object of this thesis was to study the tertiary structure FATZ-3 by 
using protein crystallography. After many difficulties expressing and producing native 
full-length FATZ-3 protein I adopted the approach of producing FATZ-3 without the N-
terminal 80 amino acids. I was able to produce enough of this truncated FATZ-3 protein 
(171 amino acids) to do some structural studies at the laboratory of Prof. Kristina 
Carugo. I undertook some preliminary experiments such as circular dichroism and 
dynamic light scattering to obtain information on FATZ-3. The circular dichroism data I 
obtained showed that the purified C-terminal region of the FATZ-3 has a high 
percentage (42%) of random coils therefore the protein may not be well folded. The 
dynamic light scattering analysis showed that the percentage of polydispersity was low, 
indicating that the protein was homogenous in solution. I went ahead and tried about 
300 crystallization conditions and started to obtain crystals after 1 month. However 
none of the crystals gave a good diffraction pattern when checked by X-ray nevertheless 
I have now defined the conditions suitable for crystal formation from purified C-
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